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With the sequencing of the genomes of individuals with rare Mendelian disease 
becoming routine, there is an emerging challenge in identifying and quantifying 
similarity between individual’s phenotypes to assist in the identification of 
commonalities in the genetic variation contributing to disease. Whilst it is relatively 
easy to assess genetic similarities between individuals, it is less trivial to assess 
phenotypic similarity due to the complexity of phenotypic information. One route 
to systematically estimate similarity between phenotypes utilises computational 
approaches applied to standardised machine-readable phenotypic descriptors, such 
as those in the Human Phenotype Ontology (HPO) or structured patient 
questionnaires. This thesis describes advances in the representation of clinical 
phenotypes in machine-readable controlled vocabulary within the context of 
genetic studies of both the diagnosis of monogenic disease patients, and common 
variant association analysis of severe acne subtypes. When using genome 
sequencing for the genetic diagnosis of individuals with rare Mendelian diseases, 
a virtual gene panel approach is often taken wherein only a curated list of genes 
suspected to cause a phenotype are considered. With the number of known 
monogenic disease-gene pairs exceeding 5,000, manual curation of personalised 
gene panels based on the entire human phenotypic spectrum is challenging. 
Methods have previously been developed that formalise the approach using the 
patient phenotype to generate candidate genes, requiring both patients and known 
disorders to be defined in standardised machine-readable terms. Work in this 
project has investigated the ways by which established phenotypic descriptions 
(OMIM free-text) can be further leveraged using simple quantification of disease 
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terms to gain a more nuanced description of known phenotypes with HPO terms, 
and how this helps to more efficiently generate candidate gene panels in real patient 
datasets. This project also examines the utility of extensive patient questionnaire 
records in patients with severe acne, enabling the identification of questionnaire 
response stratified subtypes of acne for use in downstream investigations seeking 
to identify new genetic determinants of the disease.  
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 Chapter 1 - General Introduction 
1.1 Identification of disease-causing genetic variation 
1.1.1 Genetic disease 
Genetic diseases are caused by a change in an individual’s DNA sequence which 
increases the likelihood of developing the disease. The extent to which genetic 
variation is causative of disease can range from that of fully penetrant monogenic 
disorders, where a single sequence variant is sufficient to cause the disease, to 
common complex diseases, where there are often multiple individual genetic 
variants that influence susceptibility to disease, often in addition to and in 
combination with lifestyle and environmental factors.  To generalise, monogenic 
disease is usually rare, severe and frequently presents in childhood/adolescence, 
whereas common complex diseases often present in adulthood or later life. 
Complex diseases are generally more common than monogenic diseases because 
causative variants have lower effects on disease risk and are therefore under less 
selective pressure than variation that would cause severe monogenic disease, and 
can elevate in frequency within the population (Blekhman et al., 2008). 
To make a confident statement about the role of a specific allele or group of alleles 
with similar implication in a disease phenotype requires either the recurrent 
observation of these alleles within a cohort of individuals with the phenotype, or 
the identification of a known relationship between the phenotype and allele from 
within all documented causal relationships that have been discovered. 
Relationships between disease phenotypes and alleles at genomic loci can be 
discovered though either linkage mapping (followed by candidate gene 
sequencing) or association studies. 
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1.1.2 Linkage mapping 
Linkage mapping uses genome-wide markers to reveal chromosomal segments 
shared between individuals within pedigrees in which a trait also segregates, 
enabling statistical testing for non-random associations between marker loci and 
the disease trait. Linkage mapping is most suitable for identifying loci where highly 
penetrant genetic changes cause disease but do not impact on reproductive fitness, 
hence familial segregation of the disease is observed. Roughly a third of Mendelian 
disease genes have been discovered using linkage mapping and candidate gene 
resequencing (Bamshad et al., 2011; McKusick, 2007). However, linkage mapping 
is ineffective with locus heterogeneity, small pedigrees (which are likely in 
disorders with diminished reproductive fitness or caused by de novo mutation) and 
reduced penetrance (Kaiser, 2010).  
1.1.3 Association studies 
Association studies use genotype data from individuals to identify alleles that are 
present in greater or lower frequency in those with the phenotype compared to 
unaffected controls. Association studies do not require groups of individuals from 
within the same pedigree, but rather require adequate numbers of cases and controls 
for statistical power and an appropriate method of genotyping for the genetic study 
undertaken (i.e. for the identification of either highly penetrant variation in rare 
disease, or variation with smaller effect size in complex disease). A key element of 
association studies is that they require the identification of individuals with the 
same phenotype, as well as the identification of controls without the phenotype 
(which must be appropriately stratified). In rare disease it is particularly 
challenging to recruit individuals with similar phenotypes due to the scarcity of 
cases – it is therefore crucial that observed relationships between rare phenotypes 
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and allelic variants are recorded as a reference for individuals existing outside of 
these studies, which enables them to receive a molecular diagnosis without having 
to “rediscover” disease genes that have already been identified. 
1.1.4 Association studies in rare monogenic disease 
1.1.4.1 Unit of association 
For rare monogenic disease, under the assumption of complete penetrance, putative 
causative alleles must be exclusively observed in individuals with the disease. 
However, variation at multiple positions within a gene may give rise to the aberrant 
gene function that causes the phenotype, so variant-based testing often lacks power. 
As a result, gene level testing is often employed, where genome-wide variation is 
filtered based on the expected properties of gene-disrupting variants – variation can 
then be collapsed to gene level to test for significant increases in putative 
pathogenic variation in cases compared to controls.  
1.1.4.2 Whole genome and whole exome sequencing 
Using linkage mapping, the power to identify causative variants in rare disorders 
is limited in instances where there is either a small number of cases, locus 
heterogeneity or a rare disorder arising spontaneously through de novo mutation 
(Ng, Buckingham, et al., 2010). Advances in whole genome sequencing technology 
have resulted in sequencing cost declining over four orders of magnitude compared 
to Sanger sequencing (Metzker, 2010; Wetterstrand, 2016), and as a result whole 
genome and whole exome sequencing have become widely used for the 
identification of disease genes in rare monogenic diseases, enabling genotypes at 
almost every locus in the genome/exome to be tested for association with disease 
status. Whole genome sequencing (WGS) entails the sequencing of a patient’s 
entire genome at sufficient depth (At least 20X is required to accurately call a 
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heterozygous variant (Choi et al., 2009; Depristo et al., 2011)), but a more cost-
effective option is available in whole exome sequencing (WES). WES selectively 
targets the protein coding regions, which constitute ~1.5% of the genome. It is 
estimated that ~85% of mutations with large effects on disease-related traits reside 
in the exome (Majewski, Schwartzentruber, Lalonde, Montpetit, & Jabado, 2011) 
and that exonic mutations cause the majority of monogenic diseases 
(Kuhlenbäumer, Hullmann, & Appenzeller, 2011). Due to the excess of disease-
related variation contained within this small fraction of the genome, WES has 
become a powerful cost-effective alternative to WGS (Boycott, Dyment, Sawyer, 
Vanstone, & Beaulieu, 2014). 
1.1.4.3 Filtering potential monogenic disease-causing variants 
The exome sequencing of an individual identifies ~20,000 sequence variants on 
average (Hoischen et al., 2010; Musunuru et al., 2010; Ng et al., 2009), so the 
challenge of identifying a single disease-causing variant (or pair of variants in 
recessive disease) involves a substantial reduction of information. There are several 
filters that can be applied that help to achieve this based on theorised and observed 
properties of monogenic disease-causing variants: 
• Non-rare variants: Large datasets of unaffected individuals are often used 
to estimate the population frequency of variants and remove variants with 
an allele frequency above a certain threshold. This includes datasets such 
as 1,000 genomes (n = 2,504) (1000 Genomes Project Consortium et al., 
2015), the NHLBI Exome Sequencing Project (ESP) (n = 6,503) (Fu et al., 
2013) and the Exome Aggregation Consortium (ExAC) (n = 60,706), later 
known as the Genome Aggregation Database (gnomAD) (n = 123,136 
exomes + 15,496 genomes) (Lek et al., 2016). The larger the sampled 
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population and the more it reflects the ancestry of the patient, the more 
accurate the allele frequency estimate will be. The appropriate frequency 
threshold to use is dictated by the suspected inheritance model of the 
disease, prevalence of the disease in the population and the expected 
penetrance of the variant. Some variants annotated as disease-causing of 
autosomal dominant disorders in the Human Gene Mutation Database 
(HGMD) (Stenson et al., 2009) have been found to be present in healthy 
exomes, which potentially indicates reduced penetrance and therefore 
frequency filters may be relaxed accordingly. However, this may also be 
indicative of sequencing errors or false-positive entries in HGMD (Winand 
et al., 2014). It is also useful to filter by allele frequency observed in 
databases that comprise individuals sequenced at the same facility (using 
the same platforms(s)) – this firstly provides another estimate of allele 
frequency but more importantly can reveal common variants called due to 
sequencing/calling artefacts exclusive to the facility/platform used. 
• Zygosity: Variants can be filtered on zygosity (homozygous/heterozygous) 
to reflect the suspected mode of inheritance (if known). If a recessive model 
is assumed, only variants that are homozygous or consistent with compound 
heterozygosity would be considered. To confirm that compound 
heterozygous mutations exist in trans, sequence data from the parents must 
be used to establish that the patient inherited one variant from each parent.   
• Functional consequence: Even when sequencing is not limited to the 
exome, variation is often filtered to the coding region of the genome, in 




o Synonymous variants: Synonymous variants typically constitute 
~50% of total called exonic single nucleotide variants (SNVs) 
(Bamshad et al., 2011), and these are commonly removed because 
they do not affect protein sequence. However, there is increasing 
evidence that synonymous mutations can affect protein expression, 
conformation and function, and it is estimated that 5-10% of genes 
contain at least one damaging synonymous mutation (Sauna & 
Kimchi-Sarfaty, 2011). 
o Pathogenicity prediction: Missense mutations typically comprise 
just under 50% of called SNVs, and these can have vastly varied 
effects on protein function based on the nature of the amino acid 
change and its location within the protein sequence. This has 
encouraged the development of tools that predict whether an SNV 
is damaging (alters the normal levels or biochemical function of a 
gene or gene product) or deleterious (reduces the reproductive 
fitness of carriers and would thus be targeted by purifying natural 
selection) based on a model incorporating one or many annotations. 
Although the estimation of pathogenicity based on these predictions 
can help prioritise variant data and provide additional lines of 
evidence for whether a mutation is benign or deleterious, it is not 
recommended that they are considered alone (or using consensus of 
multiple scores) as a strong line of evidence due to the uncertain 
relationship between pathogenicity and annotation-derived 
damaging/deleteriousness scores (Kircher et al., 2014; D. G. 
MacArthur et al., 2014).  
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o SIFT (Sorting Intolerant from Tolerant) (Kumar, Henikoff, & Ng, 
2009) assesses amino acid substitutions based on the premise that 
important positions in a protein sequence are evolutionarily 
conserved. SIFT conducts a protein sequence homology search to 
score all possible amino acids at a given position, and changes from 
highly conserved residues are scored as more deleterious. 
o PolyPhen2 (Adzhubei, Jordan, & Sunyaev, 2013) makes use of a 
classifier trained to predict whether genetic changes are damaging 
based on several annotations for known disease-causing mutant 
alleles (and their wild-type counterparts). Annotations are based on 
both sequence and protein structure. 
o CADD (Combined annotation dependent deletion) (Kircher et al., 
2014) makes use of an SVM classifier based on 63 annotations, 
trained to distinguish between 14.7 million high-frequency human-
derived alleles (largely fixed in the human lineage) and an 
equivalent number of simulated de novo mutations. CADD scores 
are then computed for all 8.6 billion possible human SNVs. DANN 
(Quang, Chen, & Xie, 2015) utilised the same annotations and 
training set but uses a deep-learning framework, which outperforms 
CADD in their benchmarking. 
In the absence of sequencing data from large family pedigrees to check whether a 
particular variant segregates with disease status, it is unlikely that these 
aforementioned variant filters will sufficiently narrow down towards the causative 
variant in a single individual, due to the amount of non-synonymous variation 
possessed (Bamshad et al., 2011) and rare LOF mutations harboured by each 
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individual (Daniel G. MacArthur et al., 2012). Depending on whether WES is 
undertaken to provide a genetic diagnosis or to discover novel genes, there are 
different strategies that enable identification of the single causative variant. 
1.1.5 Monogenic diagnosis using WES 
Once the causative relationship between gene and phenotype has been robustly 
defined by either linkage or association, it is possible to diagnose an individual 
based upon their phenotype and genotype. WES is now commonly used for the 
genetic diagnosis of individuals with rare disorders, particularly in instances where 
the number of possible candidate genes is sufficiently high that WES would be 
more financially viable than panel tests. This is the case when the patient’s clinical 
phenotype is sufficiently unclear that one of multiple known disorders could be 
responsible, or when a particular disorder has a large number of potential causal 
genes (Bamshad et al., 2011). The use of exome sequencing has been found to be 
more effective than gene panel tests in achieving molecular diagnoses for patients 
(Neveling et al., 2013). 
Often, standard filtering approaches are combined with virtual gene panels – 
prespecified lists of known causative genes that are prepared for specific 
phenotypic areas – and only variants in the panel are considered as potentially 
causal. Virtual panel size is variable – highly specific panels with few genes can be 
used, which may result in the exclusion of the disease gene, and some panels 
contain over 1,000 genes (such as the DDG2P developmental gene panel (Wright 
et al., 2015)) which may not be sufficiently specific to the patient phenotype and 
will result in more variants to be manually evaluated. Panels can be selectively 
augmented based on clinical evaluation of the patient phenotype but the number of 
monogenic disease-gene pairs has now surpassed 5,000 (Amberger, Bocchini, 
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Schiettecatte, Scott, & Hamosh, 2014), so it is becoming less feasible to construct 
personalised virtual panels for every patient. 
Following the sharp decrease in the cost of sequencing (Wetterstrand, 2016), it has 
become feasible in a clinical diagnostic setting. As a result, a number of diagnostic 
sequencing projects have been undertaken, either focussed around one phenotypic 
area (de Ligt et al., 2012; Y Yang et al., 2014; Yaping Yang et al., 2013) or across 
multiple broad phenotypic areas (H. Lee et al., 2014; Sawyer et al., 2016; Taylor 
et al., 2015; Wright et al., 2015). These studies either utilised a primary gene panel 
to filter variants or involved manual review of all rare deleterious variants with 
respect to patient phenotype. Diagnostic yields were consistently reported to be 
between 25 and 30% (Schwarze, Buchanan, Taylor, & Wordsworth, 2018). 
1.1.6 Monogenic gene discovery using WES 
If the patient clinical evaluation doesn’t match any known phenotypes, or diagnosis 
using virtual panels is unsuccessful, it is possible that the disease-causing variant 
resides in a gene previously undescribed to be causative of the phenotype. Novel 
gene discovery studies usually rely upon sequencing multiple unrelated patients 
with the same phenotype in order to identify the causal gene. After applying the 
filtering strategies such as removal of synonymous non-rare variants, the genes of 
the remaining variants are intersected. Studying unrelated patients minimises the 
number of identical-by-descent sequence variants. This method has been successful 
(Gilissen et al., 2010; Lalonde et al., 2010; Ng, Bigham, et al., 2010; Ng, 
Buckingham, et al., 2010; Simpson et al., 2011) although it requires a sufficient 
number of patients, and that the disorder has minimal genetic heterogeneity. Due 
to the rarity of monogenic disorders, it can be difficult to recruit patients to genetic 
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studies, as they may exist across different regions and may not be united by a single 
healthcare record system through which similarities can be identified. 
If pedigree information is available, it can be utilised to narrow the search space 
for the causative variant. The causative variant is expected to segregate with the 
phenotype status within the family, so variants present in unaffected individuals 
can be discarded. 
1.1.7 Validation of disease-causing variants 
The description of a novel causal relationship between a gene and phenotype 
crucially requires statistical evidence that a variant is significantly enriched in cases 
compared to controls. Furthermore, by using sequence data from the family, 
statistical evidence can be provided that the variant is co-inherited with disease 
status. The variant must also be rare in a large population cohort with similar 
ancestry to the patient(s) (which will likely be true due to filtering). (D. G. 
MacArthur et al., 2014) 
Informatic evidence in the form of pathogenicity prediction tools are considered 
useful additional lines of evidence based on sequence conservation and/or other 
various annotations of sequence context or resultant protein structure. This 
evidence should be supplemented by experimental evidence, which can be obtained 
by proving that the variant alters levels, splicing or normal function of the affected 
gene product. Either patient cells or an appropriate in vitro model system can be 
used. It is also useful to observe that the phenotype can be recapitulated by 
introducing the variant into a model system, as well as rescued by introducing the 
WT gene product. This requires a definition of a phenotype that is consistent with 
the human disease. (D. G. MacArthur et al., 2014) 
31
 
For the genetic diagnosis of an individual, the specific statistical evidence required 
to associate a genetic variant with a clinical phenotype is less clear. If sequence 
data is not available for family members (both affected and unaffected), evidence 
cannot be gathered to assert that a particular variant segregates with disease status 
within the family. The requirement to make such genetic diagnoses requires the 
matching of a patient’s phenotype to the phenotype of a known monogenic disorder 
(assuming it has been discovered) to a degree of confidence, as well as a rare 
deleterious variant in the relevant gene. To make such comparisons between 
individuals and known phenotypes, it is required that all discovered known 
phenotypes are recorded, as well as all known phenotype-gene causal relationships. 
1.1.8 Documented phenotype-gene pairs 
The documentation of known causal relationships between genes and phenotypes 
within databases is an increasingly useful clinical resource for the investigation of 
possible pathogenicity of candidate variants with respect to patient phenotypes.  
OMIM (Online Mendelian Inheritance in Man) (Amberger et al., 2014) is a 
database which comprehensively documents human genes and genetic phenotypes. 
It is an online continuation of McKusick’s Mendelian Inheritance in Man (MIM) 
(McKusick, 1966) and it contains information on over 15,000 genes and 6,000 
Mendelian phenotypes (and an additional 2,000 phenotypes with suspected 
Mendelian basis). Over 5,000 monogenic phenotype-gene relationships are 
recorded, and clinical synopses of Mendelian phenotypes are included. Although 
precise medical terminologies are used, it is not a standardised form of phenotypic 




Orphanet (Maiella, Rath, Angin, Mousson, & Kremp, 2013) is another database 
documenting rare disease (including infectious diseases). It contains various 
information on disease prevalence, inheritance, genes involved, as well as various 
health care resources and research activities on each disease. It also contains free-
text descriptions of the phenotypic characteristics and categorisation of disease by 
features.  
Variant databases HGMD (Stenson et al., 2009) and ClinVar (Landrum et al., 
2018) list genetic variants reported to be involved in human disease, along with 
limited information on the phenotypes caused by each variant (or mappings to 
phenotypes within OMIM or Orphanet). 
1.1.9 ACMG variant guidelines 
The American College of Medical Genetics (ACMG) has published guidelines on 
the clinical interpretation of sequence variants identified in patients (Richards et 
al., 2015). These have been widely adopted, and the UK NHS has recommended 
implementation across genetic diagnostic laboratories testing for rare diseases and 
familial cancers (Ellard et al., 2017). The guidelines use a five-tier system (Table 
1) to describe variants based on supporting evidence from a range of evidence 
sources, such as population minor allele frequency (MAF), computational 
predictions, functional study, segregation throughout family members.  
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Table 1: Five-tier variant classification from ACMG guidelines. Values in % certainty 
pathogenic are approximate recommended numerical meanings for each term rather than 
rigours calculations of probability. 
Class Description % certainty pathogenic* 
5 Pathogenic ~100 
4 Likely pathogenic ≥90 
3 Unknown significance 10-90 
2 Likely benign ≤10 
1 Benign ~0 
 
Two separate classifications for benign and pathogenic assertions have been 
designed (Figure 1), as well as rules for combining multiple sources of evidence 
into the final five-tier classification (Table 2). Although the term “likely” doesn’t 
confer a specific likelihood of a variant being either pathogenic or benign, 
guidelines recommend that “likely” corresponds to 90% certainty of either benign 
or pathogenic classification. The guidelines consider classifications of both 
pathogenic and likely pathogenic to be evidence that can be used in clinical 
decision making. Typically, variants classified as both pathogenic and likely 
pathogenic are considered to have sufficient evidence for health-care providers to 




Figure 1: Evidence framework for each of the criteria for a benign or pathogenic assertion 
of a variant – taken from Richards et al., 2015. BS, benign strong; BP, benign supporting; 
FH, family history; LOF, loss of function; MAF, minor allele frequency; path., pathogenic; 
PM, pathogenic moderate; PP, pathogenic supporting; PS, pathogenic strong; PVS, 
pathogenic very strong. 
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Table 2: Rules for combining criteria to classify sequence variants – taken from Richards 
et al., 2015. Evidence descriptors (found in Figure 1): BS, benign strong; BP, benign 
supporting; PM, pathogenic moderate; PP, pathogenic supporting; PS, pathogenic strong; 




1.1.10 Association studies in common complex disease 
1.1.10.1 Genotyping arrays 
Risk of common complex disease is contributed to by both rare and common 
genetic variation, although the majority of findings have been common variants 
(which also explain the majority of the discovered contribution to phenotypic 
variation) (Gibson, 2012). Genotyping arrays survey an individual’s common 
genetic variation (MAF>1%) by determining the genotypes of between 200,000 
and 2,000,000 single nucleotide polymorphisms (SNPs) distributed across an 
individual’s genome size (Visscher et al., 2017). Genome-wide association studies 
(GWAS) then test whether the variation in genotype at each SNP is associated with 
disease status. Controls must be carefully selected from a similar population to 
cases (taking into consideration age, sex and possibly other covariates) (Zondervan 
& Cardon, 2007). 
Imputation can be used to predict genotypes of SNPs not directly typed – a 
reference dataset of densely genotyped individuals is used to identify haplotype 
blocks shared between study individuals and the reference set (Marchini & Howie, 
2010). Imputation is unreliable in predicting rare genotypes. Alternative methods 
of genotyping that can capture rare variation exist, but they each have limitations: 
specialised exome chips are able to genotype rare variants, but these cannot capture 
the full array of rare variation; high-depth WGS is most reliable but is prohibitively 
expensive for sample numbers required; low-depth WGS is more cost-effective but 
has less accuracy for rare variants; exome sequencing is also more cost-effective 
than WGS (though still expensive compared to genotyping arrays) but is limited to 
exonic variation (S. Lee, Abecasis, Boehnke, & Lin, 2014).  
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1.1.10.2 Association testing 
In case-control studies SNP genotypes are tested for association with the phenotype 
using logistic regression (Al Olama et al., 2014; Nikpay et al., 2015; Wellcome, 
Case, & Consortium, 2007), which is able to adjust for potential confounding 
variables such as ethnicity, biometric information, genotyping batch or genotypes 
at other SNPs (Equation 1).  
Equation 1: Logistic regression commonly employed in genome-wide association testing.  
p is the expected value of the phenotype (case = 1, control = 0), given genotype X and 
confounders C, D, etc. P-values are calculated based on whether β1 significantly differs 




=  𝛽0 + 𝛽1𝑋 + 𝛽2𝐶 + 𝛽3𝐷 … 
Due to the vast numbers of SNPs tested, P-values must be corrected for multiple 
testing. Genome-wide significance is often stated as P < 5 × 10-8, the Bonferroni-
corrected family-wise error rate of 0.05 considering roughly one million 
independent SNPs tested (M. X. Li, Yeung, Cherny, & Sham, 2012).  
1.1.10.3 Power to detect association 
For a variant with a particular minor allele frequency and expected effect size, there 
is a requirement on the number of individuals to be genotyped to achieve the 
statistical power to detect a genome-wide significant association (Figure 2) 
(Visscher et al., 2017). Both lower effect sizes and lower minor allele frequencies 
impose extensive and impactful requirements on the numbers of individuals 




Figure 2: Minimum sample sizes for detecting trait-SNP associations from imputed and 
WGS data – taken from Visscher et al., 2017. Required sample sizes for detecting 
association were calculated under the assumption of a type I error rate of 5 × 10−8, 80% 
power, and Hardy-Weinberg equilibrium. Effect sizes (β) are in phenotypic standard 
deviation units. For genotyped SNPs imputed to a fully sequenced reference, the average 
imputation R2imp values reported by the Haplotype Reference Consortium (McCarthy; A 
reference panel of 64,976 haplotypes for genotype imputation.) were used.  
1.1.11 Similar phenotypes 
For both rare and common complex disease, it is a key feature of genetic studies 
that individuals sharing the same phenotype must be identified. This may be the 
recruitment of multiple individuals to one study, or the identification of a known 
phenotype-gene relationship within an individual which has previously been 
discovered by genetic study. 
For rare disease exome sequencing studies, individuals presenting with the same 
phenotypic feature or constellation phenotypic features characteristic of a 
particular clinical diagnosis are identified as cases (Ng, Buckingham, et al., 2010; 
Simpson et al., 2011). This is indicative of an implicit measure of phenotype 
similarity, particularly in studies of disorders where different members of the 
cohort have the same clinical diagnosis which can manifest as a range of different 
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constellations of phenotypic features (Ng, Bigham, et al., 2010). In studies where 
individuals are diagnosed through the identification of a known phenotype-gene 
relationship in the patient, phenotypes of candidate genes are evaluated with 
respect to the patient phenotype (The Deciphering Developmental Disorders Study, 
2014; Wright et al., 2015), again suggesting implicit measures of phenotype 
similarity. 
For common complex disease studies, there are often several criteria individuals 
must meet for inclusion in the study, which include manifestation of the phenotype 
of interest (which may include several subphenotypes), as well as age, disease 
severity score cut-offs, certain medical histories or family history of the condition 
(Al Olama et al., 2014; Nikpay et al., 2015). This is further complicated in meta-
analysis datasets, where different participating members of consortia may use 
slightly different qualification criteria. The need to identify vast numbers of 
individuals to be defined as cases may result in an introduction of phenotypic 
heterogeneity which can reduce power to detect phenotype-specific effects - 
analysing more homogenous populations of cases expressing sub-phenotypes can 
improve the efficiency of GWAS analyses (Eichler et al., 2010; Kulminski et al., 
2016; MacRae & Vasan, 2011).  
1.1.12 Phenotypic data capture 
The increasing abundance of available sequence data combined with increasing 
availability of electronic health records provides novel opportunities for genetic 
analyses. Considering how phenotypic information is used to define individuals 
with a particular disease for genetic study, it is important to capture and store these 
data in appropriate “machine-readable” language. It is also important to document 
discoveries from genetic studies in machine-readable language so that information 
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from individuals can be queried to this data. Phenotypic information can be 
recorded in several ways:  
Free-text  
Often, both patient clinical records and publications of novel phenotypes and 
disease genes are recorded in free text. Although this is the easiest and most 
accessible way to record observations, free-text alone renders systematic 
comparison across patients or between patients and known phenotypes untenable  
(P. N. Robinson & Mundlos, 2010). Simple text mining can be used extract 
meaning from free-text but to accurately translate free-text phenotype descriptions 
into machine-readable language sophisticated text mining and natural language 
processing tools are required. 
Questionnaires 
Phenotypic information can also be recorded in specialised questionnaires designed 
to gather information surrounding the particular phenotypic area of study – these 
can be filled by clinicians, nurses or be self-reporting questionnaires. Data recorded 
in this format is useful when setting inclusion requirements for cases in genetic 
studies of many individuals (i.e. common disease studies), allowing for the rapid 
identification of individuals matching specified criteria. It also enables the 
recording of quantitative measurements alongside binary observations of presence 
or absence of a phenotypic features. The use of questionnaires rather than free-text 
prompts the user to consider a prescribed set of phenotypes, and therefore require 
thoughtful design to capture meaningful information. Compliance of individuals 
completing questionnaires is an issue which is also relevant to the questionnaire 
design: questionnaires must be simple to use whilst facilitating the recording of 
maximal useful phenotype information. 
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Although questionnaires offer standardised phenotypic information to be accessed 
across single genetic studies, they may not facilitate comparison across studies that 
utilise different questionnaire designs, which presents difficulties in meta-analysis 
of datasets where phenotypic models are not standardised.  
Controlled vocabularies 
Standardised controlled vocabularies exist for the description of disease 
phenotypes. Closed source vocabularies for particular disease areas suffer from the 
same drawbacks as questionnaire usage because they do not facilitate comparison 
to external datasets that use different schema to record phenotypes, again making 
comparisons untenable (P. N. Robinson & Mundlos, 2010). However, open source 
vocabularies offer vast opportunities for the comparison of individual’s phenotypes 
to other individuals or reference datasets. In extremely rare phenotypes with 
handfuls of cases worldwide, the power to detect disease-causing variants depends 
on the ability to remotely identify patients with similar phenotypes, which is likely 
to depend on use of a common standardised phenotypic language (as well as a data 
sharing strategy to facilitate). Open-source vocabularies can be continually 
improved by curators (although version changes can incur significant costs to 
widely used vocabularies (Topaz, Shafran-Topaz, & Bowles, 2013)) and external 
applications can be designed for the storage or analysis of phenotypic information. 
A drawback to the use of controlled vocabularies is differing levels of diligence 
with which standardised terms are recorded. This is heavily dependent on the 




1.2 Controlled phenotypic vocabulary 
1.2.1 Ontology 
A useful machine-readable phenotype language needs to overcome synonymy 
(many ways to express the same concept) and hyponymy/hypernymy (a hyponym’s 
semantic field is more specific than its hypernym). Illustrating the issue of 
synonymy in phenotyping is that ‘generalized amyotrophy’, ‘generalized muscular 
atrophy’, and ‘muscular atrophy, generalized’ are all used in OMIM to describe a 
single entity  (Amberger et al., 2014; P. N. Robinson & Mundlos, 2010). Although 
humans can recognise this, search engines are not well-equipped to do so. An 
accepted definition of the aforementioned phenotypic concept must be established, 
as well as all possible synonyms (which include the three examples given). 
Hyponymy and hypernymy are illustrated by the term ‘intellectual disability’ (the 
hypernym) encompassing ‘severe intellectual disability’, ‘mild intellectual 
disability’ and ‘moderate intellectual disability’ (hyponyms). It is useful to 
machine-readable phenotype language to reflect these relationships because 
although the hyponyms are distinct terms, they possess a high degree of similarity 
in their meaning. Such relationships exist throughout the entirety of medical 
language and are not confined to only the most similar of terms. 
Ontologies are able to organise clinical definitions in a way that resolves 
synonymy, hyponymy and hypernymy, such that every term within the ontology 
represents a unique concept with defined synonyms, as well as possessing a 
relationship with every other term. Ontologies are described as ‘a set of logical 
axioms designed to account for the intended meaning of a vocabulary’ (Guarino, 
1998) and are used in virtually every field of study to limit language complexity 
and organise terminologies into explicit information structures. Ontologies are 
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largely organised into directed acyclic graphs (DAGs), consisting of nodes and 
edges. In directed graphs edges are unidirectional, and acyclic graphs do not 
contain any paths leading from one node back to itself. Nodes nearer the root node 
are more general than nodes further away and ontologies often adhere to the true-
path rule which states that all nodes assume the properties of their ancestor nodes. 
1.2.2 HPO 
The organisation of all human phenotypic terms into an ontology is realised in the 
Human Phenotype Ontology (HPO) (Köhler et al., 2014). The HPO “aims to 
provide a standardized vocabulary of phenotypic abnormalities encountered in 
human disease” and contains 13,348 phenotypic terms (as of 12/06/18). In the HPO 
(Figure 3) each node represents a single phenotypic concept (which have a range 
of defined synonyms) and as with most other ontologies, terms are organised in a 
DAG. The root term is HP:0000001 (All) and it has 5 child terms; 
• HP:0000005 – Mode of inheritance 
• HP:0040279 – Frequency 
• HP:0012823 – Clinical modifier 
• HP:0000118 – Phenotypic abnormality 
• HP:0031797 – Clinical course 
‘Phenotypic abnormality’ subsumes the bulk of the ontology (97% of terms), 
containing all the phenotypic feature definitions. These can be co-annotated with 
terms subsumed by the other root nodes of the ontology to reflect different 





Figure 3: A subsection of the Human Phenotype Ontology. Terms are arranged in a 
directed acyclic graph (DAG), hence all terms are hyponyms of their parent terms and 
terms become more specific the further they are from the root term. Terms highlighted 
with ‘*’ have multiple parent terms as they can constitute a more specific property of 
multiple general terms. Adapted from (P. N. Robinson & Mundlos, 2010). 
The HPO was initially formed by mining for common terms across multiple 
diseases in OMIM Clinical Synopsis sections and making use of the hierarchical 
nature of these annotations to provide a primitive ontology tree structure. This 
ontology structure was then manually modified based on the curators’ knowledge 
of the human genetics domain, merging similar concepts, separating generic 
concepts and the addition of more general terms to connect all terms to a common 
ancestor (Peter N. Robinson et al., 2008). The furthest level down in the ontology 
is 14 (i.e. distance to root is 13) and the mean distance from the terms to the root is 
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6.65 (Figure 4). A term’s distance to the root node is correlated with a measure of 
its specificity (Figure 5; measured in information content (IC) which based on how 
few OMIM entries are annotated with a particular term, discussed later in 1.3.2). 
Terms further from the root tend to be more specific, but a term only 3 nodes away 
from the root may be considered more specific than a term over 10 nodes away – 
this is dependent on the construction of that particular region of the ontology and 




Figure 4: Distribution of distances (in number of edges) to the root HPO term 
(HP:0000001: All) for all nodes in the HPO (HPO build #1699, 09/02/16), showing that 
HPO terms most commonly exist 6-7 levels down from the root term. 
 
Figure 5: HPO term specificit fo esrevni gol eh: t tnetnoc noitamrofni ni derusaem( y
.sv )2.3.1 ni retal dessucsid ,eugolatac MIMO eht ssorca ycneuqerf noitatonna
sedulcni ;8797=n( MIMO ot detatonna smr lla et rof edon OPH toor ot ecnatsid
tes noitatonna OPH detaruc eht no desaB .)detatonna ylticilpm smr lartsecna et i
 dekramhcneb in Chapter 2 snosirapmoc ygolodohtem  (Table 5, page 75).
 tneserp sreksihw xoB er furthest data points within 1.5×IQR (interquartile range). 
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The HPO annotations comprise 121,399 term annotations to hereditary diseases 
(n=8057) in OMIM, Orphanet and DECIPHER, establishing a common phenotype 
language for known phenotypes. The HPO can also be used to define the 
phenotypic characteristics of patients, as has been done in several of the largest 
recent rare disease sequencing projects such as the DDD (Deciphering 
Developmental Disorders) study (Wright et al., 2015), FORGE (Finding of Rare 
Disease Genes) Canada Consortium (Beaulieu et al., 2014) and the 100,000 
Genomes Project (Caulfield et al., 2015). Defining disease entities (i.e a patient or 
a known genetic disease) with the same phenotypic language enables algorithmic 
comparison between them and several have been proposed (discussed in next 
section). The HPO also release ‘negative’ annotations, where HPO terms NOT 
presented in a particular genetic disease are listed. 
1.2.3 SNOMED CT 
SNOMED CT (Systematised Nomenclature of Medicine – Clinical Terms) 
(IHTSDO, 2014) is a standardised, multilingual clinical terminology developed 
over the past 40 years. It is used by physicians and healthcare providers for the 
storage and exchange of clinical information, as well as to support clinical decision 
making and analytics in software programs. Like the HPO, it comprises 
systematically organised computer-processable medical terms, providing codes, 
terms, synonyms and definitions, although it attempts to cover all medical 
terminology rather than only rare genetic disease phenotypes, resulting in far more 
terms in total (Table 3). It is reportedly used in over 50 countries (D. Lee, Cornet, 
Lau, & de Keizer, 2013) and countries including the United States, United 
Kingdom, Canada, New Zealand and Australia have designated SNOMED CT as 
the recommended clinical reference terminology for clinical information systems 
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(Australian Digital Health Agency, n.d.; Canada Health Infoway, n.d.; Ministry of 
Health - New Zealand Government, 2017; NHS, n.d.; U.S National Library of 
Medicine, 2018). There is a wealth of SNOMED CT annotations contained in 
electronic health records of user countries and OMIM clinical synopses also 
contain mappings to SNOMED (Amberger et al., 2014). 
1.2.4 ICD 
The International Classification of Disease (ICD) is a system for the classification 
of disease to permit the “recording, analysis, interpretation and comparison of 
mortality and morbidity data collected in different countries or areas and at 
different times” (World Health Organisation, 2010). It is primarily used to record 
hospital episode statistics so that the maximal amount of machine-readable clinical 
information is available on health records, as well as for the tracking of 
epidemiological trends and for billing purposes. OMIM disorders also contain 
mappings to ICD codes (Amberger et al., 2014). 
Recently, clinical coding on electronic health records in the form of ICD codes has 
been linked with genetic data in several projects, such as HUNT (Krokstad et al., 
2013), MGI (Michigan Genomics Initiative) (The Michigan Genomics Initiative, 
2016), DiscovEHR (Dewey et al., 2016) and UK Biobank (UK Biobank, 2018). 
ICD codes have been used to recruit individuals for GWAS (Howard et al., 2018; 
Mitchell et al., 2016)  They have also been used for PheWAS studies, where 
genotype data is probed for an association with a range of clinical phenotypes, 
commonly as ICD codes (Denny et al., 2013, 2011, 2010; Ritchie et al., 2013; 
Verma et al., 2018).  
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Table 3: Number of clinical terms contained in the HPO, SNOMED and ICD-10 ontologies 
(comparison undertaken in 2014). 
 Ontology Number of terms 
HPO (all) ~11,000 
- HPO (phenotypic abnormality) ~10,000 
SNOMED (all) ~300,000 
- SNOMED CT (clinical finding) ~100,000 
- SNOMED CT (disorder) ~60,000 
ICD-10-CM (clinical modification) ~90,000 
1.2.5 Other biomedical ontologies 
The National Center for Biomedical Ontology (Musen et al., 2012) lists 716 
ontologies, spanning fields such as medical procedures, drugs, anatomy and many 
organism-specific ontologies. Relevant biomedical ontologies to human 
phenotypes (P. N. Robinson & Mundlos, 2010) include Gene ontology (GO) 
(Ashburner et al., 2000; The Gene Ontology Consortium, 2017), the Mammalian 
Phenotype Ontology (MPO) (Smith & Eppig, 2012), the Foundational Model of 
Anatomy (FMA) ontology (Rosse & Jr., 2007), the Sequence Ontology (Eilbeck et 
al., 2005), the Cell Ontology (Bard, Rhee, & Ashburner, 2005), the Chemical 
Entities of Biological Interest (ChEBI) ontology (Hastings et al., 2016) Orphanet 
Rare Disease Ontology (ORDO) (Maiella et al., 2013) and [human] Disease 
Ontology (DO) (Kibbe et al., 2015). 
1.2.6 Why this thesis will focus on HPO 
The HPO is a clinical resource, specifically designed for the study of rare diseases, 
whereas SNOMED CT and ICD are both primarily used for health provider 
analytics and billing and the user guide for the ICD states that “The ICD is neither 
intended nor suitable for indexing of distinct clinical entities” (World Health 
Organisation, 2010). The HPO is the dedicated ontology for the phenotyping of 
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patients on several rare disease projects (Beaulieu et al., 2014; Caulfield et al., 
2015; The Deciphering Developmental Disorders Study, 2014), and much of the 
published methodology for storing and using patient phenotypes to identify 
differential diagnoses and causative genes is based on the HPO (Bauer, Köhler, 
Schulz, & Robinson, 2012; Girdea et al., 2013; Köhler et al., 2009; Peter N. 




1.3 Established HPO methodologies 
1.3.1 Calculating similarity between two sets of HPO terms 
Use of standardised phenotypic language within an ontology structure to describe 
disease has enabled algorithmic comparison between two disease entities 
composed of phenotypic terms. Algorithmic scoring of similarity between sets of 
disease entities could be either: 
• Patient to patient: for establishing cases of similar phenotypes in gene 
discovery (and potentially dissimilar cases to use as controls). 
• Patient to known disease: for establishing most likely phenotypic matches 
to patient(s), enabling personalised lists of candidate genes. 
• Known disease to known disease: for analysis of similarity between known 
diseases and to reveal common disease aetiologies and gene pathways.  
There are many different methods that can be used to calculate similarity between 
two entities comprising ontology terms, many of which have been proposed to 
algorithmically calculate similarity between groups of gene ontology (GO) terms 
(Pesquita, Faria, Falcão, Lord, & Couto, 2009) – these methods will be discussed 
in the context of calculating similarity between disease entities, which are 
represented as constellations of phenotypic terms, regardless of whether they may 
have originally been developed for similarity between HPO terms, GO terms or for 
other semantic similarity applications. Measuring similarity between two sets of 
groups of ontology terms generally consists of two stages. Firstly, a measure of 
similarity is defined between individual terms, and secondly, these individual term-




1.3.2 Term-wise similarity 
Similarity between terms can be measured based on nodes or edges (or hybrid 
methods). Edge-based similarity commonly relies on distance between two nodes 
(or between the nodes and their common ancestor). However, edge-based methods 
are rarely used because they rely on nodes and edges being uniformly distributed 
throughout the ontology, and that edges within an ontology represent a consistent 
semantic distance – often, neither of these assumptions are true within biomedical 
ontologies (Pesquita et al., 2009).  
Node-based measures compare terms based on properties of the terms themselves, 
which could relate to their ontological relationships or information external to the 
ontology (e.g. probability of finding them within a particular corpus). A metric that 
is often incorporated is information content (IC), a measure of how specific a term 
is, and the central idea is that a pair of terms with a specific common ancestor 
should be scored as more similar than a pair of terms with a more general common 
ancestor. The IC of a term is calculated by taking the negative log likelihood of it 
appearing in the corpus (Equation 2) – for the purposes of HPO phenotypic 
similarity, this could be the likelihood of it being annotated to a particular OMIM 
disorder. Note that the corpus used will bias the IC values for each term – different 
knowledge bases will represent different terms (or sub-groups of terms within an 
ontology) at differing frequencies which will affect how specific each term is 
perceived to be. 
Equation 2: Information Content of term t 
(𝑡) =  −log 𝑝(𝑡) = −log (





Table 4: OMIM frequency and resultant information content (IC) for selected HPO terms 
from Figure 1. Column 2 denotes the position on the ontology in Figure 6. 
HPO term Fig. 6 OMIM freq. IC 
Phenotypic abnormality - HP:0000118 1 6518 0 
Abnormality of the cardiovascular system - HP:0001626 2 1688 1.35 
Abnormality of cardiovascular system morphology - HP:0030680 3 961 1.91 
Abnormal heart morphology - HP:0001627 4 869 2.01 
Abnormality of cardiac atrium - HP:0005120 5 213 3.42 
Abnormality of the cardiac septa - HP:0001671 6 369 2.87 
Abnormality of the atrial septum - HP:0011994 7 212 3.43 
Atria septal defect - HP:0001631 8 211 3.43 
Common atrium - HP:0011565 9 2 8.09 
 
 
Figure 6: Simplified representation of the subsection of the HPO in Figure 3, for reference 
of Table 4. 
Table 4 shows the IC of selected nodes within the HPO. Note that child nodes 
always have higher IC values than their parents due to implicit ancestor annotation. 
The Resnik measure (Equation 3) uses the IC of the most informative common 
ancestor (MICA) to calculate similarity between terms (Resnik, 1999). Using 
Resnik as an example, the highest similarity between terms in Table 4 would be 
two ‘Common atrium’ terms (IC = 8.09) as logically, the MICA of two identical 
terms would be the term itself. This would be followed by ‘Atria septal defect’ and 
‘Common atrium’, for whom the MICA would be ‘Abnormality of the cardiac 
atrium’ (IC = 3.42). The similarity between ‘Abnormality of cardiac atrium’ and 
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‘Abnormality of the cardiac septa’ (or two terms which specific properties of one 
each of these, but not both) would be lower as the MICA is the much more general 
‘Abnormal heart morphology’ (IC = 2.01). 
Equation 3: Resnik similarity between two terms (Resnik, 1999). 
𝑠𝑖𝑚(𝑡1, 𝑡2) = (𝑀𝐼𝐶𝐴(𝑡1, 𝑡2)) 
Other node-based measures including Lin (Equation 4) and Jiang-Conrath 
(Equation 5) use modified measures of term specificity which also consider the 
relative specificity of the MICA in comparison to that of the terms (therefore 
measuring distance within the ontology). 
Equation 4: Lin similarity between two terms (Lin, 1998). 
𝑠𝑖𝑚(𝑡1, 𝑡2) =
2 × (𝑀𝐼𝐶𝐴(𝑡1, 𝑡2))
(𝑡1) + (𝑡2)
  
Equation 5: Jiang-Conrath similarity between two terms (Jiang & Conrath, 1997). 
𝑠𝑖𝑚(𝑡1, 𝑡2) = (𝑡1) + (𝑡2) − 2 × (𝑀𝐼𝐶𝐴(𝑡1, 𝑡2)) 
1.3.3 Aggregating term-wise similarities between two disease entities 
1.3.3.1 Pairwise 
With a schema that defines similarity between a pair of terms, it is then necessary 
to define how these similarities would be aggregated when comparing two groups 
of terms. Pairwise approaches involve taking an average of the pairwise 
combinations between terms. An average of all pairwise combinations doesn’t 
perform well as it includes far too many terms in the equation, and instances of 
high similarity between particular terms lose relevance when the average is 
calculated. Conversely, using the maximum similarity value between all pairwise 
combinations of the terms excessively reduces the information. One solution is to 
use the best-match average (Equation 6) which balances between the two, and this 
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has proved to be beneficial when benchmarking phenotypic similarity performance 
(Buske, Girdea, et al., 2015; Pesquita et al., 2009). The best-match average gives 
asymmetric similarities between two annotated phenotypes [sim(Q,D) ≠ sim(D,Q)] 
so similarities are often made symmetrical using Equation 7. The use of Resnik to 
measure similarity between term nodes (Equation 3) combined with best-match 
average term similarity (Equation 6) and conversion to a symmetrical score 
(Equation 7) will be referred to as Resnikavg,max|sym from hereon. 
Equation 6: Best-match average term similarity between diseases Q and D 





Equation 7: Symmetrical similarity between diseases Q and D. 
𝑠𝑖𝑚𝑠𝑦𝑚𝑚𝑒𝑡𝑟𝑖𝑐(𝑄, 𝐷) =  
1
2
𝑠𝑖𝑚(𝑄 → 𝐷) +  
1
2
𝑠𝑖𝑚(𝐷 → 𝑄) 
1.3.3.2 Groupwise 
Groupwise measures simplify the ontology graph to sets of terms so that set 
similarity methods can be used. One such example is the Jaccard index (Equation 
8), which can be modified to weight terms by IC (Pesquita, Faria, Bastos, Falcão, 
& Couto, 2007). Groups of terms can also be represented as vectors, using the 
cosine rule to evaluate similarity (Equation 9). Vectors could be binary (set to 1 if 
disease is annotated HPO term; 0 if disease isn’t annotated with HPO term), 
although vector models are frequently used in information retrieval as vector 
features can be weighted by information content, as well as the frequency with 
which terms are found in text (which may have relevance in cases where certain 
phenotypic features have variable prevalence in different diseases). Quantification 
of phenotype terms and the use of vectors and cosine similarity has been used 
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outside of a clinical context in human phenome analysis (Lage et al., 2007; van 
Driel, Bruggeman, Vriend, Brunner, & Leunissen, 2006). 
Equation 8: Jaccard index, measuring similarity based on the size of the intersection 
between two groups of terms divided by the size of the union. 




Equation 9: Cosine similarity between vectors Q and D 





1.3.4 Differential diagnosis 
There are existing tools that calculate similarity between a group of HPO terms 
describing a patient and the full knowledge-base of human disease. One such 
example is the Phenomizer (Köhler et al., 2009), which uses a best-match 
Resnikavg,max|sym followed by an estimation of statistical significance to provide 
differential diagnostic phenotypes. BOQA utilises a groupwise graph-based 
approach, weighting similarity between nodes based on the probability of type I or 
II error associated with observing the similarities and differences of a query set of 
terms and a reference set of terms.  
1.3.5 Phenotype data storage 
Phenotips (Girdea et al., 2013) is a an open source software for the collection and 
analysis of patient phenotypic information, primarily in the format of HPO terms. 
It also facilitates data entry for patient demographics, medical history, family 
history, physical and laboratory measurements, physical findings and additional 
notes. Phenotips has been implemented as the standard patient information record 
in large rare disease sequencing projects such as FORGE/CARE4RARE (Beaulieu 
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et al., 2014) and the NIH Undiagnosed Diseases Program (UDP) (Gahl et al., 2016), 
as well as in genetics clinics in the UK/worldwide. 
Phenotips contains an OMIM phenotype recommender based on semantic 
similarity metrics like those of the Phenomizer discussed previously. However, this 
implementation also accounts for general population frequency of disorders taken 
from Orphanet (Rath et al., 2012) (i.e. more frequent disorders in general 
population more likely to be recommended), negative phenotypes, and handles 
free-form text inputs. However, this hasn’t been benchmarked as a diagnostic tool 
and exists only to estimate and recommend a list of the 20 most likely disorders. 
Phenotips has also integrated Phenomizer (Köhler et al., 2009) and BOQA (Bauer 
et al., 2012) similarity calculations for patients.  
1.3.6 Phenotype-driven genome/exome interpretation 
Several tools have been developed that incorporate disease similarity calculations 
for the prioritisation of variants. 
EXtasy (Sifrim et al., 2013) combines a number of different variant annotations 
(which consist of conservation and deleteriousness scores) with a gene phenotype 
score, which is generated by calculating similarity between the candidate gene and 
known genes associated with the patient phenotype, based on shared gene 
annotations using the Endeavour algorithm (Aerts et al., 2006). A random forest 
classifier is used to combine the variant annotations and the gene phenotype score 
into a final variant score. 
Phevor (Phenotype Driven Variant Ontological Re-ranking) (Singleton et al., 
2014) makes use of the annotated links between the HPO (Human Phenotype 
Ontology), MPO (Mammalian Phenotype Ontology), DO (Disease Ontology) and 
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GO (Gene Ontology), propagating information about patient phenotypes (encoded 
in HPO terms) across and throughout these ontologies to build candidate gene 
scores. Candidate gene scores are then combined with variant scores to produce a 
final prioritisation score. 
Phen-Gen (Javed, Agrawal, & Ng, 2014) scores both coding and non-coding 
variants in a unifying framework that estimates their highest possible impact, using 
different data sources for different types of mutation. Gene phenotype scores are 
calculated using Phenomizer (Köhler et al., 2009) probabilities, and these gene 
scores are then expanded to genes not previously associated with disease using a 
random walk algorithm across a gene-gene interaction network. For each gene, the 
variant and gene phenotype scores are then combined using a Bayesian framework. 
PhenIX (Zemojtel et al., 2014) combines variant frequency and deleteriousness 
prediction tools to score exome variants. Phenomizer (Köhler et al., 2009) 
similarity metrics are used to score genes by their disease phenotype similarity to 
the patient’s HPO terms. Only genes mapped to Mendelian phenotypes from 
OMIM/Orphanet/DECIPHER databases (termed the disease-associated genome) 
are scored with respect to phenotype. The variant and gene phenotype scores are 
combined into a single score for variant prioritisation, including a step where the 
variant score is modified based on the suspected mode of inheritance.  
PHIVE (Peter N. Robinson et al., 2014) uses the PhenoDigm algorithm (a variant 
of the best-match Resnik algorithm with a final normalisation step) (Smedley et al., 
2013) to calculate similarity between patient HPO terms and mouse mutants 
associated with each gene, making use of mappings between the HPO and the 
Mammalian Phenotype Ontology (MPO). Although a finding in a gene previously 
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unreported to be involved in human disease may be insufficient to issue a clinical 
diagnostics report, utilising mouse models enables a much higher coverage of the 
protein-coding exome for genetic analysis and can provide good candidates for 
follow-up. 
hiPHIVE (Smedley et al., 2015) incorporates the mouse models of PHIVE, as well 
as zebrafish and human phenotype data and protein-protein interaction data. 
1.3.7 Phenotype matchmakers 
As mentioned in 1.1.6, the discovery of novel genes in rare monogenic disorders 
requires recruitment of sufficient patients with the same disease to perform genetic 
analysis with the ability to rule out non-pathogenic variation (hence, honing in on 
pathogenic variation). Disease cases can often be both rare and sparsely located 
across the world – usually not united by a single healthcare record system. There 
are several phenotype “matchmakers” employed worldwide that link rare disease 
patient phenotype data to genetic data, and utilise HPO-based methods to identify 
similar patients so that genetic analyses can be undertaken. DECIPHER 
(Chatzimichali et al., 2015), GeneMatcher (Sobreira, Schiettecatte, Valle, & 
Hamosh, 2015) and PhenomeCentral (Buske, Girdea, et al., 2015) all facilitate the 
storage of patient phenotype and genetic data, each offering internal phenotype and 
gene matchmaking services to identify similar patients using HPO ontology 
similarity metrics previously discussed. These matchmakers are also united to 
enable external matching across the three different platforms with the Matchmaker 
Exchange API, which enables patients external to the aforementioned databases to 
be queried to each database (Buske, Schiettecatte, et al., 2015). 
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1.4 Challenges of phenotype similarity methodology 
addressed in this thesis 
1.4.1 Drawbacks of existing phenotype similarity and diagnostic 
methodologies 
Existing candidate variant prioritisation methods have been shown to be effective 
in a handful of cases or simulated patients/exomes (Peter N. Robinson et al., 2014; 
Singleton et al., 2014; Zemojtel et al., 2014), although the underpinning phenotype 
similarity metrics have limitations. Clinical features are annotated to phenotypes 
as binary present/absent observations which are unable to describe the relevance of 
each phenotypic feature to the overall disease. For example, primary microcephaly-
1 (MIM #251200) is characterised by 16 ‘Phenotypic abnormality’ terms in the 
curated HPO annotation set, including the core feature ‘Microcephaly’ (HP: 
0000252) as well as other features of lower penetrance (such as ‘Renal 
hypoplasia/aplasia’ – HP: 0008678). Binary annotation is unable to reflect the 
relative importance of terms in similarity calculations, in this case weighting the 
cardinal ‘Microcephaly’ feature equally to non-obligate features such as ‘Renal 
hypoplasia’ and ‘Hyperreflexia’. Although penetrance data is recorded for a 
proportion of HPO phenotype annotations (41% of current HPO curated 
annotations have quantification information with 48% of diseases containing at 
least one quantified phenotype term), pairwise term similarity measures such as the 
Resnikavg,max|sym do not utilise this information, although BOQA (Bauer et al., 2012) 
is a Bayesian query tool that has been built to utilise the limited existing penetrance 
information. Regardless, it is unclear how non-quantified terms, which remain in 
the majority, should be encoded and whether they should be assumed to be fully 
penetrant to the disease or not – it is uncertain if the annotations without associated 
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frequency information belong to this distribution of recorded annotation 
frequencies (Figure 7) or can be assumed to be fully penetrant. 
 
Figure 7: Boxplot showing the wide range of penetrance frequencies associated with 
annotations of HPO terms to OMIM diseases (n=49,216 annotations), including 
conversion of text-based frequencies (“Hallmark”, “common”, etc) according to guidelines 
(P. N. Robinson & Mundlos, 2010). Based on curated OMIM HPO annotation set 
benchmarked in Chapter 2 used for metrics (Table 5, page 75). Box whiskers represent 
furthest data points within 1.5 × IQR (interquartile range). 
Considering these limitations, this thesis investigates the use of a quantitatively 
annotated reference disease set, where HPO terms were weighted by relevance to 
their diseases (Figure 8). There is a wealth of free-text describing disease 
phenotypes, particularly in OMIM where it is already directly mapped to the 
disease (and genes). Simple text mining of these free-text disease descriptions is 
able to provide an effective weighting schema that can estimate the relative 
importance of each phenotypic characteristic to each phenotype, and this was 
utilised to generate phenotype annotations, using term frequency to approximate 
relevance. 
The utility of text-mined reference annotations was established by comparison to 
the curated annotation set of the same diseases employed by HPO-based tools that 
perform phenotype similarity searches between queries and reference human 
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Mendelian disorders (Bauer et al., 2012; Köhler et al., 2009). The quantified text-
mined phenotype annotations were also compared against an unquantified version 
of the same annotation set. Secondly, a vector space model (VSM) was used that 
evaluates cosine similarity between HPO-annotated diseases, comparing this to 
Resnikavg,max|sym similarity implemented in the Phenomizer, as well as the BOQA 
algorithm (Bauer et al., 2012). In this thesis it is hypothesised that the use of text-
mined phenotype term quantification to represent relevance, combined with a 
suitable similarity measure, would enhance our ability to identify similar diseases.  
 
Figure 8: Schematic representing how text-mining can quantify the relevance of certain 
phenotypic characteristics to the overall disease (lower panel) compared to a lack of 
quantification (upper panel), using Primary microcephaly-5 (OMIM:605481) caused by 
ASPM gene as an example. In the lower panel, frequency of HPO terms found in the 
OMIM description is roughly represented by the diameter of the circles. 
Benchmarking procedures employed in this thesis range from simulation of 
phenotype queries using known clinically similar entries on OMIM (Phenotypic 
Series) (Amberger et al., 2014), through to testing on real patient data. Phenotype 
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similarity methodologies were used to firstly to predict DDD patient diagnoses 
based on their clinician-assigned HPO terms (Wright et al., 2015), and then used 
to predict causative variants in patients from the Guy’s Hospital genetics clinic 
which had also been assigned HPO terms (n=103).  
1.4.2 Common complex disease phenotypes from questionnaire data 
In common complex disease, collected phenotype data can be used for analysis of 
subphenotypes (Nikpay et al., 2015) or extreme phenotypes (Al Olama et al., 2014), 
though these are often limited to the selection of one or few subphenotypes. There 
is an increasing number of studies using collected phenotype data from electronic 
health records to conduct genome-wide association analysis on common disease, 
which utilise coded data (e.g. ICD9-10-11) (Dewey et al., 2016; Krokstad et al., 
2013; The Michigan Genomics Initiative, 2016; UK Biobank, 2018), some of 
which is self-reported. Here, extensive phenotype questionnaire data collected in 
severe acne patients is used to systematically identify subphenotypes for which 
there is power to conduct novel GWAS analyses. The analysis of more 
homogenous populations of cases expressing sub-phenotypes can empower GWAS 
studies to identify novel loci associated with specific disease subphenotypes 
(Eichler et al., 2010; Kulminski et al., 2016; MacRae & Vasan, 2011), and it is 
hypothesised that the increased granularity of phenotype information recorded in 
questionnaires will enable novel associations to be identified between genomic loci 
and subphenotypes of acne.   
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 Chapter 2 - Improvements in measures of rare 
disease phenotype similarity 
2.1 Introduction 
Documented human phenotype-gene pairs have been curated for the purpose of 
cataloguing genes, genetic phenotypes and the ever-increasing numbers of reported 
gene-phenotype causal relationships, to enable user-friendly searching for clinical 
and molecular genetic researchers (Amberger et al., 2014). The representation of 
phenotypes in free-text is problematic for standard searching algorithms, but the 
majority (84% ; 6,902 of 8,184 in February 2016) of OMIM phenotypes are now 
also represented as composites of HPO terms – a machine-readable language that 
is more suited to algorithmic searching (P. N. Robinson & Mundlos, 2010). Despite 
the initial automated concept recognition stage used during the inception of the 
HPO to create the first set of OMIM-HPO annotations, these annotations are 
manually curated by the developers of the HPO and any medical concept initially 
annotated automatically to an OMIM disorder was later manually ratified (Peter N. 
Robinson et al., 2008).  
Querying patient phenotype information to known phenotype-gene pairs is used for 
the suggestion of differential clinical diagnoses for patients, as well as for the 
identification of candidate genes for genetic diagnoses (which can be found 
through mapping to genes of similar phenotypes with known genetic cause). Many 
similarity metrics have been proposed for the calculation of similarity between two 
disease entities comprising HPO terms, including: 
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- Symmetrical, best-match average Resnik (Resnikavg,max|sym) (Resnik, 1999) 
similarity measure, which is the basis of the Phenomizer (Köhler et al., 
2009), PhenIX (Zemojtel et al., 2014) and Phen-Gen (Javed et al., 2014). 
- BOQA, a Bayesian graph-based measure weighted by probability of type I 
and II errors involved in differences between reference disease annotation 
and query. 
- PhenoDigm, used to calculate similarity between human phenotypes and 
mouse models (Smedley et al., 2013), the basis of PHIVE exome variant 
prioritisation (Peter N. Robinson et al., 2014). 
The phenotype similarity methods that calculate patient similarity to a human 
disease reference set utilise the curated HPO phenotype annotations to characterise 
reference diseases. Monogenic disease phenotypes often consist of ‘core’ features 
(presented by every patient with the disease) as well as ‘non-obligate’ features (not 
presented by every patient with the disease, with variable penetrance), and it is 
important that these are represented in annotations and similarity modelling. The 
HPO annotations contain such frequency information, but it doesn’t cover all 
diseases (41% of annotations have associated penetrance data, with 48% of 
diseases having one or more quantified term). However, pairwise term similarity 
measures do not account for these frequencies. Only the graph-based BOQA is able 
to account for these frequencies but it is still uncertain how the majority of terms 
that do not possess associated frequency information should be encoded, especially 
considering the frequency distribution of known penetrance information in the 
HPO (Figure 7).  
Here, the use of a text-mined reference set of phenotypes was investigated in 
comparison to the manually curated set, using the frequency with which terms 
66
 
appear in free-text phenotypic descriptions as a simple weighting schema that 
encompasses all phenotypes. Also, the use of feature vectors and cosine similarity 
were investigated as a similarity metric, which was hypothesised to perform more 
effectively than a pairwise similarity metric in representing quantified phenotypes. 
Cosine similarity was compared to Resnikavg,max|sym, the basis of a clinical 
diagnostic disease similarity tool and several variant prioritisation tools. The 
performance of these phenotype matching algorithms was benchmarked using 
OMIM phenotypes judged to be clinically similar (in the same OMIM phenotypic 




2.2 Materials and Methods 
2.2.1 Phenotype annotation 
2.2.1.1 Curated OMIM phenotype annotations 
For comparison with text-mined OMIM phenotype annotations, the publicly 
available manually curated OMIM phenotype annotations were used (build #1233, 
Jan 13 2016, downloaded 09/02/16). Only ‘phenotypic abnormality’ annotations 
were used to ensure equivalence with annotations used by Phenomizer. 
2.2.1.2 Text-mined phenotype annotation 
Text-mined phenotype annotations were obtained by extracting phenotype free-text 
descriptions from OMIM (date: 05/02/16) and submitting to the NCBO Annotator 
API (Shah et al., 2009) to identify instances of HPO terms. Annotator is an open 
Web service made available by the National Centre of Biomedical Ontology 
(Musen et al., 2012) which infers ontology annotations from text. Annotator utilises 
‘an exact string comparison (a “direct” match) between the text and ontology term 
names, synonyms, and IDs’ (Shah et al., 2009). Again, HPO terms were filtered to 
include only ‘Phenotypic abnormality’ terms (HP: 0000118) to ensure equivalence 
to the manually curated OMIM phenotype annotations. 
Due to the different numbers of annotated OMIM phenotypes available for the 
curated set and text-mining (6,902 and 7,600 respectively), benchmarking was 
performed on the intersection of these phenotypes (n=6,518 –Table 5, page 75). 
2.2.2 Phenotype similarity calculation 
2.2.2.1 Resnikavg,max|sym (Equation 3, Equation 6, Equation 7) 
Once annotated, similarity between phenotypes was calculated. The performance 
of the symmetrical max-average Resnik algorithm implemented in the Phenomizer 
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(Köhler et al., 2009; Resnik, 1999) was compared to cosine similarity, which is 
used in various information retrieval methods. 
Equation 3 (repeat): Resnik similarity between two terms (Resnik, 1999). 
𝑠𝑖𝑚(𝑡1, 𝑡2) = (𝑀𝐼𝐶𝐴(𝑡1, 𝑡2)) 
Equation 6 (repeat): Best-match average term similarity between diseases Q and D 





Equation 7 (repeat): Symmetrical similarity between diseases Q and D. 
𝑠𝑖𝑚𝑠𝑦𝑚𝑚𝑒𝑡𝑟𝑖𝑐(𝑄, 𝐷) =  
1
2
𝑠𝑖𝑚(𝑄 → 𝐷) +  
1
2
𝑠𝑖𝑚(𝐷 → 𝑄) 
2.2.2.2 Cosine similarity (Equation 9) 
Diseases are represented as feature vectors, with each dimension indicating the 
presence (or absence) of a particular HPO term. Similarity between two disease 
vectors is measured using the cosine of the angle between them. In this application 
of cosine similarity, the score ranges from 1 (corresponding to an angle of 0⁰, 
indicating identical vectors) to 0 (corresponding to 90⁰, indicating orthogonality). 
In its simplest form a vector space model requires vector components to be set to 1 
(indicating the HPO term is present) or 0 (indicating the HPO term is absent). It 
can be advanced from this simple binary setting using a variety of techniques (this 
implementation incorporates all of the following): 
Use of the semantic inheritance structure of terms; recalling that annotation of a 
particular ontology term implicitly annotates every ancestor of that term on the 
DAG, ancestral terms can also be included in the disease vectors. 
Using term frequency; pertinent when using text-mined annotations, the number of 
times a disease is annotated with a particular HPO term is used.  
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Use of term weights; vector components can be modified by multiplying them by 
the information content (IC) of their terms (Equation 2). This up-weights vector 
features that correspond to specific terms.  
Equation 9 (repeat): Cosine similarity between vectors Q and D 




2.2.3 Simulated queries using OMIM Phenotypic Series 
When benchmarking information retrieval methods, approaches generally involve 
defining a set of entities (diseases) within the corpus that are ‘known’ to be similar 
(by consulting literature/experts or generating simulations) and then observing how 
well a particular method performs in classifying such entities as similar. The 
approach developed here made use of the OMIM phenotypic series (PS) as the set 
of known similar diseases. The OMIM phenotypic series are defined as a set of 
‘phenotype entries [that] overlap significantly in their clinical manifestations’, and 
that they are classified according to clinical judgement, not computed similarity 
(Amberger et al., 2014). Phenotypic series have variable size, grouping from 2 to 
78 diseases (mean = 8.03). There are 353 phenotypic series, covering 2785 diseases 
in the OMIM catalogue (PS information downloaded: 15/02/16).  
For each disease in a phenotypic series, the disease was removed and its terms used 
as a query to the remaining OMIM reference set. The diseases in the remaining set 
were ranked by similarity to the query, evaluating based on the ranks of the diseases 
within the same phenotypic series. Methods were evaluated by conducting this test 
on all diseases in phenotypic series and aggregating the results. Only diseases that 
were annotated by all methods (subscript N in Table 5, page 75) were included in 
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the analysis and diseases in multiple phenotypic series were not used (n=47), 
leaving 2,317 phenotypes. 
2.2.4 Evaluation of simulated queries 
The performance of an individual simulated query is evaluated using the list of 
similar phenotypes generated (n=6,517, one less than the intersection of all 
phenotypes), and based on where the phenotypes in the same PS are situated in this 
list – the higher they are ranked, the better the performance of the method. 
Benchmarking in this chapter does not consider the magnitude of phenotype 
similarity score, only the rankings of phenotypes by similarity score. Due to the 
variable size of the OMIM PS, ‘Top N’ measures of sensitivity are not appropriate, 
nor is only presenting the distributions of the ranks and performing simple 
statistical hypothesis tests to compare between methods. 
2.2.4.1 Interpolated precision-recall 
Receiver operating characteristic (ROC) metrics are commonly used to evaluate 
binary classifier models (the results of the query are dichotomised into ‘similar’ 
and ‘not similar’). The measures that contribute to the ROC curve are true positive 
rate (recall/sensitivity; Equation 10) and false positive rate (Equation 11), 
calculated at a series of ranks and plotting the two measures against each other to 
form a curve, the area under which is descriptive of the performance of the model.  
Equation 10: Recall (R) for a query at rank r. Also known as sensitivity or true positive 
rate. 
𝑅𝑟  =  
𝑠𝑖𝑚𝑖𝑙𝑎𝑟 𝑑𝑖𝑠𝑒𝑎𝑠𝑒𝑠 𝑤𝑖𝑡ℎ 𝑛 𝑟𝑎𝑛𝑘 𝑟
𝑡𝑜𝑡𝑎𝑙 𝑠𝑖𝑚𝑖𝑙𝑎𝑟 𝑑𝑖𝑠𝑒𝑎𝑠𝑒𝑠
 
Equation 11: False positive rate (FPR) for a query at rank r. 
𝐹𝑃𝑅𝑟  =  





Due to the skewed class distribution of this benchmarking (a maximum of 2% of 
the query results are classed “positive”; the rest will be classed “negative”), ROC 
metrics are unsuitable as the relatively large number of “negatives” (the 
denominator of Equation 11) will keep the FPR very low and unable to distinguish 
between different methods. Precision is often used instead of FPR in information 
retrieval evaluation where the class distribution is skewed (Fawcett, 2006). Starting 
from rank 1 and iterating through further ranks, the precision and recall were 
calculated (defined in Equation 12 and Equation 10 respectively) for each query. 
Equation 12: Precision (P) for a query at rank r. 
𝑃𝑟 =  
𝑠𝑖𝑚𝑖𝑙𝑎𝑟 𝑑𝑖𝑠𝑒𝑎𝑠𝑒𝑠 𝑤𝑖𝑡ℎ 𝑛 𝑟𝑎𝑛𝑘 𝑟
𝑟
 
To overcome difficulties in averaging performance over queries with variable 
numbers of positive results, an interpolation step was included (Manning & 
Raghavan, 2009). This involved defining 11 standard recall points (0 … 0.1 … 0.2 
… … 1) and using the maximum precision found above each point as the 11-point 
interpolated precision recall (Equation 13).  
Equation 13: Interpolated precision (I) for a query at standard recall level R 
𝐼𝑅 =  max
𝑅′≥ 𝑅
𝑃(𝑅′) 
To evaluate a method where n queries were tested, the n interpolated precision 
points at each standard recall point were averaged, showing the decline of precision 
as recall increases. It intractable to perform statistical hypothesis tests comparing 
methods represented by 11 different performance values so to facilitate statistical 
comparison between methods, the mean average precision (MAP) was also 
calculated across the queries (Equation 14). MAP is highly correlated with the area 
under a precision-recall curve and the single value metrics (rather than a curve with 
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11-points) enable simple hypothesis testing using a Student’s paired t test 
(Smucker, Allan, & Carterette, 2007). 
Equation 14: Average precision (AP) for a query where N is the total number of results, d 
is the number of relevant results, P(k) is the precision at k results and ∆r(k) is the change 













2.3.1 Phenotype annotation 
OMIM phenotype annotation statistics are shown in Table 5. Compared to the 
curated annotations, unquantified text mining assigned more phenotype terms to 
each disease on average but detected a far narrower range of different terms overall, 
which tended to be more general (closer to the root node). Possible reasons for this 
are that text-mining identifies more general terms where descriptive text is not 
sufficiently specific to distinguish between relevant sub-nodes of the ontology, and 
that additional general terms are identified in the text that annotation curators 
would consider redundant (due to applying a more specific term). These reasons 
would also explain the greater number of total annotations for text-mining, with 
the HPO terms sharing more OMIM phenotypes on average. Text mining also 
detected a lower proportion of the full range of HPO terms due to only using the 
OMIM text description as an input, whereas the curated annotations utilise 
additional data sources, such as published clinical studies and individual clinical 
experience. When the text-mined terms were quantified, it resulted in over double 
the total annotation count. 
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Table 5: Metrics for different methods of annotating the OMIM phenotype catalogue with 
HPO terms. The subscript N denotes the group of phenotypes captured by all annotation 
methods. The subscript X denotes those phenotypes exclusively captured by each 
annotation method (curated vs. text-mined). “Quantified” text-mined annotations reflect 
the frequency with which HPO terms are found in OMIM descriptions, whereas 
“unquantified” annotations have been reduced so the frequency of every term is 1. 










      
Curated 6,902 90,236 6,825 13.2 6.50 
Text mining, unquantified 7,600 105,644 4,719 22.4 6.43 
Text mining, quantified 7,600 230,274 4,719 22.4 6.43 
      
Curated N 6,518 88,533 6,765 13.1 6.50 
Text-mined, unquantified N 6,518 99,126 4,679 21.2 6.43 
Text-mined, quantified N 6,518 215,895 4,679 21.2 6.43 
      
Curated X 384 1,703 918 1.86 6.11 
Text-mined, unquantified X 1,082 6,518 1,598 4.08 6.19 
Text-mined, quantified X 1,082 14,379 1,598 4.08 6.19 
 
2.3.2 Correlation between penetrance data and text-mined frequency 
Where both term penetrance data and text-mined frequency data is available, there 
is a weak positive correlation between them (Figure 9). This becomes slightly 
stronger when removing the penetrance data described in the HPO by words such 
as “Hallmark”, “Common”, “Rare” which have approximate frequency definitions 




Figure 9: Correlation between HPO term penetrance statistics and derived text-mined 
frequency. Text-mined frequency was calculated by dividing term frequency by the highest 
HPO term frequency within the OMIM disease. A: Only congruent HPO annotations were 
considered (i.e. the HPO term was annotated to the OMIM entry in both the curated and 
text-mined dataset) and only OMIM entries that contained at least 5 quantified terms in 
both datasets were considered. This resulted in 5651 HPO annotations being tested, 
spanning 597 OMIM entries. B: HPO terms quantified in the curated dataset using text 
descriptions such as “Hallmark”, “Common”, “Rare”, etc. were excluded, resulting in 435 




2.3.3 Interpolated precision-recall and mean average precision (MAP) 
results 
Two different similarity measures (cosine and Resnikavg,max|sym) and three different 
phenotype annotation methods (curated, quantified text-mined and unquantified 
text-mined) were tested using the OMIM PS as a set of known similar phenotypes 
with which to simulate queries. Only diseases annotated by all methods (n=6,518; 
Table 5) were included in the analysis and diseases in multiple phenotypic series 
were not queried (n=47). 2,317 OMIM PS queries were used for analysis (Figure 
10), which were a good representation of phenotypic spectrum of the overall 
OMIM disease catalogue (Figure 11). Queries were evaluated for each method 
using interpolated precision-recall (Figure 12; Equation 13) and mean average 
precision (Figure 13; Equation 14) was also used as a single value metric for each 
query. Mean average precision (MAP) was highly correlated with interpolated 
precision-recall (Figure 14) and enabled statistical hypothesis testing for 
comparison between methods using a paired Student’s t test. P-values have been 
corrected for multiple testing under dependency (Benjamini & Yekutieli, 2001) 
unless stated otherwise. 
 
Figure 10 fo noitubirtsiD : n umber of OMIM phenotypes in each phenotypic series (PS)  
 ;CQerp( erofeb blue) and after (postQC; orange) removal of phenotypes in multiple 





Figure 11: Range of disease phenotypes tested in the OMIM PS benchmarking, as compared to the full annotated OMIM catalogue (annotated by each method), 




When HPO annotations were not quantified (curated (c) and unquantified text 
mining (u)) the performance of cosine similarity had a modest but significant 
advantage over Resnikavg,max|sym (Pc = 4.62 × 10
-13, Pu = 4.47 × 10
-14), but cosine 
similarity was far superior when the HPO terms were quantified (Pq = 2.83 × 10
-
95) (Figure 12A; Figure 13A). When annotations were not quantified the similarity 
in performance between the two algorithms was expected due to their similar 
premise – Resnikavg,max|sym aggregates similarity in pairwise fashion while cosine is 
a groupwise method, but without quantification the only schema to weight terms is 
the specificity (IC).  
When phenotype annotations are quantified, cosine similarity performs better due 
to its ability to down-weight the vector features of more general terms (which have 
a lower IC) and noise terms (which are likely to be found at a lower frequency to 
‘genuine’ terms) that text mining is more prone to detecting. Using cosine 
similarity, the performance of each annotation method was assessed. Using these 
benchmarking tests and metrics, quantified text mining is superior to curated 
annotation (P = 9.02 × 10-58), although unquantified text mining is inferior to 
curated and quantified methods (P = 2.38 × 10-10 and P = 1.02 × 10-151, 
respectively). Having observed that querying a disease consisting of quantified 
phenotype terms against a quantified reference set was the optimal setting, the 
quantified reference set was tested against others, without quantification of the 
query terms. 
The quantified reference disease set compares favourably to both the curated and 
unquantified text-mined reference sets when using unquantified text-mined queries 
(P = 2.55 × 10-64 and P = 1.38 × 10-63, respectively) (Figure 12B; Figure 13B). 
However, when querying with curated phenotype annotations, a quantified 
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reference set provides no clear benefit in comparison to the curated annotation set 
(P = 0.658a, Figure 12C; Figure 13C). Curated queries were more effective with 
the curated reference set while text-mined queries were more effective with the 
text-mined reference sets.  
                                                 




Figure 12: Average 11-point interpolated precision-recall for 2317 queries using different 
combinations of phenotype annotation and similarity methods.  Similarity measure is 
denoted by linestyle (solid = cosine similarity; dashed = Resnikavg,max|sym). Reference
 tes annotation is denoted by line colour (red = HPO curated annotation;
green = unquantified text mining; blue = quantified text mining). Area under the precision-
recall curve and mean average precision (MAP) are indicated in the legend. A: All 
combinations of annotation and similarity measure were tested, keeping the annotation 
setting of the query the same as the annotation of the reference set. B: All reference 
annotation methods tested with queries from the unquantified text-mined set only. C: All 
annotation methods tested with queries from the curated set only. B&C: only the cosine 




Figure 13: Mean average precision (MAP) plots for 2317 queries using different 
combinations of phenotype annotation and similarity methods (corresponding to the 
interpolated precision plots in Figure 12). A: All combinations of annotation and similarity 
measure were tested, keeping the annotation setting of the query the same as the annotation 
of the reference set. B: All reference annotation methods tested with queries from the 
unquantified text-mined set only. C: All annotation methods tested with queries from the 
curated set only. B&C: only the cosine similarity measure was displayed as it was superior 
to Resnikavg,max|sym in all cases. Box whiskers represent furthest data points within 1.5 × 





Figure 14: Correlation between MAP and 11-pt precision recall AUC for methods in 






This chapter presents a method for the identification of similar diseases where the 
reference diseases were annotated by text mining for phenotype terms, which 
included term quantification to make optimal use of the most relevant phenotypic 
features. This approach offers a clear advantage over current methods that 
incorporate binary phenotype annotations that indicate only the presence or 
absence of clinical terms in genetic disease. Ideally, clinical terms could be 
quantified in the representation of a genetic disease using a full dataset on their 
prevalence among individuals having that disease. However, such a comprehensive 
dataset does not yet exist (41% of current HPO curated annotations have 
quantification information with 48% of diseases containing at least one quantified 
phenotype term) and it is unclear how some currently employed similarity methods 
can integrate knowledge of feature prevalence.  
Whilst frequency extracted from text mining phenotypic descriptions is not 
expected to fully capture the penetrance of terms across affected cases, there is a 
weak positive correlation where term penetrance data is available (Figure 9) and it 
serves as an effective weighting scheme that encompasses all phenotypes. It is 
likely that the performance of this text-mining approach would further improve 
using additional relevant input phenotype descriptions, including for example, text 
input from OMIM literature references and further literature on MEDLINE. This 
method of annotation has obvious limitations – simplistic text mining is unable to 
account for the context in which disease terms are mentioned, and therefore will 
include noise due including terms mentioned following negation or when 
discussing/comparing to other phenotypes. Despite the limitations of this method 
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of annotation, this relatively simple method of term quantification aids the retrieval 
of similar diseases. 
None of the tested methods incorporate HPO negative annotations, which have also 
been curated alongside the HPO disease phenotype annotations file. Although this 
is a potentially useful dataset, as it records phenotype characteristics that are NOT 
presented in genetic disease, it is unclear how similarity methods would incorporate 
this information. With the vector representation of diseases, phenotypic 
characteristics are already set to 0 if they aren’t present in the annotation file – 
perhaps incorporating the negative annotations to set them to a negative number 
could improve performance. Negative annotations could also be used to augment 
the text-mined phenotype annotation file, helping to remove false positive 
annotations. 
Additionally, a cosine similarity measure was investigated as an alternative to 
currently used phenotype similarity measures, as its construction is less sensitive 
to noise associated with quantitative annotation. Resnikavg,max|sym was selected as 
the measure to compare to due to its usage in both differential diagnostic and 
upstream variant prioritisation methods, although ideally these benchmarking 
methods should be additionally applied to BOQA and PhenoDigm methods of 
calculating phenotype similarity. 
Validation involved testing the ability of different combinations of annotation and 
similarity methods to group known similar OMIM diseases closely to each other. 
Quantification of phenotypic information enhanced the ability to identify similar 
diseases, compared to both the curated annotation set and an unquantified version 
of the same reference set, when both the query and reference set are quantified. 
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Cosine similarity performed roughly as well as the Resnikavg,max|sym measure of 
similarity when unquantified reference sets were used, but greatly outperformed it 
when quantifying reference phenotype terms. It is less clear whether the use of a 
quantified reference set is beneficial when the query is not quantified, shown in the 
differential relative performance of the quantified reference set compared to the 
curated reference set when using either unquantified-text mined queries or curated 
queries. Curated queries performed better with the curated reference set and text-
mined queries performed better with the text-mined reference sets. This represents 
a drawback in the validation of the methodologies, as the use of OMIM phenotypic 
series may not resolve potential biases within the reference phenotype annotation 
sets. There is a possibility that some curated annotations are copied across 
phenotypic series, and that text mining makes use of copied text within OMIM 
entries from the same phenotypic series. However, the use of OMIM phenotypic 
series as the known similar diseases enabled the methods to be tested across a 
considerable number of phenotypes (~35% of annotated OMIM records), 
representing a very diverse range of diseases. The validation of phenotypic 
similarity methods is always challenging, as until recently there has not been a large 
amount of real-world data to perform benchmarking on, so simulations or small 
patient datasets are used. In these datasets and simulations it has been standard to 
simulate noise (adding random terms) and imprecision (converting specific terms 
to more general terms) in the queries (Javed et al., 2014; Köhler et al., 2009; 
Smedley et al., 2014; Zemojtel et al., 2014). This has not been performed here – 
the high number (2,317) of queries for these benchmarking metrics, as well as that 
the OMIM phenotypic series contained diseases that were distinct [though 
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clinically similar] entities comprising slightly different phenotypic constellations, 
were considered sufficient for the simulation of noise. 
Work in the next chapter involves the testing of these methods on real patient 
datasets, where consideration is given to the magnitude of the phenotype similarity 
score and its representation of the belief that a particular clinical diagnosis can be 
made and a particular disease gene identified. One drawback of the method 
presented here is that it does not currently incorporate a measure of statistical 
significance, as in the Phenomizer (Köhler et al., 2009), so it is unable to assess 
what level of cosine similarity represents a good match for the particular 
phenotype. However, to run accurate simulations of HPO queries in order to 
calculate P-values, the prevalence for each HPO term must be estimated rather than 
picking any HPO term randomly. The population prevalence (or rare disease 
population prevalence) of clinical phenotypes is difficult to estimate with data 
currently available – Orphanet has prevalence information on many rare disorders 
(Maiella et al., 2013) but these are constellations of phenotypic characteristics 
rather than the characteristics themselves.   
Text mining for phenotype annotations can also have utility in a clinical context; 
its quick and systematic nature could make it highly valuable in large clinical 
genetics services. Manual assignment of clinical ontology terms has only recently 
become widely undertaken and is performed with variable degrees of diligence. As 
an alternative, the text mining of patient clinic letters for phenotypic terms would 
enable rapid and systematic definition of patient phenotypes. Term quantification 
would enable scoring of terms based on the belief that they are truly descriptive of 
the patient, and evidence presented here suggests that querying quantified 
phenotypes onto a quantified phenotype reference set improves performance of 
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phenotype similarity algorithms, so it may be worthwhile to pursue this. The 
incorporation of more sophisticated text mining features such as detection of term 
negation and modifiers for severity would also be of value. Text mining patient 
records that encompass a prolonged period would also enable longitudinal 
phenotype data to be collected. This is particularly pertinent in the context of 
syndromes where different clinical features appear at different ages. Patients could 
then be compared based on their clinical presentation at defined timepoints. 
To summarise, this chapter demonstrates that quantifying clinical terms can be an 
effective method of refining phenotype descriptions, beyond a simple 
representation as binary observations. When calculating similarity, term frequency 
becomes an additional feature by which terms can be weighted rather than only 
their IC. A simple vector-based method has been utilised for calculating cosine 
similarity between quantified phenotypic definitions, which is able to consider term 
frequency and specificity, and this method shows improvement compared to 
currently employed methods in classifying related OMIM diseases as similar.  
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 Chapter 3 - Using patient similarity to a 
reference set to predict disease genes in 
diagnosed cases 
3.1 Introduction 
The previous chapter was an investigation into a novel method of identifying 
similar disease phenotypes, through using different methods of phenotype 
annotation and quantifying similarity. In the following two chapters these methods 
are tested using the molecular diagnosis of real rare disease patients, to evaluate 
their ability to identify causative genes through identifying similar phenotypes to 
the patient.  
This chapter utilises data released by a rare disease sequencing project from the 
DDD consortium, who undertook exome sequencing to attempt to identify the 
causative genetic variants of 1,133 undiagnosed patients with developmental 
disorders (The Deciphering Developmental Disorders Study, 2014; Wright et al., 
2015). There have been several recent projects undertaking the sequencing of 
patients with rare disease for genetic diagnosis, either focussed on one phenotypic 
area (de Ligt et al., 2012; Y Yang et al., 2014; Yaping Yang et al., 2013) or across 
multiple broad phenotypic areas (H. Lee et al., 2014; Sawyer et al., 2016; Taylor 
et al., 2015; Wright et al., 2015). Standard variant filters (frequency, consequence, 
zygosity, predicted pathogenicity) are not sufficient in achieving a diagnosis 
(Bamshad et al., 2011), so genetic variants are either further filtered using a primary 
gene panel for the phenotypic area (H. Lee et al., 2014; Wright et al., 2015) or all 
remaining variants are investigated for causality (de Ligt et al., 2012; Sawyer et al., 
2016; Taylor et al., 2015; Y Yang et al., 2014; Yaping Yang et al., 2013). 
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Diagnostic yields were consistently reported to be between 25 and 30% (Schwarze 
et al., 2018), leaving the majority of patients without a diagnosis. However, it is 
difficult to assess and compare diagnostic rates of rare disease sequencing projects, 
as they may cover different phenotypic areas (where a diagnosis may be 
easier/harder to achieve) and some datasets may contain cases which have been 
previously investigated without a positive finding (and therefore enriched for 
‘difficult’ cases, that indeed may not be monogenic) (The Deciphering 
Developmental Disorders Study, 2014). 
All 1,133 DDD patients were children (median age 5.5 years) recruited to the DDD 
study by their UK NHS or Irish Regional Genetics Service, where patient HPO 
terms were also recorded. The most commonly presented phenotypic features were 
intellectual disability or developmental delay (87% of children), abnormalities 
revealed by cranial MRI (30%), seizures (24%) and congenital heart defects (11%). 
The DDD diagnosis strategy involved exome sequencing all patients (as well as 
performing aCGH on 1,009) to identify SNVs, indels and CNVs. Standard variant 
filters were used to exclude common (>1% minor allele frequency) and non-
functional (not protein-altering) variants. Variants were then filtered by gene, 
retaining only those within genes in the Developmental Disorders Genotype-to-
Phenotype (DDG2P) database (Firth et al., 2009), a continuously updated list 
spanning over 1,000 genes causative of developmental disorders – the November 
2013 version used includes 1,128 genes. Each remaining variant was evaluated 
with respect to its potential causality of the patient phenotype, considering whether 
the patient phenotypic presentation is consistent with phenotypes/syndromes 
caused by the gene, as well as the genetic mechanisms previously reported for 
diseases caused by the gene (autosomal dominant, autosomal recessive, X-linked) 
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and whether this is consistent with the variant consequence on gene product (loss 
of function, activating mutation, increased gene dosage, etc.) (Wright et al., 2015). 
317 patients were reported a likely diagnosis of a SNV, indel or CNV, and a further 
35 patients were reported to have a pathogenic mutation in a novel gene linked to 
developmental disorders following functional validation.  
The phenotype querying methods tested in the previous chapter were tested again 
here on the patients, evaluating their ability to prioritise the correct diagnostic gene 
based on the phenotypic presentation of the patient (using the recorded HPO terms). 
Analysis was initially based on ranks of causative genes, enabling comparison 
between methodologies to be undertaken. Further work was carried out to assess 
the level of belief assigned to the causative gene, based on the magnitude of the 
similarity score rather than the rank. This enabled methodology to be compared 
across different phenotype query methods, but also against the gene panel method 
employed – the gene panel was considered a uniform distribution of belief across 
the ~1,000 genes in the panel, whereas the results of phenotype similarity searching 
confer different levels of belief for each gene. A phenotype query method would 
be considered superior to a gene panel approach if the assigned probability of the 
causative gene was greater than drawing it randomly from all genes in the panel. 
This work involved the rescaling of phenotype similarity scores to value reflecting 
the probability of phenotype similarity, rather than assuming a linear relationship 




3.2 Materials and Methods 
3.2.1 DDD data 
The patient genetic diagnosis data released by the DDD contained 411 reported 
variants, belonging to 351 patients – this included 17 digenic diagnoses where two 
different genes containing pathogenic variants were reported, and the patient 
presented a composite phenotype. The remaining excess of reported variants were 
due to compound heterozygosity, hence two variants reported rather than a single 
homozygous variant. The 317 diagnoses and 35 novel genes added to 351 patients 
with reports (rather than 352) because one patient possessed both a diagnostic 
variant and a variant in a novel gene.  
For straightforward benchmarking, these 351 patient diagnostic reports were 
filtered to 283 patients with pathogenic variants in a single gene (rather than digenic 
diagnoses, CNVs, UPDs or mosaicisms). These monogenic patients were further 
filtered to 258, whose gene mapped to an OMIM phenotype contained in the 
intersection of phenotypes covered by all 3 reference sets tested (Table 5). 
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Table 5 (repeated): The three OMIM reference disease HPO annotation sets tested in this 
chapter. Only OMIM diseases captured by all annotation methods, denoted by subscript 
N, were queried against. The subscript X denotes those phenotypes exclusively captured 
by each annotation method (curated vs. text-mined). “Quantified” text-mined annotations 
reflect the frequency with which HPO terms are found in OMIM descriptions, whereas 
“unquantified” annotations have been reduced so the frequency of every term is 1. 










      
Curated 6,902 90,236 6,825 13.2 6.50 
Text mining, unquantified 7,600 105,644 4,719 22.4 6.43 
Text mining, quantified 7,600 230,274 4,719 22.4 6.43 
      
Curated N 6,518 88,533 6,765 13.1 6.50 
Text-mined, unquantified N 6,518 99,126 4,679 21.2 6.43 
Text-mined, quantified N 6,518 215,895 4,679 21.2 6.43 
      
Curated X 384 1,703 918 1.86 6.11 
Text-mined, unquantified X 1,082 6,518 1,598 4.08 6.19 
Text-mined, quantified X 1,082 14,379 1,598 4.08 6.19 
 
3.2.2 Reference disease annotations and similarity methods 
For these 258 patients, their HPO terms were queried to the same three reference 
disease annotation sets from the previous chapter (curated, quantified text-mined 
and unquantified text-mined; Table 5), again only querying against the intersection 
of phenotypes covered by them (n=6518). 
As with the benchmarking in the previous chapter, the performance of 
Resnikavg,max|sym. Additionally, BOQA (Bauer et al., 2012) was tested using all 
reference sets (all combinations of similarity and annotation methods listed in 
Table 6). BOQA is able to incorporate frequency information, so the frequencies 
associated with curated HPO annotation frequencies were also used. To use BOQA 
with a compatible representation of text-mined phenotype annotation frequencies, 
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term counts were converted to derived penetrance statistics by dividing the count 
of each annotated HPO term by the highest HPO count within the phenotype. 
Equation 3 (repeat): Resnik similarity between two terms (Resnik, 1999). 
𝑠𝑖𝑚(𝑡1, 𝑡2) = (𝑀𝐼𝐶𝐴(𝑡1, 𝑡2)) 
Equation 6 (repeat): Best-match average term similarity between diseases Q and D 





Equation 7 (repeat): Symmetrical similarity between diseases Q and D. 
𝑠𝑖𝑚𝑠𝑦𝑚𝑚𝑒𝑡𝑟𝑖𝑐(𝑄, 𝐷) =  
1
2
𝑠𝑖𝑚(𝑄 → 𝐷) +  
1
2
𝑠𝑖𝑚(𝐷 → 𝑄) 
Equation 9 (repeat): Cosine similarity between vectors Q and D 







Table 6: Methods tested in DDD benchmarking. 
Annotation method Similarity method 
Curated 
Resnikavg,max|sym Text-mined (unquantified) 
Text-mined (quantified) 
Curated 








3.2.3 DDG2P genes 
The DDG2P gene panel (Firth et al., 2009) used in the initial DDD consortium 
diagnostic workflow was the November 2013 version, containing 1,128 genes 
(Wright et al., 2015). For this benchmarking, an updated version of the DDG2P 
panel was used from January 2016 (downloaded: 05/01/16), containing 1,313 genes 
(encompassing 1,814 gene-phenotype relationships), which was presumed to 
contain all the novel gene-phenotype relationships presented in the initial 
publication (The Deciphering Developmental Disorders Study, 2014). This panel 
was filtered to 1,268 genes that possessed causal relationship mappings to OMIM 




3.2.4 Mapping phenotype scores to DDG2P genes – rank analysis 
After querying a patient phenotype with a particular query method, 6,518 
phenotype scores are returned. These similarity scores were converted to gene 
scores for each gene in the DDG2P list (n=1,268) by taking the highest score 
mapping to each gene (some OMIM phenotypes map to multiple genes). The rank 
of the causative gene for each patient is then able to be compared across multiple 
methods. 
3.2.5 Logistic function development – score analysis 
Further analysis considered the magnitude of similarity score returned by similarity 
methods for each gene within the DDG2P panel, and how predictive these were of 
the causative gene beyond selecting the gene from the panel at random. Rather than 
assuming a linear relationship between similarity score and probability of 
similarity, data from the first chapter was used to establish the relationship between 
similarity score and probability of similarity. For each annotation and similarity 
method, each phenotype within an OMIM phenotypic series (PS) was queried back 
to the reference set, using similarity scores between phenotypes in the same series 
as examples of true positive similarity scores, and scores between all other 
phenotypes as examples of false positives. At evenly spaced bins (n=100) 
throughout the range of similarity scores, the proportion of true positive matches, 
T, was calculated (Equation 15). These were plot (Figure 15), and a generalised 
logistic function was selected to fit the data (Equation 16). 
Equation 15: Calculation of T for each bin – TP is the number of scores between “true 








Figure 15: T, the proportion of true positives for each similarity score bin, with the 
generalised logistic function fit. Quantified text-mined phenotypes were queried in this 
example. 
Equation 16: Generalised logistic function fit to the T data using midpoint x of each bin. 
Data was fit to using non-linear least squares, optimising variables K, Q, B, M and v. K: 
the upper asymptote; Q: fixes the point of inflection; B: the growth rate; M: the point of 





The generalised logistic function was fit for each method (apart from BOQA which 
is already calculated probabilistically) and used to rescale the phenotypic similarity 
scores to reflect probability of similarity. These rescaled similarity scores were then 
converted to DDG2P gene scores using the highest disease score that mapped to 





3.3.1 Logistic function optimisation 
For each combination of annotation and similarity methods, a logistic function was 
fit to the fraction of true positive scores within each similarity bin, using 
phenotypes within OMIM PS as true positive matches (Figure 16, Table 7). 
 
Figure 16: Logistic function fit to the fraction of true positive scores within each similarity 
bin (T) for each combination of annotation and similarity methods, using phenotypes 
within OMIM PS as true positive matches. Left: Resnikavg,max|sym; Right: cosine similarity; 
Red: curated; Green: text-mined (unquantified); Blue: text-mined (quantified). 
Table 7: Optimised generalised logistic function variables from Equation 16 for each 
combination of annotation and similarity method. Functions are plot in Figure 16. 
Annotation method Similarity 
method 
K Q B M v 
Curated 
Resnik 
0.847 6.92 0.832 -0.626 0.21 
Text mining, unquantified 1 3.5 0.965 1.15 0.334 
Text mining, quantified 1 1.54 1.09 3.1 0.63 
Curated 
Cosine 
0.81 0.515 6.15 0.207 0.0569 
Text mining, unquantified 1 0.628 5.46 0.753 0.598 
Text mining, quantified 0.678 2.17 15.1 0.807 2.02 
3.3.2 DDD patients 
Of these 351 patient diagnostic reports, 283 were due to pathogenic variants in a 
single gene (rather than digenic diagnoses, CNVs, UPDs or mosaicisms). 258 of 
these monogenic diagnoses were in a gene that mapped to an OMIM phenotype 
which was contained in the intersection of phenotypes covered by all 3 reference 
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sets tested (Table 5). This dataset covers developmental disorders – 49% of patients 
had global developmental delay, as well as roughly 20% presenting microcephaly, 
delayed speech and language development, muscular hypotonia or intellectual 
disability. 81% of these patients were annotated with at least one of these top 5 
terms (Table 8). Compared to the OMIM PS benchmarking, the DDD tests a 
narrower phenotypic spectrum of patients, heavily skewed towards ‘Abnormality 
of the nervous system’, ‘Abnormality of head or neck’ and ‘Abnormality of the 
skeletal system’ (Figure 17). 
Table 8: Most common 15 HPO terms found within the monogenic DDD patient dataset 
(n=258). Terms were limited to only those within two nodes from the end of an ontology 
branch so only the most specific terms are displayed. 
HPO term Description Patient count (/258) 
HP:0001263 Global developmental delay 127 
HP:0000252 Microcephaly 61 
HP:0000750 Delayed speech and language development 54 
HP:0001252 Muscular hypotonia 47 
HP:0001249 Intellectual disability 43 
HP:0100886 Abnormality of globe location 33 
HP:0200006 Slanting of the palpebral fissure 32 
HP:0001999 Abnormal facial shape 29 
HP:0001328 Specific learning disability 27 
HP:0000494 Downslanted palpebral fissures 23 
HP:0000729 Autistic behavior 22 
HP:0000717 Autism 21 
HP:0001290 Generalized hypotonia 21 
HP:0000486 Strabismus 20 





Figure 17: Range of disease phenotypes tested by the two different benchmarking strategies (DDD patients and OMIM PS) , characterised by the proportion of 





3.3.3 Correct gene rank analysis 
The different combinations of reference disease sets and phenotype similarity 
calculation methods (Table 6) were used to rank genes in the DDG2P list (used as 
a virtual panel in the original DDD study (Wright et al., 2015)) to determine which 
methods were most effective in prioritising genes within this large gene panel. 
After querying the 258 patients’ HPO terms to the different OMIM disease 
reference sets, the disease similarity scores were converted to DDG2P gene scores 
using the OMIM gene-disease mappings (taking the top disease score for genes that 
cause multiple OMIM diseases). The ranks of the correct gene for each of the 258 
patients were compared across methods using the Wilcoxon test followed by 
adjustment for multiple testing under dependence. 
There was no significant difference between Resnikavg,max|sym and cosine similarity 
with the unquantified text-mined reference set ) (Figure 18) (P = 0.481a), and with 
the curated reference set the improvement was borderline significant after multiple 
testing correction (P = 0.0210) – this is contrary to the finding in the OMIM PS 
benchmarking in the previous chapter where improvements conferred by vector-
based cosine similarity were significant, though they were only marginal 
improvements. However, using cosine similarity resulted in an improvement for 
the quantified text-mined reference set (P = 1.57 × 10-4), which was consistent with 
the OMIM PS findings of the previous chapter. Using cosine similarity, 
comparison between reference sets showed no significant difference between the 
unquantified text-mined annotation set ahead of the curated annotations (P = 0.36a), 
but the quantified set showed a significant improvement in correct phenotype ranks 
                                                 
a Without multiple testing correction 
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over the curated set (P = 1.39 × 10-4). The quantified text-mined reference set also 
showed a significant improvement in comparison to its unquantified counterpart (P 
= 1.03 × 10-7), again supporting observations in the previous chapter. Using 
quantified text mining in combination with cosine similarity showed dramatic 
improvements over using BOQA with both the same quantified text-mined 
reference set, as well as the curated set for which BOQA could utilise penetrance 
statistics (P = 1.85 × 10-6 and P = 8.62 × 10-6 respectively). There was no significant 
difference between using BOQA with and without the incorporation of phenotype 
frequency data for both the curated and text-mined reference sets (P = 0.325a and 
P = 0.13 respectively). Interestingly, for each reference set, using both BOQA and 
Resnikavg,max|sym similarity methods predicted more correct genes at rank 1 than 
using vector space, although this trend is reversed at rank 10, where vector space 
becomes more sensitive than other similarity methods.  
  
                                                 




Figure 18: Ranks of the ‘correct’ gene for 258 queries from the diagnosed DDD patient dataset, for the different combinations of reference annotations and 
query methods. Only phenotypes in all reference sets were queried (n=6518) and phenotype ranks were converted to DDG2P gene ranks (n=1268). Boxplot 





3.3.4 Correct gene score-based analysis  
Further analysis attempted to rescale the phenotype similarity scores to gene scores 
that reflected the probability of causality for each of the genes in the DDG2P list. 
After querying the patient HPO terms using the different methods, the generalised 
logistic function (Equation 16 with optimised variables for each method delineated 
in Table 7) was used to rescale the phenotypic similarity scores. BOQA outputs a 
probability for each disease and therefore rescaling wasn’t used. The rescaled 
similarity scores were then converted to DDG2P gene scores using the OMIM 
gene-disease mappings (taking the top phenotype score for genes that cause 
multiple OMIM diseases) and normalised to sum to one to give an estimate of the 
probability for each gene. The gene scores of the causative gene for each patient 
were plotted against a baseline of the probability of selecting a random gene from 
the DDG2P list (Figure 19). The rescaled correct gene scores for each of the 258 
patients were compared across methods using the Student’s t test followed by 
adjustment for multiple testing under dependence. 
For each reference set, cosine similarity outperformed Resnikavg,max|sym 
similarity in assigning a higher average probability to the disease-causing gene 
(Figure 19, Table 9), although this advantage is significant only for the curated (P 
= 2.03 × 10-3) and the quantified text-mined reference sets (P = 1.91 × 10-3).  
Compared to vector space and Resnikavg,max|sym, using BOQA to measure 
patient similarity to the respective reference sets resulted in a much higher mean 
probability assigned to the correct gene, which was due to a handful of outlying 
patients having a very high probability assigned to the causative gene (Each BOQA 
method had 15-25 patients with Δ>0.2 for the correct gene). However, both BOQA 
and Resnikavg,max|sym approaches resulted in a low median Δ and performed 
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poorly for the majority of patients (in the best case, 61 of 258 patients had a positive 
Δ). This was also the case when querying the curated reference set using cosine 
similarity, which achieved a high average probability but was also offset by poor 
median performance, with over half of the correct genes having a lower probability 
than selecting the gene at random from the DDG2P list. The quantified reference 
set combined with vector-based cosine similarity space achieved the highest 
median probability for the correct genes. The quantified reference sets also 
achieved the highest number of patients with a positive Δ (probability subtracted 
by prior) for the correct gene. Additionally, the Resnikavg,max|sym similarity 
measure has a slight advantage over vector space in this respect. Again, the 
quantification of both curated and text-mined reference phenotypes made no 




Figure 19: Probability (after logistic function rescaling) assigned to the correct gene for 
258 DDD patient queries to different reference sets using different query methods. 
Probability was plot against a baseline of selecting a DDG2P gene at random (1/1268). 
Number of patients for which probability is higher than randomly selecting a DDG2P gene 
is indicated on the plot. 
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Table 9: Metrics for score-based analysis (after logistic function rescaling) of different phenotype annotation and similarity methods used to identify the 
causative genes for diagnosed DDD patients (from Figure 19). Δ = probability – prior; Fold change = Δ/prior.  
Annotation method Similarity method Average Δ Average fold change Median Δ Median fold change n(Δ > 0) 
Curated 
Resnik 
2.31E-03 2.927 9.26E-04 1.175 198 
Text mining, unquantified 2.69E-03 3.414 1.12E-03 1.422 204 
Text mining, quantified 1.88E-03 2.388 9.01E-04 1.143 220 
Curated 
Vector space 
2.27E-02 28.731 -5.86E-05 -0.074 128 
Text mining, unquantified 2.79E-03 3.532 1.05E-03 1.327 196 
Text mining, quantified 3.43E-03 4.345 1.17E-03 1.479 212 
Curated 
BOQA 
5.33E-02 67.529 -7.79E-04 -0.987 52 
Text mining, unquantified 8.31E-02 105.426 -7.69E-04 -0.975 59 
Text mining, quantified 7.65E-02 97.020 -7.54E-04 -0.956 61 





3.3.5 Correlation between different benchmarking metrics across methods 
Method performance in this benchmarking procedure was assessed using both 
ranks and scores of causative genes, and within the score-based analysis both 
median and average scores were considered. There was a negative correlation 
between the median and average causative gene scores for each method (Figure 20) 
– some methods were able to identify the correct causative gene with very high 
confidence in a small subset of patients but performed poorly on the rest, while 
other methods were able to prioritise the majority of causative genes, but with less 
confidence. The latter group of methods were also stronger at ranking genes, with 
a negative correlation between median gene score and gene rank, whilst the 
opposite is true for the former (Figure 21). 
 
Figure 20: Negative correlation between method average causative gene score and median 





Figure 21: Correlations between different method evaluation metrics. Left – Negative 
correlation between method performance as measured by the median causative gene rank 
and average causative gene score (for all methods in Table 6); Right – Positive correlation 
between method performance as measured by the median causative gene rank and method 






In this chapter the phenotype similarity methods tested in the previous chapter were 
applied to real patient dataset – those of the DDD consortium project (The 
Deciphering Developmental Disorders Study, 2014). Results were largely 
concordant between these tests and the OMIM PS benchmarking of the previous 
chapter, specifically in the correct gene rank analysis (Figure 18) and the median 
correct gene score (Table 9) – the use of cosine similarity was superior to 
Resnikavg,max|sym when reference disease phenotype annotations were quantified, 
and that the text-mined disease reference set was superior to both the unquantified 
text-mined and the curated reference set at prioritising candidate genes. These 
improvements were apparent despite the query HPO terms not having any 
quantification. Whilst the OMIM PS testing may have contained bias, as 
demonstrated by the relatively strong performance when the reference set and 
query were both either curated or text-mined, the DDD dataset contains no such 
bias as it consisted of real patients with HPO terms assigned before diagnosis. It is 
impossible to estimate what bias may be associated with the assignment of HPO 
terms to patients – clinicians may phenotype patients with a particular diagnosis 
under consideration, possibly leading to an ascertainment of phenotypic 
annotations from that particular disorder (from the OMIM clinical synopsis or other 
relevant database). 
However, when comparing to the OMIM PS benchmarking, the DDD tests a much 
narrower phenotypic spectrum of patients, heavily skewed towards ‘Abnormality 
of the nervous system’, ‘Abnormality of head or neck’ and ‘Abnormality of the 
skeletal system’ (Figure 17). These methods are developed for patients across the 
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entire human phenotypic spectrum so such benchmarking may be less predictive 
of how the methods will perform across it.   
This benchmarking makes use of a logistic function to rescale patient-to-OMIM 
phenotype similarity scores to estimate probability of phenotype similarity, rather 
than assume a linear relationship. The logistic functions take the phenotype 
similarity between phenotypes in the same OMIM phenotypic series as the example 
of true similarity, and considers similarity between phenotypes and all phenotypes 
outside their phenotypic series as dissimilar. It is not ideal to use this simulated 
data, but in absence of a large dataset of patients with monogenic diagnoses and 
HPO deep phenotyping, the ~2,000 queries simulated queries was used as a 
pragmatic alternative. The development of the logistic function also assumes a 
constant level of significance for a particular level of Resnikavg,max|sym and cosine 
similarity across all OMIM phenotypes, which may not be the case – for one 
particular OMIM phenotype a certain level of patient similarity score may represent 
a strong match while for another OMIM phenotype this may represent a weak 
match. Again, a large dataset of patients with monogenic diagnoses and HPO deep 
phenotyping would help to resolve this, from projects such as 100,000 genomes 
(Genomics England, n.d.). 
These benchmarking metrics tested whether methods could use patient HPO terms 
assigned prior to genetic diagnosis to predict the causative gene for each patient. 
They primarily work under the assumption that all diagnoses were correct in fully 
explaining the patient phenotype, something which is unable to be assessed here. 
Although these methods seek to predict the causative gene through assessment of 
all gene-phenotype relationships, in practice, the identification of a causative gene 
for a patient is carried out after sequencing, considering only the observed genetic 
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variation – there may be ~1,000 genes in the DDG2P panel used by DDD in this 
example but in practice this panel would be reduced to a few genes in which there 
is observed rare, functional variation. In the absence of available patient genetic 
data, one solution is to simulate exomes and spike in the pathogenic variants, which 
would be a viable next step in benchmarking these methods. However, the strategy 
undertaken here enables the assessment of the candidate gene within all possible 
developmental genes rather than the subset of genes in which there is variation, 
which is less realistic but a more stringent test of phenotype similarity querying 
methods. 
There were interesting correlations between the different rank-based and score-
based method performance metrics, with a negative correlation between the median 
and average causative gene scores for each method (Figure 20). Some methods 
were able to identify the correct causative gene with very high confidence in a small 
subset of patients but performed poorly on the rest (BOQA similarity with all 
reference sets and cosine similarity with the curated reference set), while other 
methods were able to prioritise the majority of causative genes, but with less 
confidence (cosine similarity with the text-mined reference sets). At one extreme, 
the use of BOQA resulted in the identification of the diagnostic gene with very 
high confidence in a small number of patients (<10%) and predicted more causal 
genes at rank 1, although a maximum of 23% of patients had a positive Δ. The 
group of methods with strong median causative gene scores were also stronger at 
ranking genes, as evidenced by the negative correlation between median gene score 
and gene rank, whilst the opposite is true for the former (Figure 21). This 
dichotomy between the two different metrics of method performance represent two 
valid applications of phenotype similarity methodology to candidate gene 
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prioritisation – some methods perform strongly on a small subset of patients, for 
which they can make a highly confident guess at the diagnostic gene, whereas the 
methods developed in this thesis demonstrate strong prioritisation performance 
which would be beneficial to a wider patient population. 
Despite the advances shown by methods developed here, sensitivity remains 
relatively low for the challenging task of identifying disease-causing gene. Each 
combination of methods tested herein failed to assign a high rank to the causative 
developmental gene for a large subset of DDD patients. The top-performing 
method only found the causative gene within rank 10 in 23% of cases and rank 100 
in 56% of cases (Figure 18). However, this is likely to reflect the dataset being 
enriched for patients that had a developmental disorder that was initially difficult 
to diagnose. More straightforward cases would therefore be depleted in this dataset 
(The Deciphering Developmental Disorders Study, 2014), and we would expect 
this methodology to perform better at solving such cases - a valid alternative 
application. In addition, the DDD study also identified novel gene-phenotype links, 
such as that of the MED13L gene. MED13L variants have previously been 
described in patients with congenital heart defects such as dextro-looped 
transposition of the great arteries (d-TGA; MIM #608808) (Muncke et al., 2003), 
but this study identified 8 patients with variants in MED13L gene that had 
intellectual disability but lacked congenital heart malformations (Adegbola et al., 
2015). 
To summarise, this chapter demonstrates the use of methods developed in the first 
chapter to prioritise causative genes using patient phenotypes from a diagnosed 
developmental disorder dataset. This also required the development of a function 
that rescales similarity scores to reflect the probability of phenotype similarity 
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which was trained on known phenotypic similarity data. Methods developed in this 
thesis were superior to methods developed by other groups at ranking the causative 
genes, although some of the previously developed methods were better at 
predicting diagnoses with high confidence in a small subset of the patients. 
Generally, the methods were poor at predicting causative genes for a large subset 
of the patients, although this may have been due to the nature of the dataset tested, 
consisting of patients that were difficult to diagnose. Application to patient data in 
combination with genetic data (performed in the next chapter) may help streamline 
method performance, because the filtered observed genetic variation will reduce 




 Chapter 4 - Use of patient phenotype similarity 
for genetic diagnosis in the clinic 
4.1 Introduction 
This chapter builds on the work done in the previous chapter where phenotype 
similarity methods were applied to the prioritisation of genes within a gene panel 
for patients with developmental disorders. Here, phenotype similarity methods 
were applied to the gene and variant prioritisation of exome-sequenced rare disease 
patients from the Guy’s Hospital genetics clinic with a wide range of phenotypes. 
For patients with both HPO terms and a genetic diagnosis, methods developed in 
the previous two chapters were again compared, measuring their ability to prioritise 
the diagnostic gene and variant. Methods were also compared to a currently 
employed variant prioritisation method, PhenIX (Zemojtel et al., 2014). For 
patients with HPO terms and no genetic diagnosis, the methods were used to aid 
the identification of candidate variants. 
Diagnosis of rare genetic disease has historically been an imprecise process, 
complicated by the differing access of clinicians and patients to diagnostic 
resources (e.g. diagnostic criteria), and that differing clinical specialisations of 
attending physicians may result in focussing on different aspects of patient 
phenotypes (Institute of Medicine (US) Committee on Accelerating Rare Diseases 
Research and Orphan Product Development, 2010). Diagnosis often requires 
timely referral to genetics clinics from primary care physicians that are unlikely to 
recognise a large number of rare diseases (Department of Health & UK 
Government, 2013). Prior to the widespread use of exome sequencing it was the 
clinical geneticist’s role to evaluate the patient’s clinical presentation, and then 
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request the appropriate genetic test to confirm the clinical diagnosis based on expert 
knowledge in rare genetic disease phenotypes and consultation with relevant 
literature (van Zelst-Stams, Scheffer, & Veltman, 2014). Whole exome and whole 
genome sequencing are now commonly employed because of their decline in cost 
– exome sequencing has been demonstrated to be more effective than gene panel 
testing in achieving molecular diagnoses (Neveling et al., 2013). This has changed 
the clinical geneticist’s role – with patient genotypes from the whole exome readily 
available, a single variant that explains the patient’s phenotype (or pair of variants 
in recessive disease) must be identified from within this data.  
To identify a diagnostic variant, it is imperative to provide evidence that it causes 
phenotypes sufficiently similar to the patient (or that the variant is deleterious and 
present within a gene that harbours variation causing similar phenotypes). This is 
implicitly performed when constructing lists of genes that have been reported to 
cause similar phenotypes to that of the patient, which are used as a ‘virtual gene 
panel’ to filter genetic variation alongside standard variant filtering strategies (e.g. 
removal of synonymous and common variation). These gene lists can range from 
small, manually curated lists that are precisely constructed with consideration of 
the patient phenotype, to standard panels used for either narrow or broad disease 
areas (H. Lee et al., 2014; Wright et al., 2015). Gene panels assume a uniform 
distribution of belief across the panel that each gene could be causal – small gene 
lists indicate high confidence but may miss genes, while larger panels do not fully 
capitalise on the phenotypic similarity between the patient and known diseases – 
the DDG2P list comprises over 1,000 genes (Firth et al., 2009; Wright et al., 2015). 
Standard panels can be selectively augmented to include additional genes of 
interest but with the number of known monogenic gene-disease pairs now 
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exceeding 5,000 (Amberger et al., 2014) it is becoming less feasible to manually 
curate personalised virtual panels that incorporate knowledge of the entire human 
rare disease phenotypic spectrum.  
Systematically collected patient phenotype data provides an opportunity to 
implement automated methodology that can utilise exhaustive knowledge of the 
human phenotypic spectrum for the identification of candidate genes. Methods that 
generate candidate gene lists tailored to the patient can offer improvements over 
standard virtual gene panel approaches. Firstly, automated searching across the 
entire human phenotypic spectrum mitigates the aforementioned issue of the 
growing number of known monogenic gene-disease pairs. Secondly, within a 
virtual panel all genes are considered equally likely to cause the disease, whereas 
searching across the entire human phenotypic spectrum confers the ability to score 
each gene based on its relevance to the patient’s disease, enabling the construction 
of more concise and relevant gene panels. 
There are several variant prioritisation tools that utilise machine-readable patient 
phenotypes (annotated as HPO terms) to score genes based on the belief that they 
could harbour variation that would cause the patient phenotype, making use of 
knowledge available in phenotype-gene databases and biomedical ontologies. 
These gene phenotype scores are then combined with variant scores of 
deleteriousness to produce final variant prioritisation scores. As discussed in the 
general introduction, eXtasy (Sifrim et al., 2013), Phen-Gen (Javed et al., 2014), 
Phevor (Singleton et al., 2014), PhenIX (Zemojtel et al., 2014), PHIVE (Peter N. 
Robinson et al., 2014) and hiPHIVE (Smedley et al., 2015) all utilise this multi-
step process of defining both variant and gene phenotype scores and then 
combining them.  
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This chapter focusses on the analysis of exome sequence data of individuals that 
attended the genetics clinic at Guy’s Hospital. Sequence data was available for 200 
individuals, of whom 100 were assigned HPO terms by their clinician on Phenotips 
software (Girdea et al., 2013). Additionally, 95 of the 200 individuals received 
diagnostic variant reports – these were either class 3 (variant of unknown 
significance; VUS), class 4 (likely pathogenic) or class 5 (pathogenic), according 
to the ACMG guidelines (Ellard et al., 2017; Richards et al., 2015). In patients with 
both HPO terms and a likely genetic diagnosis (defined as class 4 or 5 variant 
report), the method comparisons from Chapters 2 and 3 were repeated to estimate 
their abilities to prioritise the correct diagnostic gene by querying patient HPO 
terms to a reference set of diseases. This also required the incorporation of a 
suitable variant filtering strategy. The methods developed in this thesis were 
compared to PhenIX  (Zemojtel et al., 2014) to benchmark their ability to prioritise 
genetic variants based on patient phenotype – PhenIX was selected due to its strong 
performance against other published methods as reported in multiple reviews 
(Pengelly et al., 2017; Smedley & Robinson, 2015). PhenIX scores variants for 
both gene phenotype similarity (using the Phenomizer (Köhler et al., 2009)), and 
variant predicted deleteriousness using CADD (Kircher et al., 2014), PolyPhen2 
(Adzhubei et al., 2013), MutationTaster (Schwarz, Cooper, Schuelke, & Seelow, 
2014) and SIFT (Kumar et al., 2009), and then combines the scores to produce the 
final ranked prioritisation. This final prioritisation score can also be further 
modified to reflect whether or not the variant genotype is consistent with the 
suspected mode of inheritance (if any). 
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4.2 Materials and Methods 
4.2.1 Patient details 
This chapter makes use of patient genetic and phenotypic data from 200 individuals 
that attended the genetics clinic at Guy’s hospital, with exome sequence data 
generated for patients within this group from 2014 onwards. All families provided 
informed consent for patient clinical information and sequence data to be used for 
research. 100 of 200 had HPO terms recorded in PhenoTips (Girdea et al., 2013), 
and 95 of 200 were returned diagnostic reports (following sequencing and analysis 
in the diagnostic lab pipeline, which involved the use of standard variant filters and 
virtual gene panels), of which 65 were class 4 or 5 variants (Table 10). Negative 
HPO term annotations were also included in HPO term annotations, but these were 
not incorporated into any analysis. For a further 20 patients who weren’t assigned 
HPO terms, anonymised clinic letters were provided for the text mining of HPO 
terms to ascertain machine-readable clinical phenotypes. 
Table 10: Number of patients from Guy’s Hospital genetics clinic for whom whole exome 
sequence data was available, indicating numbers of patients with particular classes of 
diagnostic variants and whether (HPO(+)) or not (HPO(-)) their phenotypes were 
annotated with HPO terms. 
 N HPO(+) HPO(-) 
Total patients 200 100 100 
Class 5 diagnostic report 9 7 2 
Class 4 or 5 diagnostic report 65 31 34 
Class 3, 4 or 5 diagnostic report 95 45 50 
No diagnostic report 105 55 50 
 
4.2.2 Exome sequencing analysis pipeline 
For genetic reanalysis, sequences were aligned to hg19 using NovoAlign 
(Novocraft, 2014) and variants were called using SAMtools (H. Li et al., 2009). 
ANNOVAR (Wang, Li, & Hakonarson, 2010) was used for functional annotation 
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of variants, adding information on variant consequence, minor allele frequency in 
1,000 genomes (1000 Genomes Project Consortium et al., 2015), ESP (Fu et al., 
2013)  and ExAC (Lek et al., 2016) datasets, and variant pathogenicity predictions 
using CADD (Kircher et al., 2014), SIFT (Kumar et al., 2009) and PolyPhen2 
(Adzhubei et al., 2013). In-house control database (n=6,000) homozygous and 
heterozygous variant counts were also annotated. 
4.2.3 Virtual gene panels 
Primary virtual gene panels were prescribed for all patients, ranging in size from 1 
to 562 genes. If a pathogenic variant was not found within the primary panel, a 
secondary, and possibly a tertiary, panel was applied – these panels may represent 
the addition of a handful of genes to augment the panel or the introduction of a 




Figure 22: Primary, secondary and tertiary virtual gene panel sizes for each patient 
(n=200). If a secondary or tertiary panel was not used its size was considered to be zero.  
The subscript U denotes that the panel is the union of itself and panels previously 
prescribed – SecondaryU is the union of the primary and secondary panels; TertiaryU is the 
union of the primary, secondary and tertiary gene panels.  
4.2.4 Comparison of phenotype query methods to prioritise genes  
As with analysis in the previous chapter, for the patients with both diagnostic 
reports and HPO terms, the different phenotype query methods were tested and 
their ability to prioritise the correct causative gene was assessed. Of the 31 patients 
with a class 4 or 5 diagnostic report, two had been reported with two variants in 
different genes (i.e. a digenic diagnosis), so they were removed from the analysis 
for simplicity. For the remaining patients their phenotype information was queried 
to the three different reference sets (Table 5) using both cosine similarity (Equation 
9) and Resnikavg,max|sym (Equation 3, Equation 6, Equation 7). OMIM diseases were 
ranked by cosine similarity to the patient, and these phenotypic similarity scores 
were converted to gene scores for all OMIM-mapped genes by taking the highest 
phenotypic similarity score for each gene. Using this procedure, each gene was 
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ranked by phenotypic similarity to the patient, and methods were assessed based 
on the ranks of the diagnostic gene. 
Table 5 (repeated): The three OMIM reference disease HPO annotation sets tested in this 
chapter. Only OMIM diseases captured by all annotation methods, denoted by subscript 
N, were queried against. The subscript X denotes those phenotypes exclusively captured 
by each annotation method (curated vs. text-mined). “Quantified” text-mined annotations 
reflect the frequency with which HPO terms are found in OMIM descriptions, whereas 
“unquantified” annotations have been reduced so the frequency of every term is 1. 










      
Curated 6,902 90,236 6,825 13.2 6.50 
Text mining, unquantified 7,600 105,644 4,719 22.4 6.43 
Text mining, quantified 7,600 230,274 4,719 22.4 6.43 
      
Curated N 6,518 88,533 6,765 13.1 6.50 
Text-mined, unquantified N 6,518 99,126 4,679 21.2 6.43 
Text-mined, quantified N 6,518 215,895 4,679 21.2 6.43 
      
Curated X 384 1,703 918 1.86 6.11 
Text-mined, unquantified X 1,082 6,518 1,598 4.08 6.19 
Text-mined, quantified X 1,082 14,379 1,598 4.08 6.19 
 
Equation 3 (repeat): Resnik similarity between two terms (Resnik, 1999). 
𝑠𝑖𝑚(𝑡1, 𝑡2) = (𝑀𝐼𝐶𝐴(𝑡1, 𝑡2)) 
Equation 6 (repeat): Best-match average term similarity between diseases Q and D 





Equation 7 (repeat): Symmetrical similarity between diseases Q and D. 
𝑠𝑖𝑚𝑠𝑦𝑚𝑚𝑒𝑡𝑟𝑖𝑐(𝑄, 𝐷) =  
1
2
𝑠𝑖𝑚(𝑄 → 𝐷) +  
1
2
𝑠𝑖𝑚(𝐷 → 𝑄) 
Equation 9 (repeat): Cosine similarity between vectors Q and D 






Furthermore, using the logistic function developed in Chapter 3 (Equation 16), with 
the same optimised variables (Table 7), patient-OMIM phenotypic similarity scores 
were rescaled to reflect the probability of true similarity. These were then converted 
to gene scores by taking the top rescaled score for each OMIM-mapped gene, and 
gene scores were normalised to sum to 1.  
Equation 16: Generalised logistic function used to convert phenotype similarity scores (x) 
to a score reflective of probability of phenotype similarity (T). Variables K, Q, B, M and v, 
listed for each method in Table 7, were optimised using non-linear least squares for each 
method in Chapter 3. K: the upper asymptote; Q: fixes the point of inflection; B: the growth 





Table 7: Optimised generalised logistic function variables from Equation 16 for each 
combination of annotation and similarity method. 
Annotation method Similarity 
method 
K Q B M v 
Curated 
Resnik 
0.847 6.92 0.832 -0.626 0.21 
Text mining, unquantified 1 3.5 0.965 1.15 0.334 
Text mining, quantified 1 1.54 1.09 3.1 0.63 
Curated 
Cosine 
0.81 0.515 6.15 0.207 0.0569 
Text mining, unquantified 1 0.628 5.46 0.753 0.598 
Text mining, quantified 0.678 2.17 15.1 0.807 2.02 
 
The list of all genes that have been established as causative of genetic disease has 
been termed the disease-associated genome (Zemojtel et al., 2014) – here, only 
genes that mapped to OMIM phenotypes within the intersection of all phenotypes 
annotated (Table 5) were used (n=3,303). 
4.2.5 Exome variant filtering strategy 
To compare different phenotype query methods to prioritise exonic variants, the 
following variant filtering strategy was employed: 
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- Removal of synonymous variants 
- Removal of homozygous and compound heterozygous variants with a 
minor allele frequency of over 1% in either 1000 genomes (1000 Genomes 
Project Consortium et al., 2015), ESP (Fu et al., 2013) or ExAC (Lek et al., 
2016) databases. 
- Removal of remaining heterozygous variants with a minor allele frequency 
above 0.1%. 
- Removal of homozygous and compound heterozygous variants that appear 
in the in-house variant database (n=6,000 individuals) more than 6 times as 
homozygous (0.1% of individuals) or more than 60 times as heterozygous 
(1% of individuals), and removal of remaining non-compound 
heterozygous variants appearing more than 6 times as heterozygous (0.1% 
of individuals) in the database. 
4.2.6 Comparison of phenotype query methods to prioritise exome variants 
The phenotype query methods were combined with exome variant filtering to test 
their ability to prioritise causative variants. After filtering, remaining variants were 
ranked by gene-phenotype similarity score as ranked by the aforementioned 
methods (4.2.4 - Comparison of phenotype query methods to prioritise genes), and 
compared in their ranking of the causative variant. These were also compared to 
the PhenIX variant prioritisation method (Zemojtel et al., 2014), which scores 
variants on both phenotype similarity (using the Phenomizer (Köhler et al., 2009)) 
and deleteriousness (incorporating CADD (Kircher et al., 2014), Polyphen2 
(Adzhubei et al., 2013) and SIFT (Kumar et al., 2009) and MutationTaster 
(Schwarz et al., 2014) into a single metric), and combines these variant and 
phenotype scores into a single prioritisation score. The variant-only, phenotype-
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only and combined scores were tested. Only variants that passed the filters listed 
above were included in the input VCF for PhenIX to ensure that all variant 
prioritisation was conducted with equivalent inputs.  
Again, using the logistic function and optimised variables for each method 
(Equation 16, Table 7), patient-OMIM phenotypic similarity scores were rescaled 
to reflect the probability of similarity. These were then converted to variant scores 
for each filtered variant by taking the top rescaled score of their OMIM-mapped 
genes, and post-filtering variant scores were normalised to sum to 1 (variants were 
collapsed by gene during score normalisation). 
4.2.7 Text mined patient annotation 
For 14 patients within this dataset (for whom HPO terms were not available) a 
single anonymised clinic letter was made available for text mining of HPO terms 
(Table 11). These clinic letters were written following a visit to the genetics clinic 
and consisted of free form text describing the patients’ clinical phenotype(s), as 
well as listing features present in affected family members where applicable. Two 
of these individuals were reported a likely pathogenic diagnostic variant and two 
others had been reported a VUS. To avoid sending potentially sensitive patient 
information to unauthorised external servers (despite anonymisation), NCBO 
Annotator was not used. Instead, a concept recogniser was built to identify HPO 
terms, synonyms and IDs, equivalent to the NCBO annotator function. 
Quantification was not used for text-mined patient terms, as there would be limited 
benefit to quantifying terms in a single letter describing a clinic visit.  
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Table 11: Number of exome sequenced patients from Guy’s Hospital genetics clinic for 
whom a clinic letter was available for HPO term text mining. 
 Letter(+) 
Total 14 
Class 5 diagnostic report 0 
Class 4 or 5 diagnostic report 2 
Class 3, 4 or 5 diagnostic report 4 






4.3.1 Clinic patient HPO phenotypes 
When categorising patient phenotypes using the top HPO terms directly beneath 
‘Phenotypic abnormality’, the clinic patients demonstrated a reasonably similar 
phenotypic composition to the DDD and OMIM phenotypic series (PS) query 
datasets used in the previous chapters, again most commonly being represented by 
‘Abnormality of the nervous system’, ‘Abnormality of the skeletal system’ and 
‘Abnormality of the head or neck’ clinical terms (Figure 23, Figure 24). 
Additionally, there was some enrichment for ‘Abnormality of prenatal 
development or birth’, ‘’Growth abnormality’ and ‘Abnormality of the 





Figure 23: Range of disease phenotypes presented by the sequenced genetics clinic patients (where HPO terms were recorded), as characterised by the proportion 






Figure 24: Range of disease phenotypes presented by the sequenced genetics clinic patients (where HPO terms were recorded) compared to the phenotypic 
composition of the DDD and OMIM phenotypic series datasets tested in previous chapters, as characterised by the proportion of patients covered by each HPO 





4.3.2 Method comparison on causative gene ranks 
All combinations of methods for calculating gene phenotype similarity to a 
reference set of diseases performed similarly in prioritising genes from the OMIM 
disease-associated genome (n=3,303) (Figure 25).  
 
Figure 25: Ranks of the diagnostic gene for the 29 patients with class 4/5 monogenic 
diagnoses and their phenotype described with HPO terms, using different combinations of 
reference annotations and query methods. Only phenotypes in all reference sets were 
queried (n=6,518) and phenotype ranks were converted to OMIM disease-associated gene 
ranks (n=3,303). Similarity measures: Res – Resnikavg,max|sym; Cos – cosine similarity; 
Disease phenotype reference sets: c – curated; u – text-mined (unquantified); q – text-
mined (quantified). Boxplot limits represent the 5th and 95th percentiles; black diamond 
indicates the mean rank. 
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The ranks of the correct gene for each of the 30 patients were compared across 
methods using the Wilcoxon test followed by adjustment for multiple testing under 
dependence, although before multiple testing correction, no two methods produced 
statistically significant results to one another (P > 0.05). Querying the unquantified 
text-mined reference set with cosine similarity produced the lowest median gene 
rank (42.5 / 3,303), while querying the quantified text-mined reference set with 
cosine similarity produced the lowest mean (215 / 3,303). Using Resnikavg,max|sym 
similarity with either of the text-mined sets resulted in the highest number of 
patients with the causative gene ranked first (4 / 29 patients). Here, there was no 
indication here that cosine was superior to Resnikavg,max|sym, or that there was any 
benefit in quantifying the reference disease phenotype set. 
4.3.3 Method comparison on causative gene scores 
The rescaled scores for the correct gene for each of the 29 patients were plotted 
against the probability of randomly selecting a gene from the OMIM disease-
associated genome (Figure 26). Scores were compared across methods using the 
Student’s t test followed by adjustment for multiple testing under dependence. 
After multiple testing correction, only one comparison was statistically significant 
– the use of unquantified text-mined phenotypes with Resnikavg,max|sym similarity 
was significantly better than using the quantified text-mined phenotypes (with the 
same similarity measure) (P = 1.11 × 10-2). The use of cosine similarity appeared 
to be superior to Resnikavg,max|sym in achieving a higher average fold change in 
correct gene probability above random (Table 12). Additionally, using cosine 
similarity with the curated disease phenotype reference set resulted in the greatest 
average causative gene probabilities for the patient group, but it had fewest patients 
with a probability higher than selecting an OMIM disease-associated gene at 
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random. The curated reference set also outperformed the other reference sets for 
median gene probability. Quantification of the text-mined reference set only 
appeared to be an improvement ahead of the unquantified version in the average 
gene score, and it was the unquantified version that achieved higher median score. 
 
Figure 26: Probability (after logistic function rescaling) assigned to the diagnostic gene for 
the 29 patients with class 4/5 monogenic diagnoses and their phenotype described with 
HPO terms, using different combinations of reference annotations and query methods. 
Probability was plot against a baseline of selecting an OMIM disease-associated gene at 
random (1/3303). Similarity measures: Res – Resnikavg,max|sym; Cos – cosine similarity; 
Disease phenotype reference sets: c – curated; u – text-mined (unquantified); q – text-
mined (quantified). Number of patients for which probability is higher than randomly 
selecting a OMIM disease-associated gene is indicated on the plot. 
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Table 12: Metrics for score-based analysis (after logistic function rescaling) of different phenotype annotation and similarity methods used to identify the 
causative genes for diagnosed genetics clinic patients (from Figure 26) Δ = probability – prior; Fold change = Δ/prior. 
Annotation method Similarity method Average Δ Average fold change Median Δ Median fold change n(Δ > 0) 
Curated 
Resnik 
2.66E-03 8.781 1.14E-03 3.773 27 
Text-mined, unquantified 2.78E-03 9.177 1.06E-03 3.495 27 
Text-mined, quantified 2.02E-03 6.669 8.40E-04 2.775 27 
Curated 
Cosine 
1.35E-02 44.429 2.32E-03 7.677 22 
Text-mined, unquantified 3.64E-03 12.016 1.34E-03 4.417 26 







4.3.4 Exome sequencing 
 
Figure 27: Exome coverage statistics for all sequenced genetics clinic patients (n=200). Percentage coverage (y-axis) given for each individual (x-axis) at 20X, 





Sequence coverage was assessed after exome sequencing (Figure 27, Figure 28). 98.5% of individuals had 75% coverage at 20X (including all 
diagnosed individuals) and 93% had 90% coverage at 20X. 
 
Figure 28: Exome coverage statistics for sequenced genetics clinic patients with monogenic diagnoses and assigned HPO terms (n=29). Percentage coverage 





4.3.5 Exome variant filtering 
Filters were applied to the annotated exome variants leaving a median of 316 
variants in all HPO-annotated patients, of which there were a median of 71 variants 
in OMIM disease-associated genes (Figure 29). 
 
Figure 29: Exome variant filtering statistics, for both the entire HPO-annotated patient 
group (blue; n=100) and the HPO-annotated group with monogenic class 4/5 diagnoses 
(red; n=29). Filtering was applied sequentially, applying steps stated on the x-axis from 
left to right. Patients with low coverage sequencing were not included in this plot. 
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4.3.6 Identification of diagnostic variants 
Of the 29 patients with HPO terms and monogenic diagnoses, the diagnostic variant 
was captured following the exome filtering strategy in 27 cases. The two variants 
that weren’t captured are as follows: 
Variant (i) MED12:NM_005120:exon42:c.6256_6258del:p.2086_2086del  
A heterozygous nonframeshift deletion in exon 42 of MED12 in a patient (HPO 
terms in Appendix 1) with good phenotypic matches to the three autosomal 
dominant MED12 disorders, Opitz-Kaveggia syndrome (OMIM:305450), Lujan-
Fryns syndrome (OMIM:309520) and X-linked OHDO syndrome 
(OMIM:300895).  
The reported nonframeshift mutation was not represented in any of the public 
databases (1,000 genomes, ESP or ExAC), and had no pathogenicity prediction 
scores available. It was observed 8 times as heterozygous in the in-house database, 
and therefore was rejected by the variant filtering strategy. The variant also exists 
in ClinVar with recently reported conflicting interpretations of pathogenicity 
(twice as a VUS, once as likely benign). Although there is a possibility that this is 
the true causative variant due to the phenotypic match, this may a misclassification 
of a variant of unknown significance, as the ClinVar reports were unlikely to be 
available at the time of diagnosis. 
Variant (ii) CREBBP:NM_004380:exon14:c.C2678T:p.S893L 
A heterozygous nonsynonymous SNV in exon 14 of CREBBP in a patient (HPO 
terms in Appendix 1) with a good phenotypic match to Rubinstein-Taybi syndrome 
(OMIM:180849), an autosomal dominant disorder. The variant had a CADD score 
indicative of pathogenicity (21.0), although SIFT and PolyPhen2 scores were less 
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indicative (0.21 and 0.357 respectively). The variant was found at a MAF slightly 
below 0.1% in ExAC and 1,000 genomes, but it was found at 0.14% in ESP and 
therefore was rejected by the filtering strategy used. The variant was also found in 
ClinVar reported as either ‘benign’ or ‘likely benign’, which again may be a 
misclassification made before the reports on ClinVar, despite the strong gene-
phenotype match with the patient and a CADD score that is indicative of 
deleteriousness. 
4.3.7 Method comparison on causative variant ranks 
The phenotype-aware methods of variant prioritisation (all methods but PhenIX-
V, which only considers variant score) all performed reasonably similarly in 
ranking causative variants (Figure 30). The ranks of the correct gene for each of 
the 27 patients were compared across methods using the Wilcoxon test followed 
by adjustment for multiple testing under dependence. No method performed 
significantly better than any other after multiple testing correction (P > 0.05). All 
phenotype-aware methods showed an improvement over the PhenIX variant-only 
score prioritisation, although this difference did not survive multiple testing 
correction. The optimal method for achieving a top median variant rank was cosine 
similarity combined with the unquantified text-mined reference set, which also 
ranked the highest number of causative variants in first place (14 of 27). There was 
no indication that cosine similarity outperformed Resnikavg,max|sym with these 
benchmarking metrics, nor was there any indication that there was any benefit in 
quantifying reference phenotype data. Methods developed in this work performed 
similarly to the PhenIX phenotype and phenotype-variant combined prioritisation. 
There was no indication that incorporating the variant score into the combined 
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score resulted in greater performance of PhenIX (apart from a fractionally better 
average rank). 
 
Figure 30: Ranks of the diagnostic variant (after filtering) for the 27 patients with class 4/5 
monogenic diagnoses and their phenotype described with HPO terms, using different 
combinations of reference annotations and query methods. Only phenotypes in all 
reference sets were queried (n=6,518) and variants were ranked by gene phenotype 
similarity to the patient. Similarity measures: Res – Resnikavg,max|sym; Cos – cosine 
similarity; Disease phenotype reference sets: c – curated; u – text-mined (unquantified); q 
– text-mined (quantified); PhenIX prioritisation settings: PhenIX-V – PhenIX variant 
pathogenicity score; PhenIX-P – PhenIX variant gene phenotype score; PhenIX-C – 
PhenIX combined score. Boxplot limits represent the 5th and 95th percentiles; black 
diamond indicates the mean rank. 
4.3.8 Method comparison on causative variant probabilities 
The scores for the diagnostic variant for each of the 27 remaining patients were 
plot against the baseline probability of selecting variants from a random gene as 
causative, using the median number of post-filtering variants: 62 (Figure 31). Here, 
the post-filtering variants were collapsed by gene (hence the discrepancy with 
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Figure 29). Scores were compared across methods using the Student’s t test 
followed by adjustment for multiple testing under dependence. Using cosine 
similarity combined with the curated reference set was significantly better than all 
other methods but cosine similarity with quantified text-mined phenotypes, 
although it had fewest patients for whom the probability of the diagnostic variant 
was higher than randomly selecting a post-filtering OMIM variant. The curated 
reference set also outperformed the other reference sets for median gene probability 
(Table 13). Using cosine similarity with the quantified text-mined reference 
phenotypes was only significantly better in scoring causative variants compared to 
using Resnikavg,max|sym with the same reference phenotypes. There was some 
indication that cosine similarity was superior to Resnik similarity for these 
benchmarking metrics, which was statistically significant for the curated and 





Figure 31: Probability (after logistic function rescaling) assigned to the diagnostic variant 
for the 27 patients with class 4/5 monogenic diagnoses and their phenotype described with 
HPO terms, using different combinations of reference annotations and query methods. 
Probability was plot using the median number of variants remaining after filtering (whose 
gene was mapped to an OMIM phenotype) as a baseline of selecting a variant at random 
(1/62). Similarity measures: Res – Resnikavg,max|sym; Cos – cosine similarity; Disease 
phenotype reference sets: c – curated; u – text-mined (unquantified); q – text-mined 
(quantified). Number of patients for which probability is higher than randomly selecting a 




Table 13: Metrics for score-based analysis (after logistic function rescaling) of different phenotype annotation and similarity methods used to identify the 
causative variants for the diagnosed genetics clinic patients (from Figure 31). Δ = probability – prior; Fold change = Δ/prior.
 Annotation method Similarity method Average Δ Average fold change Median Δ Median fold change n(Δ > 0) 
Curated 
Resnik 
1.05E-01 6.482 6.37E-02 3.95 25 
Text-mined, unquantified 1.02E-01 6.333 6.95E-02 4.312 25 
Text-mined, quantified 7.76E-02 4.81 4.58E-02 2.839 25 
Curated 
Cosine 
3.11E-01 19.268 1.97E-01 12.191 20 
Text-mined, unquantified 1.24E-01 7.69 7.04E-02 4.366 24 







4.3.9 Candidate variants in patients without diagnoses 
Of the 55 patients without diagnostic reports and with HPO terms describing their 
phenotypes, filtered variants were prioritised according to the results of querying 
the patient phenotype to the quantified text-mined OMIM reference set using 
cosine similarity (and assigned a variant score using the logistic function). Variants 
were evaluated with respect to patient phenotype, their zygosity was compared to 
the reported mode(s) of inheritance of gene OMIM phenotypes, and pathogenicity 
scores from CADD, SIFT and PolyPhen2. This process yielded interesting 




Table 14: Patient I – LRP5 variant(s) identified after querying patient HPO terms to the 
quantified text-mined OMIM disease phenotype reference set using cosine similarity. 
Va [r iatio ]n  gene rank is the rank of the gene within all OMIM disease-associated genes
 rof which there was observed variation that passed the exome variant filters. Variant 
probability is calculated using the same procedure used for benchmarking methods (4.2.6 
- Comparison of phenotype query methods to prioritise exome variants). OMIM 
phenotypes are listed in order of similarity to the patient HPO terms, along with their 
reported mode of inheritance. Minor allele frequencies (MAF), CADD, SIFT and 
Polyphen2 scores, as well as ClinVar assessments are listed for each variant (separated by 
`//` where multiple variants are identified). 
Patient P(i) 
HPO terms 
HP:0009778 - Short thumb 
HP:0001156 - Brachydactyly syndrome 
HP:0010239 - Aplasia of the middle phalanx of the hand 













OMIM:607636 VAN BUCHEM DISEASE, TYPE 2 (AD) 
OMIM:144750 ENDOSTEAL HYPEROSTOSIS, (AD) 
OMIM:601884 BONE MINERAL DENSITY QUANTITATIVE TRAIT 
LOCUS 1; BMND1 (AD) 
OMIM:166710 OSTEOPOROSIS (AD) 
OMIM:607634 OSTEOPETROSIS, AUTOSOMAL DOMINANT 1; 
OPTA1 (AD) 
OMIM:259770 OSTEOPOROSIS-PSEUDOGLIOMA SYNDROME; 
OPPG (AR) 
OMIM:601813 EXUDATIVE VITREORETINOPATHY 4; EVR4 
(AD/AR) 
ESP MAF 0 // 0 
ExAC MAF 0 // 0 
1000 
genomes MAF 
0 // 0 
CADD NA // 31 
SIFT NA // 0 
PolyPhen2 NA // 0.999 




Table 15: Patient II – ZNF423 variant(s) identified after querying patient HPO terms to the 
quantified text-mined OMIM disease phenotype reference set using cosine similarity. See 
Table 14 legend for a breakdown of the headings. 
Patient P(ii) 
HPO terms 
HP:0000104 - Renal agenesis 
HP:0000151 - Aplasia of the uterus 
Gene ZNF423 




OMIM:614844 NEPHRONOPHTHISIS 14; NPHP14 
(AD/AR) 
ESP MAF 0.0002 











Table 16: Patient III – COL4A3BP variant(s) identified after querying patient HPO terms 
to the quantified text-mined OMIM disease phenotype reference set using cosine 
similarity. See Table 14 legend for a breakdown of the headings. 
Patient P(iii) 
HPO terms 
HP:0000179 - Thick lower lip vermilion 
HP:0001654 - Abnormality of the heart valves 
HP:0001169 - Broad palm 
HP:0001263 - Global developmental delay 
HP:0000426 - Prominent nasal bridge 
HP:0000455 - Broad nasal tip 
HP:0000637 - Long palpebral fissure 
HP:0000316 - Hypertelorism 
HP:0000470 - Short neck 
HP:0000914 - Shield chest 
HP:0000736 - Short attention span 
Gene COL4A3BP 





OMIM:616351 MENTAL RETARDATION, AUTOSOMAL 
DOMINANT 34; MRD34 (AD) 
ESP MAF 0 











Table 17: Patient IV – FAT4 variant(s) identified after querying patient HPO terms to the 
quantified text-mined OMIM disease phenotype reference set using cosine similarity. See 
Table 14 legend for a breakdown of the headings. 
Patient P(iv) 
HPO terms 
HP:0009778 - Short thumb 
HP:0005321 - Mandibulofacial dysostosis 
HP:0000256 - Macrocephaly 









OMIM:615546 VAN MALDERGEM SYNDROME 2; VMLDS2 (AR) 
OMIM:616006 HENNEKAM LYMPHANGIECTASIA-
LYMPHEDEMA SYNDROME 2; HKLLS2 (AR) 
ESP MAF 0.0011 // 0.0002 




0.0003994 // 0.0003994 
CADD 25.4 // 27 
SIFT 0.35 // 0.5 
PolyPhen2 0.997 // 0.979 




Table 18: Patient V – DNM2 variant(s) identified after querying patient HPO terms to the 
quantified text-mined OMIM disease phenotype reference set using cosine similarity. See 
Table 14 legend for a breakdown of the headings. 
Patient P(v) 
HPO terms 
HP:0000220 - Velopharyngeal insufficiency 
HP:0001199 - Triphalangeal thumb 
HP:0003508 - Proportionate short stature 
HP:0001643 - Patent ductus arteriosus 
HP:0002020 - Gastroesophageal reflux 
HP:0000324 - Facial asymmetry 
HP:0000405 - Conductive hearing impairment 
Gene DNM2 





OMIM:160150 MYOPATHY, CENTRONUCLEAR, 1; CNM1 (AD) 
OMIM:615368 LETHAL CONGENITAL CONTRACTURE 
SYNDROME 5; LCCS5 (AR) 
OMIM:606482 CHARCOT-MARIE-TOOTH DISEASE, DOMINANT 
INTERMEDIATE B; CMTDIB (AD) 
ESP MAF 0 












Table 19: Patient VI – NOD2 variant(s) identified after querying patient HPO terms to the 
quantified text-mined OMIM disease phenotype reference set using cosine similarity. See 
Table 14 legend for a breakdown of the headings. 
Patient P(vi) 
HPO terms 
HP:0000988 - Skin rash 
HP:0001382 - Joint hypermobility 
HP:0012432 - Chronic fatigue 
Gene NOD2 
Variant(s) Het exon4:c.G2332A:p.E778K 
 1 
Probability 0.1968 
OMIM phenotypes OMIM:186580 BLAU SYNDROME; BLAUS (AD) 
ESP MAF 0.0002 
ExAC MAF 0.0002 








Table 20: Patient VII – COL4A3 variant(s) identified after querying patient HPO terms to 
the quantified text-mined OMIM disease phenotype reference set using cosine similarity. 
See Table 14 legend for a breakdown of the headings. 
Patient P(vii) 
HPO terms 
HP:0000077 - Abnormality of the kidney 
HP:0011604 - Aortopulmonary window 
HP:0010880 - Increased nuchal translucency 
HP:0002251 - Aganglionic megacolon 
HP:0009601 - Aplasia/Hypoplasia of the thumb 
HP:0000598 - Abnormality of the ear 
Gene COL4A3 




OMIM:203780 ALPORT SYNDROME (AR) 
OMIM:104200 ALPORT SYNDROME (AD) 
OMIM:141200 HEMATURIA, BENIGN FAMILIAL; BFH (AD) 
ESP MAF 0 












4.3.10 Clinic letter text mining 
Anonymised clinic letters were provided for 14 of the sequenced patients, which 
were text-mined for HPO terms. These were letters describing a single visit to the 
genetics clinic, between 359 and 1,068 words (Figure 32). Patient phenotypes were 
again queried to the quantified text-mined phenotype reference set using cosine 
similarity as with the undiagnosed patients described in the previous section 
(4.3.9). 
 
Figure 32: Word counts of the 14 anonymised clinic letters available for text mined HPO 
phenotype annotation.  
Class 4 diagnostic variants (n=2) 
Two of the sequenced patients for whom anonymised clinic letters were available 
for text mining had class 4 diagnostic variants. Both of these were heterozygous 
variants: one in exon 52 PIEZO2 (Table 21) and one in exon 6 TP63 (Table 22). 
Following variant filtering (4.2.5) and gene phenotype ranking, both causative 
variants were ranked first out of the remaining variants (n = 64 and 57 respectively). 
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Table 21: PIEZO2 variant diagnosis captured at the top variant rank after using text mining 




HP:0012825 – Mild 
HP:0009821 - Forearm undergrowth 
HP:0000260 - Wide anterior fontanel 
HP:0002804 - Arthrogryposis multiplex congenita 
HP:0012385 - Camptodactyly 
HP:0000175 - Cleft palate 
HP:0000006 - Autosomal dominant inheritance 
HP:0004322 - Short stature 
HP:0004324 - Increased body weight 
HP:0001371 - Flexion contracture 
HP:0000431 - Wide nasal bridge 
HP:0000316 - Hypertelorism 
HP:0001883 - Talipes 
HP:0000347 – Micrognathia 
Gene PIEZO2 




OMIM:114300 ARTHROGRYPOSIS, DISTAL, TYPE 3; DA3 
(AD) 
OMIM:248700 MARDEN-WALKER SYNDROME; MWKS 
(AD) 
OMIM:108145 ARTHROGRYPOSIS, DISTAL, TYPE 5; DA5 
(AD) 
ESP MAF 0 
ExAC MAF 0 








Table 22: TP63 variant diagnosis captured at the top variant rank after using text mining 




HP:0000668 – Hypodontia 
HP:0000975 - Hyperhidrosis 
HP:0000164 - Abnormality of the teeth 
HP:0001649 - Tachycardia 
HP:0012825 - Mild 
HP:0100874 - Thick hair 
HP:0001263 - Global developmental delay 
HP:0000691 - Microdontia 
HP:0000968 - Ectodermal dysplasia 
HP:0001903 - Anemia 
HP:0000964 – Eczema 
Gene TP63 





OMIM:604292 ECTRODACTYLY, ECTODERMAL DYSPLASIA, AND 
CLEFT LIP/PALATE SYNDROME 3; EEC3 (AD) 
OMIM:103285 ADULT SYNDROME (AD) 
OMIM:129400 RAPP-HODGKIN SYNDROME; RHS (AD) 
OMIM:106260 ANKYLOBLEPHARON-ECTODERMAL DEFECTS-
CLEFT LIP/PALATE (AD) 
OMIM:603543 LIMB-MAMMARY SYNDROME; LMS (AD) 
OMIM:605289 SPLIT-HAND/FOOT MALFORMATION 4; SHFM4 
(AD) 
ESP MAF 0 










Interesting variants in an undiagnosed patient 
An interesting set of variants was identified in the ADAMTS10 gene (Table 23), 
which had the top gene phenotype similarity ranking amongst the post-filtering 
variants. The ADAMTS10 gene was not contained within any virtual gene panels 
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used for the patient. Weill-Marchesani syndrome was also the top phenotypic 
match to the patient. All variants were not observed in the ESP, ExAC and 1000 
genomes datasets. Two of the variants were frameshifts, while the splicing variant 
in exon 14 had a CADD score of 19.84 (just outside the top 1% of all variant scores 
for deleteriousness). Further investigation is necessary including sequencing of 
parental samples will reveal if these variants exist in cis or trans.  
Table 23: Interesting variants in ADAMTS10 at the top variant rank following use of text 
mining to identify query HPO terms. See Table 14 legend for a breakdown of the headings. 
Patient TM(iii) 
HPO terms 
HP:0012837 – Generalized 
HP:0012531 - Pain 
HP:0001156 - Brachydactyly syndrome 
HP:0004322 - Short stature 
HP:0001642 - Pulmonic stenosis 











OMIM:277600 WEILL-MARCHESANI SYNDROME 1; WMS1 
(AR) 
ESP MAF 0 (all) 




CADD 19.84 for the exon 14 variant (others: NA) 
SIFT NA (all) 
PolyPhen2 NA (all) 






The clinical genetics patient dataset used in this study was reasonably similar in 
phenotypic constitution to the OMIM phenotypic series and DDD datasets of the 
previous two chapters (Figure 24) (with some enrichments for a few additional root 
HPO terms), so similar benchmarking results were expected. However, only 50% 
of the 100 patients had their phenotypes described with HPO terms (Table 10), and 
only 47.5% of all patients had been issued reports with diagnostic variants. This 
left 22.5% (45 of 200) with both HPO terms and a diagnostic report – however, to 
accurately benchmark these methods, class 3 diagnoses (variants of unknown 
significance) were discarded, leaving only clear likely pathogenic diagnostic 
variants (31 of 200; 15.5%). A further two patients were discarded due to having 
diagnostic reports in multiple genes, and the diagnostic variants for an additional 
two patients were not identified using the variant filtering strategy employed. With 
only 27 patients available for benchmarking there was lower statistical power to 
make conclusions on the differences between gene/variant prioritisation methods 
compared to the DDD and OMIM PS datasets of previous chapters, which utilised 
258 and 2317 queries respectively. 
There were also limitations in the comparison between the utility of phenotype-
based gene prioritisation techniques and the use of virtual gene panels in this 
dataset. Firstly, it was unclear to what extent the initial process of identifying 
diagnostic variants was performed independently of assigned HPO (or other 
phenotypic) terms, or if tools that utilise machine-readable phenotype tools were 
used to help curate the virtual gene panels. PhenoTips contains an in-built 
differential diagnosis recommender (Girdea et al., 2013), and although the use of 
tools such as the Phenomizer (Köhler et al., 2009) are not standard practice in the 
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clinic, this does not preclude the possibility of individual clinicians making use of 
online resources. Secondly, as displayed by the varied sizes of gene panels used for 
each patient (and that in some instances secondary and tertiary panels were used) 
(Figure 22), the application of virtual gene panels in these cases represents a wide 
range of levels of confidence in the panel. 73 of 200 primary panels contained five 
or fewer genes and 35 comprised a single gene, demonstrating very high confidence 
in such genes, whilst some secondary panels (only applied if the primary panel 
yielded no results) contained more than 1,000 genes. Although it is implicit in the 
design of these methods that they should perform well on patients for whom there 
is less difficulty in identifying the diagnostic variant, a key reason for their 
development is for more ‘difficult’ cases, as there are now many documented 
monogenic causative gene-phenotype relationships which are not necessarily all 
readily known. The DDD dataset consisted of patients for whom diagnosis using 
standard gene testing was unsuccessful and therefore was a good representation of 
patients for whom this methodology would benefit the most. Differential method 
performance between these two datasets perhaps reflects this – in the best case the 
causative gene was identified within rank 10 for 23% of DDD patients (Figure 18), 
whereas the same was true for 34% of the clinic patients tested in this chapter 
(Figure 25), despite only genes within the DDG2P panel being tested for the DDD 
patients, which had roughly half the number of genes as the OMIM disease-
associated genome. It would also be useful to test machine-readable phenotype 
similarity methods on different datasets that cover separate disease areas (or to have 
a large enough sample size to be able to separate the dataset) – this may reveal 
phenotypic areas for which there is greater need for ontology development, as well 
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as disease areas where there are a lack of documented phenotype-gene relationships 
which need further exploration. 
The two diagnostic variants that were excluded by the filtering strategy employed 
here were heterozygous variants in MED12 and CREBBP genes – one did not pass 
the 0.1% MAF filter in the public variant databases, and the other did not pass the 
0.1% heterozygous filter in the in-house database. Both variants were in genes with 
good phenotypic matches to their respective patients, although both variants were 
annotated as either VUS or benign by multiple reporters on ClinVar. Considering 
the frequency at which these variants were found, it is possible that these are 
variants of unknown significance rather than likely pathogenic diagnoses.  
Although the benchmarked sample size tested here was too small to draw many 
statistically significant conclusions regarding the differential performance of 
methods in prioritising variants and genes, there was some concordance observed 
with the DDD benchmarking, along with some instances of discordance. As 
observed in the DDD patients, using cosine similarity to measure similarity 
between patient and reference set was advantageous over Resnikavg,max|sym in 
assigning high probabilities to causative genes within the disease-associated 
genome (Figure 26, Table 12) and causative variants (Figure 31, Table 13). Cosine 
similarity also appeared to have an advantage over Resnikavg,max|sym in ranking 
causative variants (Figure 30) but, discordant to observations from the DDD 
dataset, it showed no advantage over Resnik in for ranking causative genes within 
the disease-associated genome (Figure 25). Also concordant with the DDD results, 
using cosine similarity with the curated disease phenotype reference set resulted in 
the greatest average causative gene probabilities for the patient group, as well as 
the fewest diagnostic genes with a probability higher than selecting an OMIM 
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disease-associated gene at random. Unlike the DDD benchmarking, using the 
curated reference set also outperformed the other reference sets for median gene 
probability. The quantified text-mined phenotype reference set showed some 
benefit, but only compare to the curated reference set in ranking causative variants 
(Figure 30). However, unlike the DDD benchmarking, quantification of 
phenotypes showed no benefit ahead of either of the unquantified reference sets 
(curated and text-mined) in ranking genes within the disease-associated genome 
(Figure 25). The quantification of phenotypes was expected to demonstrate the 
same benefit as it had in previous benchmarking experiments – no evidence was 
observed here but a larger sample size would be required to confirm this. The 
phenotype-based variant prioritisation methods were superior to variant-based 
prioritisation of PhenIX, consistent with phenotype-based prioritisation methods 
outperforming variant methods in many benchmarking investigations (Singleton et 
al., 2014; Smedley & Robinson, 2015; Zemojtel et al., 2014). Incorporating variant 
score into the phenotype score for a combined score showed no significant benefit, 
although this would be expected in a larger dataset. 
These variant prioritisation experiments were conducted blind to the suspected 
mode of inheritance in these patients. Incorporating mode of inheritance into 
phenotype search would greatly reduce the gene search space as only relevant 
genes for each genotype would remain – heterozygous variation in disease genes 
of recessive disease would not be considered. Also, variant search space could be 
further reduced by filtering using pathogenicity prediction scores. Considering 
such scores as strong individual lines of evidence is not recommended (D. G. 
MacArthur et al., 2014) and therefore they were not used in the filtering schema, 
but in practice a variant is seldom considered if prediction tool scores unanimously 
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indicate non-pathogenicity. Pathogenicity prediction scores can be discordant 
across different tools due to the different annotations/models used, and scoring is 
not available for all variants, but it would be reasonable to remove variants with 
unanimous predictions that suggest they are benign. 
Of the 55 patients without diagnostic reports who were assigned HPO terms, 7 
patients were highlighted for whom the use of phenotype-based variant 
prioritisation identified variants of interest that warrant further investigation. In 5 
of the 7 cases the variant ranked in the top 10 when sorting exome variants by gene 
phenotypic similarity to the patient. In each case (apart from the NOD2 
heterozygous variant) there were variants with higher gene phenotypic similarity 
than the candidate selected, though these were ruled out, due to either: (i) the 
variant zygosity being inconsistent with the reported mode of inheritance of 
phenotypes associated with the gene; (ii) CADD/SIFT/PolyPhen2 scores that were 
not suggestive of pathogenicity; (iii) reports of them being benign in ClinVar. As 
stated when discussing the benchmarking of variant prioritisation, this search space 
could be reduced automatically (i) by removing single heterozygous variants in 
genes causative of recessive disease. Also, (ii) variants with unanimous benign 
prediction scores could be removed, although manual appraisal of variant 
pathogenicity prediction scores would still be required. For example, in patient IV, 
both of the highlighted FAT4 variants had CADD and PolyPhen2 scores that 
indicated pathogenicity, whilst SIFT predicted that they were tolerated protein 
changes. However, (iii) filtering based on ClinVar reporting would be less simple 
as there are often multiple reports to be considered for many variants which may 
conflict in their assessment of pathogenicity, and this information is not readily 
computationally accessed for automatic variant filtering.  
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It is interesting that the split between patients with and without HPO terms was 
relatively even between diagnosed and undiagnosed patients. Given the capabilities 
of HPO-based tools to either suggest candidate clinical diagnoses and prioritise 
genes, it is surprising that many of the undiagnosed cases were not annotated with 
HPO terms – in these cases, unstructured phenotypic information may have been 
used in individual cases to suggest clinical diagnoses or genes. Demonstrated here, 
the use of a HPO-based methodology of prioritising genetic variants helped 
identify promising candidates in 7 of the cases (and candidates in other cases not 
discussed) – if only a fraction of these are established as molecular diagnoses, the 
use of this methodology would be vindicated because it only requires the trivial 
effort of defining patients with HPO terms.  
If there are groups of patients without machine-readable phenotypes, there are data 
sources available that can be leveraged to capture phenotypic data if retrospective 
phenotype annotation is not available. Firstly, clinic letters from patients can be 
text-mined to identify occurrences of HPO terms, which was demonstrated in the 
subset of patients (n=14) with anonymised clinic letters available. Calculating 
similarity to the reference set using HPO terms annotated by text mining identified 
the causative genes at the top rank for both individuals with a diagnostic variant. 
In an additional patient, a group of variants were identified within a highly 
phenotypically relevant gene (for an autosomal recessive disorder), though 
sequencing of parents is required to establish whether these occur in trans. HPO 
terms were not assigned to this patient and the identified gene was not in the virtual 
gene panel, so this variant may not have been highlighted if it weren’t for the use 
of text mining. This demonstrates the value of annotating undiagnosed cases with 
HPO terms through automated methods in cases where manual annotation is not 
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possible. Additionally, the gene panels selected for each patient contain latent 
phenotypic information, which can be ‘reverse-engineered’ by identifying the 
OMIM phenotypes caused by each gene and extracting the HPO terms to construct 
a composite predicted HPO phenotype. Querying this reconstructed phenotype can 
help expand the gene list through consideration of similar phenotypes – this can be 
particularly useful when virtual gene panels were constructed years ago, and 
reverse-engineered phenotypes can be used to update them to include recently 
made discoveries. 
The use of approaches such as those developed in this thesis, or tools such as 
PhenIX, that investigate all known human disease genes (termed the disease-
associated genome) are appropriate in a diagnostic setting, which requires that 
identified variants are in genes with a previously described role in causing 
Mendelian disorders. However, in a research setting, the use of gene discovery 
tools such as PHIVE and hiPHIVE from the Exomiser suite (Smedley et al., 2015) 
may be more appropriate for the identification of candidate variants based on 
phenotypic similarity to both human phenotypes and animal models. This can be 
used in combination with phenotypic matchmakers to identify individuals across 
the world with similar phenotypes (and genotypes) (Buske, Girdea, et al., 2015) to 
provide the additional lines of evidence that variants in a particular gene are 




 Chapter 5 – Utilisation of phenotype 
questionnaire data in a common complex disease 
dataset (acne) to aid interpretation of GWAS 
results 
5.1 Introduction 
Aside from rare diseases, the use of machine readable phenotypes is also becoming 
increasingly important in the genetic analysis of common complex disease. Several 
genetic studies utilise disease codes (e.g. ICD9-10-11) within electronic health 
records to identify disease phenotypes of interest (Dewey et al., 2016; Howard et 
al., 2018; Krokstad et al., 2013; Mitchell et al., 2016; The Michigan Genomics 
Initiative, 2016; UK Biobank, 2018) and further granularity can be achieved by 
using self-reported phenotypes (UK Biobank, 2018) or questionnaires filled by the 
attending clinician or nurse. In large scale GWAS, the necessity to identify vast 
numbers of cases may result in the use of an umbrella diagnosis that may cover 
many subphenotypes. This introduction of heterogeneity to the phenotype 
definition can reduce power to detect phenotype-specific effects, and analysing 
more homogenous populations of cases expressing subphenotypes can lead to 
insight into the genetic basis of such subphenotypes in GWAS analyses (Eichler et 
al., 2010; Kulminski et al., 2016; MacRae & Vasan, 2011). The aim of this chapter 
is to evaluate the potential of using phenotypic information gathered from 
questionnaires filled for patients with severe acne.  
Acne is an inflammatory disease that affects the skin through the pilosebaceous 
unit – hair follicles in the skin that are associated with an oil gland. Acne primarily 
affects the face, chest and back, where pilosebaceous units are most densely 
concentrated. Acne often starts in early puberty and clinical features include 
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seborrhoea, lesions (inflammatory on non-inflammatory), and various degrees of 
scarring. Many classifications exist for acne lesions based on whether they are non-
inflammatory (open and closed comedones) or inflammatory (papules, pustules, 
nodules and cysts) (Shalita, 2004), with nodulocystic acne representing a severe 
classification (Williams, Dellavalle, & Garner, 2012). The severe inflammatory 
response to acne can result in permanent scarring, with classifications such as ice-
pick, atrophic, keloid, hypertrophic and perifollicular elastolysis (Alster & West, 
1997; Jacob, Dover, & Kaminer, 2001; Varadi & Saqueton, 1970). A commonly 
used severity grading score is the Leeds technique, which involves counting and 
categorising lesions as inflammatory or non-inflammatory (Burke & Cunliffe, 
1984; Purdy & de Berker, 2011). 
Biological mechanisms underlying disease development are thought to involve 
sebum production, follicular keratinization, inflammation, and colonisation of 
follicles by Propionibacterium acnes, but are poorly understood (Williams et al., 
2012). Acne impacts the psychological health of affected individuals, and is 
associated with depression, suicidal ideation, anxiety, psychosomatic symptoms, 
shame, embarrassment and social inhibition (Kubota et al., 2010), and effective 
treatment helps to resolve such issues (Hahm et al., 2009). Topical and systemic 
agents are typically used to treat severe acne, which act to suppress the microbiome 
repertoire or the activity of sebaceous glands, though regimes can be ineffective 
and cause skin irritation which may result in discontinuation (Williams et al., 
2012). 
Twin studies have indicated the importance of genetic factors in acne risk, with 
heritability estimates of 78% and 81% in Chinese and UK Caucasian populations 
respectively (Bataille, Snieder, MacGregor, Sasieni, & Spector, 2002; Wei et al., 
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2010). GWAS have been conducted on severe acne phenotypes, identifying 
associations with several genomic loci, including two in Han Chinese populations 
(He et al., 2014) and a further 15 in European populations (Navarini et al., 2014; 
Petridis et al., 2018). These loci have highlighted the potential role of several genes 
and pathways in disease pathogenesis. Pathway analysis of genes surrounding hit 
loci has indicated the importance of the TGFβ pathway, which can be linked to 
acne pathogenesis through its involvement in keratinocyte proliferation (Navarini 
et al., 2014). Fine mapping of loci signals has highlighted variants likely to underlie 
observed association signals within WNT10A and SEMA4B (where the latter is at a 
critical position of a TP63 binding motif), and regional colocalisation with skin 
eQTLs has identified LAMC2 and LGR6 as putative causal genes: all of these genes 
have established roles in controlling the development, morphology and activity of 
hair follicles (Petridis et al., 2018).  
Questionnaire data was collected for patients from both Navarini et al. (discovery 
stage) and Petridis et al. UK GWAS studies. In this chapter, the clinical information 
provided is used to identify acne subphenotypes for genetic association testing, 
hypothesising that common genetic variation contributes to the differences 
between acne subphenotypes. There are several challenges in interpreting the 
questionnaire data, as it is not coded or represented in ontology terms, and also 
contains a large amount of missing data. Furthermore, any subphenotypes defined 




5.2 Materials and Methods 
5.2.1 Questionnaire 
Clinical information was recorded for patients from Navarini et al. (discovery 
stage) and Petridis et al. UK GWAS studies, for which ethical approval was 
obtained from the NRES Committee London-Westminster (reference CLRN 
05/Q0702/114). Data collected from each patient consisted of (i) a case report form 
(CRF) filled by the attending clinician or nurse detailing diagnostic information 
(following assessment by a trained dermatologist) and (ii) self-reported 
information from a questionnaire filled by patients. Patients were recruited through 
a network of 45 dermatology centres in the UK (17 centres in the initial discovery 
study), which included: patients from Guy’s and St Thomas’ (GSTT), patients 
recruited from visits to other hospital sites, and patients who were sent letters by 
their hospital and asked to join. A different CRF form was used for non-GSTT 
patients (but this only differed in clinical information later marked as ‘irrelevant’) 
and there were further minor differences in the self-reporting questionnaires used 
for patients recruited by sending letters (rather than from hospital visits).  
The full questionnaire dataset comprised a total of 162 different questions, 
separated into 6 broad categories: 
- Patient details: Basic information such as name (anonymised to single 
initials), date of birth, sex and ethnicity. 
- Family history: Of acne and other dermatological disorders (psoriasis, 
eczema, hidradenitis suppurativa). 
- Diagnosis: Age and year of both diagnosis and onset. 
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- Acne diagnosis: Acne clinical variants such as infantile acne, nodulocystic 
acne, polycystic ovary syndrome acne (some of which were 
inclusion/exclusion criteria, listed below). 
- Clinical: Anthropometric data (weight, height, BMI), a breakdown of 
different lesion and scarring types (and where they are situated) and disease 
severity scores (Leeds score and dermatology life quality index (DLQI)). 
- Treatments: treatment type, date(s), dosing and response. 
Among these fields were questions that comprised the inclusion and exclusion 
criteria, which were as follows: 
Inclusion criteria (any of the following):  
- A clinical diagnosis of nodulocystic acne vulgaris 
- A clinical diagnosis of moderate to severe acne vulgaris requiring treatment 
with isotretinoin 
- A clinical diagnosis of acne vulgaris with a Leeds Grading Score of more 
than or equal to 5 in at least one site 
- A clinical diagnosis of either acne conglobata, acne fulminans, sandpaper 
acne OR submarine acne (clinical subtypes of acne vulgaris) 
Exclusion criteria:  
- Be unable to give informed consent 
- Blood transfusion received within last 4 weeks 
- Any evidence of acne agminata, acne rosacea, or other acne form eruption 
not fulfilling the inclusion / exclusion criteria 
- Acne associated with evidence of virilisation or other significant hormonal 
abnormality based on clinical assessment by a trained dermatologist 
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- Drug induced acne (determined by a trained dermatologist) e.g. steroid 
induced acne 
- Patients with acne due to their occupation 
- Patients with acne due to working with halogenated hydrocarbons 
- Body builders 
5.2.2 Data filtering 
To include only data that is phenotypically relevant, and that can also be simply 
converted to machine-readable format (e.g. not free-text), the following filtering 
steps were applied to the dataset:  
- Removal of questionnaires in instances where the same individual had two 
or more completed questionnaires completed at different times added to the 
databases. All such questionnaires were removed to avoid issues of possible 
discrepancy between different responses (n=106). 
- Removal of questionnaires that did not originate from individuals contained 
in the final analysis of the initial Navarini et al. study or the subsequent 
Petridis et al. study (from here named DS1 and DS2 respectively). 
- Removal of questions not containing useful information pertaining to acne 
clinical presentation. These were in one of three broad categories (removed 
questions and reasons listed in Appendix 2):  
- Basic patient details with no phenotypic relevance (e.g. “name”, 
“date of visit”) 
- Questions with free-text responses which cannot be 
computationally processed and incorporated into similarity models 
(e.g. “acne other specify”, “lesion overall”, “scarring overall”). 
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- Questions detailing phenotypic information not related to the acne 
phenotype (e.g. “eczema family history”, “psoriasis family 
history”). 
- Removal of questions with monomorphic responses. This required initially 
standardising uninformative responses to single value (e.g. “unknown”, 
“incomplete”, “indeterminate”, “[BLANK]”) before assessing whether 
responses were monomorphic for a question. Binary questions were 
considered to have monomorphic responses if they only contained “No” 
and uninformative responses, which was considered appropriate due to the 
nature of questionnaires, which asked for presence of acne clinical variants 
or lesions/scarring types. This filtering step resulted in the removal of all 
study exclusion criteria (as only “No”/blank responses remained after 
selecting individuals used in final analysis of the genetic studies).  
- Removal of poorly filled questions. Questions where <1% of individuals 
responded were removed. 1% is a somewhat arbitrary threshold and only 
resulted in the removal of biometric data (height, weight, BMI) which was 
available for only 0.6% of genotyped individuals. 
Questions included after filtering are listed in Appendix 3. 
5.2.3 Missingness clustering 
Responses were clustered by missingness to assess structure of the data that was 
due to different patterns of questionnaire missingness rather than phenotype 
similarity. To perform this data was recoded to binary format based on the presence 
or absence of response. 
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5.2.3.1 By question 
Question vectors were clustered by missingness using hierarchical clustering, 
which considers all vectors as separate clusters, and in each iteration of the 
algorithm the two closest clusters are combined until there is only one cluster 
remaining. A Euclidean distance measure between question vectors was used and 
the distance between clusters was defined as the minimum between any of their 
constituent vectors. Questions were visualised on a heatmap coloured by Pearson 
correlation coefficients. 
5.2.3.2 By patient 
Principle component analysis (PCA) was used to identify clusters of individuals 
for which the same parts of the questionnaire had been filled. PCA transforms a 
dataset of possibly correlated variables into a smaller number of uncorrelated 
variables (principle components). Each sequential principle component explains as 
much of the variance as possible, enabling lower dimension representations of 
datasets with high dimensionality. 
5.2.4 Response clustering 
Three data types exist in the questionnaire dataset: binary, quantitative and factors 
(categorical variables). Binary response data was simply encoded as 0 (“No”) and 
1 (“Yes”). Quantitative data was linearly normalised to between 0 and 1. Factor 
data was one-hot encoded (i.e. the creation of separate vectors for each unique 
response value, each with binary encoding).  
Missing values are not permitted by clustering algorithms, and this can be resolved 
by either removing cases with missing values or imputing missing values (or a 
combination of the two). To retain the maximum number of individuals with 
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clinical information the following imputation strategy was employed for the 
different data types: 
- Missing binary data was encoded as 0 – assuming missing data is equivalent 
to a “no” response.  
- Missing quantitative data was filled with the median value. 
- There were no missing values for factor variables. 
5.2.4.1 By question 
After recoding the response data, questions were again clustered using hierarchical 
clustering and visualised on a heatmap coloured by Pearson correlation 
coefficients. 
5.2.4.2 By patient 
5.2.4.2.1 t-SNE 
To identify patient clusters for genetic study, PCA was not sufficient to reduce the 
data to a two-dimensional representation as it explained only 37% of the dataset 
variance. Therefore, t-distributed stochastic neighbour embedding (t-SNE) was 
employed – t-SNE enables high-dimensional datasets to be visualised by 
computing low-dimensional embeddings where pairwise distances between data 
points are reflective of pairwise distances between the high-dimensional input. 
(Van Der Maaten & Hinton, 2008). t-SNE was performed on the first 16 principle 
components of the original data, the minimum number of principle components to 
explain 85% of the variance. 
5.2.4.2.2 DBSCAN 
Density-based spatial clustering of applications with noise (DBSCAN) was used to 
cluster the data based on the two-dimensional t-SNE embeddings. DBSCAN is a 
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widely used density-based clustering algorithm which uses the following 
parameters: minimum points – the number of data points within a neighbourhood 
required to define a cluster (here: 100); ε – the maximum distance between two 
points to be considered neighbours (here: 8). 
5.2.5 Power calculation 
For each explicitly defined binary subphenotype within the questionnaire data, 
genome-wide association testing could be conducted using the following cohorts 
as controls: 
- Unselected population controls from original Navarini et al. and Petridis et 
al. studies. 
- Individuals within the case cohort for whom the subphenotype was 
explicitly stated not to be present (i.e. “No” responses).  
- All individuals within the case cohort who weren’t stated to have the 
subphenotype (i.e. all non-“Yes” responses). 
For each potential genome-wide association test (subphenotype vs. each of the 
respective control populations) statistical power was calculated using equations 
implemented in the GAS power calculator (Skol, Scott, Abecasis, & Boehnke, 
2006). Using the number of cases and controls for each potential analysis, the 
power to detect a SNP with genome-wide level of significance of association (P = 
5 × 10-8) was calculated, looking for a SNP with 50% allele frequency and genotype 
relative risk of 2 (assuming a multiplicative model and a disease prevalence of 




Genome-wide association testing was performed for each case/control group with 
sufficient statistical power (as defined above) using the same meta-analysis 
pipeline followed in Petridis et al.  
Genotyping, quality control and imputation (summarised from Navarini et al. and 
Petridis et al.) 
In DS1, genome-wide genotyping was conducted on Illumina 
HumanOmniExpress-12v1_H microarrays for cases and on Illumina 1.2M 
platform (at the Sanger Institute, Cambridge) for controls, which were either 
healthy blood donors from the United Kingdom Blood Service (UKBS, n=2,478) 
or individuals from the 1958 Birth Cohort (58C, n=2,661). Genotyping was 
conducted in two batches in DS2 cases, using the Human 250 Illumina Omni 
Express Exome 8v1-2 (2,567 cases) and Illumina Omni Express Exome 8v1-3 
(1,961 cases) and control genotypes were obtained from the English Longitudinal 
Study of Aging (ELSA, genotyped on the Illumina Human Omni 2.5) and the 
Understanding Society Project (USP, genotyped on the Illumina Human Core 
Exome v12.0). All control cohorts used were unselected population control 
cohorts. Quality control was performed in the respective datasets using accepted 
quality control procedures (Weale, 2010), considering call rate, Hardy-Weinberg 
equilibrium, discrepancy of inferred gender with sample information, excessive 
heterozygosity, cryptic relatedness and ancestry outliers (Navarini et al., 2014; 
Petridis et al., 2018). QC was performed in two batches within DS2: one containing 
genotypes from 2,567 cases and 7,452 controls from ELSA and the other with 
1,961 cases and 9,500 controls from USP. Phasing and imputation was undertaken 
using the Haplotype Reference Consortium (HRC version r1.1) reference panel on 
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the Michigan Imputation Server (Das et al., 2016). After imputation, SNPs with R2 
< 0.7 were excluded. In this testing SNPs with a minor allele frequency of < 5% in 
either study batch were excluded from downstream analysis.  
Association 
Association testing was performed within DS1 and DS2 with a logistic Wald 
association test (EPACTS), including the first four principal components (as well 
as the QC/imputation batch in DS2 only) as covariates. For subphenotype analyses 
with insufficient numbers of cases or controls (<10 of either) in DS1 or DS2 for 
stable association testing on EPACTS, summary statistics were reported for 
analysis in the single dataset, and meta-analysis was not conducted. This 
consideration was reflected in power calculations. 
Meta-analysis 
Results from the DS1 and DS2 association analyses were incorporated into a 
standard error-weighted meta-analysis with GWAS summary statistics performed 





5.3.1 Data filtering 
The original acne patient questionnaire dataset contained 7,911 patients and 
responses for up to 162 questions. 5,476 patients remained after removing any 
duplicate records and selecting only individuals that were included in the final 
analysis of Navarini et al. (DS1) and Petridis et al. (DS2). 1,747 of 1,779 of DS1 
individuals and 3,729 of 3,823 DS2 individuals (98% of entire dataset) had 
questionnaire data without duplicate entries. After all filtering 66 questions 
remained (Table 24). 
Table 24: Acne questionnaire dataset size following each filtering step. The number of 
questions removed for each reason may not be the correct number of questions with that 
property (i.e. some questions defined as irrelevant were also monomorphic or poorly filled 
and were therefore removed before that step). 
Stage Questions Patients 
Original dataset 162 7955 
Remove duplicate entries 162 7849 
Genotyped patients only 162 5476 
Remove irrelevant questions 81 5476 
Remove monomorphic response questions 69 5476 
Remove poorly filled questions (<1%) 66 5476 
 
5.3.2 Response Rates 
The response rates differed greatly between DS1 and DS2, with questions filled at 
a much higher rate in DS2 individuals on average (Figure 33). “Sex” and 
“ethnicity” data fields were fully populated in both datasets, while “hirsutism” and 
“androgenic alopecia” clinical variants were largely left blank across datasets. 
“Age of onset”, “nodulocystic acne”, “acne before puberty” and the Leeds score 
questions were filled with reasonable rates that were comparable across datasets, 
and the remaining questions were filled much more in DS2 than DS1 (Figure 34) 




Figure 33: Questionnaire response rates by question and patient (left and right 
respectively), before and after data filtering (top and bottom respectively). 
 
Figure 34: Comparison of question response rates (after data filtering) between dataset 1 
and 2 (n=33). Green: questions filled universally highly; Red: questions with low response 
rates in both datasets; Blue: questions with comparable response rates; Yellow: questions 
filled to a much greater degree in DS2 than DS1. 
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5.3.3 Missingness clustering 
5.3.3.1 By patient 
When plotting the first two principal components of the data (explaining 53.1% of 
the variance; Figure 35) two populations emerged – referred to as population 1 and 
2  (green and grey respectively in Figure 36). Population 1 (n=4,839) contained 
individuals from both genotyped datasets, while population 2 (n=637) almost 
exclusively comprised individuals from dataset 2. There was a dramatic difference 
in mean overall questionnaire fill rates between these populations (18.0% and 
78.6% respectively), which was most evident in scarring data (as well as lesion 
data to a lesser degree). This difference largely corresponded to the presence of 
more “No” values (Appendix 4).  
 
Figure 35: PCA plot for missingness of acne patient questionnaire responses. DS1 patients 
are shown alone in the central panel, DS2 patients are shown alone in the right panel, and 






Figure 36: PCA plot for missingness of acne patient questionnaire response tnelaviuqe( s
 gniwohs ,)53 erugiF fo lenap tfel ot the two patient populations that emerged based on
 neerg deruoloc( ssengnissim f snrettap o and grey). 
5.3.3.2 By question 
Hierarchical clustering and Pearson correlation coefficients were used to visualise 
patterns of missingness among different groups of questions (Figure 37). Spatial 
lesion and scarring data was plot separately (Figure 38, Figure 39).  
There were certain “blocks” of questions that tended to be completed in similar 
groups of patients, which included lesion data (summary), scarring data 
(summary), Leeds scores (spatial and overall) and clinical variants within the 
inclusion criteria (nodulocystic, sandpaper, submarine, fulminans, conglobata) 
(Figure 37). Age of onset response was correlated with indication of onset before 
puberty. Hirsutism and androgenic alopecia had no correlation with the response 
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patterns of many of the other questions as they represented the minor difference in 
the self-reporting questionnaire for the patients recruited by letter correspondence. 
Note that correlation between response patterns does not necessarily indicate that 
responses themselves were similar. 
 
Figure 37: Correlation (Pearson) between question response missingness (ordered after 
hierarchical clustering). Spatial lesion and scarring data was plot separately. % value for 





With the exception of cysts, lesion types were filled more consistently across 
spatial locations than lesion type, though correlations were still observed across 
lesion types (Figure 38). 
 
Figure 38: Correlation (Pearson) between lesion data missingness (ordered after 




The response patterns across many scarring types and locations was highly 
correlated, with the exception of “face” and “summary” data for atrophic, ice-pick, 
postinflammatory and generic scarring questions (Figure 39).  
 
Figure 39: Correlation (Pearson) between scarring data missingness (ordered after 




5.3.4 Response clustering 
After encoding data appropriately and imputing missing values according to 5.2.4, 
clustering was performed according to specific response rather than presence or 
absence of data. 
5.3.4.1 By question 
Structures of missingness were still apparent for lesion and scarring types after 
encoding responses, although structure between inclusion criteria no longer existed 
as only one of these was required for inclusion in the study (Figure 40). Predictably, 
age of onset became inversely correlated with indication of acne before puberty 
after encoding the data. Presence of cysts and indication of nodulocystic acne were 
correlated with each other, and were correlated with male acne, as were higher 
Leeds scores and “hair before eleven”. Higher DLQI scores, “has been pregnant”, 
“unwanted facial hair” and “acne before puberty” were correlated with female 




Figure 40: Correlation (Pearson) between question response values (ordered after 
hierarchical clustering). Spatial lesion and scarring data was plot separately. % value for 





Missingness structure remained after encoding responses for spatial and summary 
lesion data (Figure 41). 
 
Figure 41: Correlation (Pearson) between lesion response values (ordered after hierarchical 





After encoding scarring data much of the missingness structure disappeared (Figure 
42), as there were many “No” responses for these questions – particularly in the 
well-filled population (Appendix 4). Responses were correlated more within 
subtypes rather than the location affected. 
 
Figure 42: Correlation (Pearson) between scarring response values (ordered after 




5.3.4.2 By patient 
 
Figure 43: PCA plot of acne questionnaire data after response encoding and imputation 
(left) and % cumulative variance shown by each principle component (right). 
PCA dimensionality reduction did not reveal any obvious clusters and explained 
only 37% of the variance (Figure 43). Therefore, dimensionality reduction was 
performed using t-SNE using 16 principal components as input (which explained 
85% of the variance: additional principle components contribute minimal additions 
to the explained variance). Clusters were identified in the two-dimensional 
embeddings using DBSCAN (Figure 44). 12 clusters in total were identified with 
the parameters used. Four of these clusters were of interest, with clusters 1 and 3 
containing a large number of densely concentrated individuals, and clusters 2 and 
4 containing large numbers of patients less densely packed but distinct from the 
rest of the dataset. However, when scrutinising these clusters, they only 
corresponded to individuals with largest amounts of missing data. Of the densely 
packed clusters, cluster 1 (blue) corresponds to female individuals with largely 
empty questionnaires, and cluster 3 (purple) corresponds to male individuals with 
largely empty questionnaires. Of the distal clusters, cluster 2 (green) corresponds 
to male individuals with empty questionnaires but indication of nodulocystic acne 
(the most common clinical variant of acne contained in the study, Appendix 5), and 
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cluster 4 (red) corresponds to male individuals with empty questionnaires but 




Figure 44: t-SNE plot of acne questionnaire data after response encoding and imputation. 
Top: two-dimensional embeddings after running t-SNE. Middle: 12 patient clusters 
(indicated by colour) identified using DBSCAN on the two-dimensional embeddings of 
the top plot (grey: individuals not included in a cluster). Bottom: 4 interesting clusters from 
the middle plot remain coloured, while the remaining individuals are coloured grey.  
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5.3.5 GWAS on binary variables 
Due to the challenges of robustly identifying putative subphenotypes across all 
responses using dimensionality reduction and density-based clustering techniques, 
subsetting of the cohort was undertaken using binary responses to individual 
questions. Cases were defined as individuals with “Yes” responses to the question 
and these were compared against controls, which can be defined in a number of 
ways: (i) controls from original tested datasets, (ii) individuals where the trait was 
explicitly stated as absent (i.e. “No” responses) and (iii) all individuals for whom 
the trait was not stated as present (i.e. all non-“Yes” responses). Only analyses 
where there was sufficient power to detect genome-wide association of SNPs were 
undertaken (32 analyses in total; Appendix 5). To restrict the number of analyses 
conducted, spatial lesion and scarring data were removed and only the summary 
questions for these data were considered. 14 genome-wide association signals were 
identified across the 6 subphenotypes, within 6 of the known acne susceptibility 




Table 25: Genome-wide significant hits for binary subphenotype analysis. Controls column states which cohort was used as controls: C – controls from original 
studies; N – “No” responses for question; N+X – all non-“Yes” responses for the question (for which no GW hits were found). Previously discovered loci from 
Petridis et al. were indicated with * in the band column. 
Subphenotype Controls Band Lead SNP Freq P-val OR (95% CI) 
familyHistory: Acne_FamilyHistory C 4q27-28.1* rs216101 0.2967 4.96E-08 0.75 (0.65-0.86) 
familyHistory: Acne_FamilyHistory C 15q26.1* rs908045 0.5478 5.79E-09 1.38 (1.27-1.48) 
acneDiagnosis: Acne_Nodulocystic C 2p16.1* rs7560605 0.5844 2.02E-09 1.23 (1.17-1.30) 
acneDiagnosis: Acne_Nodulocystic C 5q11.2* rs626726 0.3326 3.85E-08 0.82 (0.75-0.89) 
acneDiagnosis: Acne_Nodulocystic C 11p15.3-15.2* rs4757109 0.887 3.59E-08 0.75 (0.65-0.85) 
acneDiagnosis: Acne_Nodulocystic C 15q26.1* rs34560261 0.833 1.73E-08 1.40 (1.28-1.51) 
clinical: Comedones_Summary C 1q25.3* rs6703054 0.4927 9.83E-09 0.80 (0.73-0.88) 
clinical: Papules_Summary C 15q26.1* rs34560261 0.8338 4.40E-08 1.37 (1.25-1.48) 
clinical: Pustules_Summary C 1q25.3* rs640069 0.4938 3.40E-08 0.82 (0.75-0.89) 
clinical: Pustules_Summary C 5q11.2* rs626726 0.3317 3.93E-08 0.81 (0.74-0.89) 
clinical: Pustules_Summary C 11p15.3-15.2* rs61877990 0.6777 8.14E-10 0.79 (0.72-0.87) 
clinical: Pustules_Summary C 15q26.1* rs908045 0.5471 1.27E-08 1.26 (1.18-1.34) 
clinical: Cysts_Summary C 5q11.2* rs626726 0.3311 2.44E-08 0.78 (0.70-0.87) 





5.3.6 Hits within previously discovered loci 
Restricting the cases of the original GWAS meta-analysis to only individuals with 
family history of acne identified two of the 15 previously discovered loci as 
genome-wide significant, and both of these signals appear to have significantly 
larger odds ratios compared to the original analysis (Figure 45). These signals are 
not replicated when comparing against inviduals within the acne cohort for which 
there was no family history (either explicitly stated or comparing against all 
remaining individuals). 
 
Figure 45: Loci where genome-wide significant levels of association were identified in 
individuals with family history of acne. Odds ratios are shown for the SNP in both the 
original study meta-analysis (O; red) and each subphenotype analysis undertaken here 
(where genome-wide significant hits are shown in blue): C – using controls from original 
study; N – using “No” responses as controls; N+X – using non-“Yes” responses as 
controls. If there were insufficient numbers of individuals to conduct one arm of the meta-
analyses, the summary statistics were reported for the single arm where numbers were 
sufficient (*). 
Restricting the original meta-analysis to only cases of nodulocystic acne identified 
four of the previously discovered loci at genome-wide significance, but the odds 
ratios were not significantly greater at any locus (Figure 46). These signals were 
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not replicated when comparing against individuals without nodulcystic acne, 
whether stated explicity or including individuals with no response. 
 
Figure 46: Loci where genome-wide significant levels of association were identified in 
individuals with nodulocystic acne. Odds ratios are shown for the SNP in both the original 
study meta-analysis (O; red) and each subphenotype analysis undertaken here (where 
genome-wide significant hits are shown in blue): C – using controls from original study; 
N – using “No” responses as controls; N+X – using non-“Yes” responses as controls. If 
there were insufficient numbers of individuals to conduct one arm of the meta-analyses, 




Restricting the original meta-analysis to only individuals with comedone lesions 
identified one of the previously discovered loci at genome-wide significance, but 
the odds ratio was not significantly greater than that of the original hit (Figure 47). 
Again, this signal did not replicate when comparing against individuals without 
comedones, whether stated explicity or including individuals with no response. 
 
Figure 47: Locus where genome-wide significant levels of association were identified in 
individuals with comedone lesions. Odds ratios are shown for the SNP in both the original 
study meta-analysis (O; red) and each subphenotype analysis undertaken here (where 
genome-wide significant hits are shown in blue): C – using controls from original study; 
N – using “No” responses as controls; N+X – using non-“Yes” responses as controls. If 
there were insufficient numbers of individuals to conduct one arm of the meta-analyses, 




Restricting the original meta-analysis to only individuals with papule lesions 
identified one of the previously discovered loci at genome-wide significance, but 
the odds ratio was not significantly greater than that of the original hit (Figure 48). 
This signal did not replicate when comparing to individuals without indication of 
papules (i.e. including missing data), and interestingly, an opposite direction of 
effect is seen when comparing to individuals stated to not have papules, though this 
is not statistically significant.  
 
Figure 48: Locus where genome-wide significant levels of association were identified in 
individuals with papule lesions. Odds ratios are shown for the SNP in both the original 
study meta-analysis (O; red) and each subphenotype analysis undertaken here (where 
genome-wide significant hits are shown in blue): C – using controls from original study; 
N – using “No” responses as controls; N+X – using non-“Yes” responses as controls. If 
there were insufficient numbers of individuals to conduct one arm of the meta-analyses, 
the summary statistics were reported for the single arm where numbers were sufficient (*). 
Restricting the original meta-analysis to individuals with pustule lesions identified 
four of the previously discovered loci at genome-wide significance, but the odds 
ratios were not significantly for any locus (Figure 49). Again, these signals were 
not replicated when comparing to individuals who were identified as not having 




Figure 49: Loci where genome-wide significant levels of association were identified in 
individuals with pustule lesions. Odds ratios are shown for the SNP in both the original 
study meta-analysis (O; red) and each subphenotype analysis undertaken here (where 
genome-wide significant hits are shown in blue): C – using controls from original study; 
N – using “No” responses as controls; N+X – using non-“Yes” responses as controls. If 
there were insufficient numbers of individuals to conduct one arm of the meta-analyses, 




Restricting the original meta-analysis to only individuals with cysts identified one 
of the previously discovered loci at genome-wide significance, but the odds ratio 
was not significantly than that of the original hit (Figure 50). Again, this signal was 
not replicated when comparing to individuals without cysts, whether stated 
explicity or including individuals with no response. 
 
Figure 50: Locus where genome-wide significant levels of association were identified in 
individuals with cysts. Odds ratios are shown for the SNP in both the original study meta-
analysis (O; red) and each subphenotype analysis undertaken here (where genome-wide 
significant hits are shown in blue): C – using controls from original study; N – using “No” 
responses as controls; N+X – using non-“Yes” responses as controls. If there were 
insufficient numbers of individuals to conduct one arm of the meta-analyses, the summary 
statistics were reported for the single arm where numbers were sufficient (*). 
5.3.7 10q26.13 locus associated with cysts 
Comparison of DS2 individuals with and without cysts identfied a genome-wide 
significant hit (P = 1.34 × 10-8) at a locus not previously described to be associated 
with acne (Figure 51). This locus was not signifiacntly associated with severe acne 
in the DS2 arm of the original meta-analysis in Petridis et al. (P = 0.361). When 
comparing individuals with cysts to unselected controls from the original analysis, 
the effect size is smaller than when comparing to acne individuals with 
confirmation of no cysts, though this falls short reaching genome-wide levels of 
statistical association (P = 6.45 × 10-3). The same is true when comparing to 
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individuals without cysts in which responses were interpreted as absence of cysts 
(P = 1.60 × 10-4).  
 
Figure 51: Novel locus where genome-wide significant levels of association were 
identified in individuals with cysts compared to individuals without cysts. Odds ratios are 
shown for the SNP in both the original study meta-analysis (O; red) and each subphenotype 
analysis undertaken here (where genome-wide significant hits are shown in blue): C – 
using controls from original study; N – using “No” responses as controls; N+X – using 
non-“Yes” responses as controls. Only the DS2 arm of the meta-analysis had sufficient 
individuals in the analysis that identified the genome-wide significant hit, so the summary 
statistics were reported for DS2 analyses only. 
The protective allele is uncommon, with a frequency of 6.2% in 1142 individuals 
with cysts, 13.1% in 295 individuals where cysts were explicitly stated as absent, 
and 7.8% in the original healthy controls used for DS2.  None of the genome-wide 
significant SNPs were directly genotyped but were imputed with an R2 of at least 
0.97. Association testing was only carried out on DS2 individuals because there 
were no individuals in DS1 for whom there was a “No” response for cysts. Further 
research is required to disentangle the mechanism through which variation at this 
locus may be involved in the cyst subphenotype. The only notable eQTLs 
associated with the lead SNP are in ATE1 and RP11-500G22.2 genes, differentially 
expressed in thyroid, lung, artery, nerve, adipose and transformed fibroblasts. The 
subphenotype-associated locus sits approximately 400 kb away from the FGFR2 
gene (Figure 52), the protein-product of which is a binding receptor for the FGF2 
ligand, which has been previously associated with acne through eQTL 
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colocalization. FGF2 has established roles in wound healing and scarring (Petridis 
et al., 2018). Furthermore, rare mutations in FGFR2 cause several bone dysplasia 
phenotypes. 
 
Figure 52: rof sucol 31.62q01 eht ta sPNS fo seulav-P noitaicossA stneitap enca  with
cysts in DS2 (vs.  2SD individuals with acne and no cysts) gnitacidni ,






In this chapter phenotype data from acne patient questionnaires was used to identify 
suitable subphenotypes for genetic analysis. After filtering and encoding the data, 
applying dimensionality reduction and using density-based clustering, there were 
no robustly identified, interesting and sufficiently distinct subphenotypes with 
sufficient numbers for genetic analysis. Instead, subphenotypes were defined 
directly from question responses directly asked within the questionnaire, and those 
with sufficient numbers for genome-wide association analysis with a defined level 
of power were taken forward for analysis. Several loci previously associated with 
disease (Petridis et al., 2018) were associated with subphenotypes to genome-wide 
levels of significance, although there were no analyses of interest where 
subphenotypes were significantly more associated than the overall phenotype at 
any previous discovered loci. Analysis also identified one signal at a novel locus 
associated with cyst lesions, which warrants further investigation. 
Collected data consisted of a CRF and a self-reported questionnaire for each 
patient. This contained a lot of extraneous information which required removal, 
such as basic patient/visit information, phenotypically irrelevant information and 
exclusion criteria. The data also contained potentially interesting question 
responses that existed in free-text, where computational encoding of the data for 
downstream analysis is not trivial. Furthermore, treatment information was also 
present, for which responder status would be of particular interest, but the section 
describing treatment information was generally very poorly filled (all questions 
had <2% response) and therefore was removed. 
The questionnaires contained a large amount of missing information, and there was 
a large discrepancy between overall response rates between DS1 and DS2 due to 
198
 
the presence of a subpopulation within DS2 with very highly filled questionnaires. 
This corresponded to negative responses in the scarring and lesion data. It is unclear 
how confidently the absence of a particular clinical trait can be imputed in a dataset 
of this nature, where most questions pertain to indication of presence of a particular 
clinical variant or lesion/scarring type. Here, blank responses in binary variables 
were assumed to be “No” responses for clustering and for one of the three arms of 
genetic analyses. However, they could also be interpreted as ‘inconclusive’, in 
which case a non-zero value could be argued to be more appropriate – the specific 
value may depend on the overall rarity of the trait within the dataset. Ultimately, 
the meaning of missing questionnaire data is dependent on the curation of the 
questionnaire, instructions given for filling them, and how these instructions are 
interpreted by individuals completing the questionnaire – therefore it can vary 
across different studies as well as within studies. It is important that such issues are 
considered when designing questionnaires and phenotype data models. Again, the 
same trade-off exists as with rare disease, where asking to fill deep phenotype 
information with maximal granularity will produce the most useful data for study 
but is more time-consuming and more likely to suffer from lack of compliance 
compared to more simple phenotype capture models. 
The clustering methods employed a dimensionality reduction using t-SNE to 
calculate two-dimensional embedding representative of the distances between the 
high-dimensional data. The clustering didn’t identify any sufficiently populous and 
distal phenotypic clusters which may have corresponded to an interesting 
subphenotype to study (e.g. the combination of a lesion type, scarring type and 
clinical variant, exclusively in males or females). Another potentially fruitful 
method of clustering includes combining questions (using either union or 
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intersection of “Yes” responses) based on disease knowledge (e.g. combination of 
nodulocystic acne and cyst lesion types into a single question) – the unsupervised 
dimensionality reduction approach was instead used it is potentially generalisable 
to other datasets without prior disease knowledge. One future direction of study is 
to analyse rare variants of individuals in this dataset, where identification of smaller 
phenotypic clusters would be more suitable. 
Explicitly stated subphenotypes from questionnaire responses were instead used 
for genome-wide association analysis. Only binary variables were analysed, and 
spatial lesion and scarring data were not included because these were considered 
less clinically meaningful than the scarring/lesion types themselves. Potential 
quantitative traits such as disease severity scoring and age of onset were also not 
tested, which require further processing as none of them were normally distributed. 
Case-control analyses were conducted using different available genotyped cohorts 
as controls: (i) controls from the original studies (Navarini et al., 2014; Petridis et 
al., 2018) (ii) all individuals explicitly stated not to have the trait (iii) all individuals 
not stated to have the trait. Only analyses with 80% power to detect a common 
variant (50%) with a genotype relative risk of 2.0 at genome-wide levels of 
significance were conducted. Using the original control dataset as controls, 13 
associations were identified at previously discovered loci in 6 subphenotypes, but 
none of the effect sizes were significantly larger than in the original GWAS meta-
analysis apart from loci associated with cases with specified family history. No 
genome-wide associations were identified when defining controls as individuals 
within the acne cohort who weren’t stated to have the subphenotype (i.e. 
considering blank data as “No” responses). However, when using explicit “Yes” 
and “No” responses as cases and controls, one locus without previous association 
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with acne was identified as associated with presence of cysts. There are eQTLs for 
nearby genes at this locus but neither the genes nor the expressed tissues are of 
particular phenotypic interest. The locus is near the FGFR2 gene in which rare 
mutations cause several bone dysplasias, and a ligand of FGFR2 (FGF2) has also 
been associated with acne through eQTL localisation (Petridis et al., 2018) – this 
warrants further investigation into the underlying mechanisms that drive 
association of this locus with only cysts but not the umbrella acne phenotype. The 
lack of other genome-wide associated signals may be due to a lack of statistical 
power in the analyses (thresholds were not stringent), or that the contribution of 
common genetic variation to the determination of acne subphenotypes is minimal. 
However, such methods may be applicable to other datasets where clinical 
information of a similar nature is recorded.  
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 Chapter 6 – General Discussion 
The first three results chapters in this thesis detail the development and application 
of methodologies for calculating phenotype similarity between a HPO term query 
and a reference set of diseases, including comparisons of performance in different 
clinical contexts. Computational identification of diseases similar to patient queries 
is important for the suggestion of differential clinical diagnoses, as well as for the 
identification of candidate genes in sequenced patients. Another important 
application of machine-readable phenotype similarity calculations is to identify 
subgroups of genotyped individuals with similar phenotypic presentations, 
something not tested in this thesis with rare disease, but with a dataset of acne 
patient questionnaires in the final results chapter. In this concluding chapter the 
main findings of the thesis are summarised and the key remaining challenges in 
these areas are discussed. 
6.1 Benchmarking procedures 
Benchmarking method performance began with simulations of queries against the 
OMIM reference phenotype set, where evaluation was based on the ranks of known 
similar phenotypes (Chapter 2). This was followed by querying HPO terms of 
patients from an external published dataset against the OMIM reference set, where 
evaluation was based on both the rank and score of the diagnostic gene (Chapter 
3). This was repeated for diagnosed patients from a genetics clinic for whom whole 
exome sequencing data was available, evaluating based on rank and score of both 
diagnostic gene and variant (Chapter 4). 
These benchmarking procedures compared several methodologies that form the 
composite process of estimating the phenotype similarity of a query to a reference 
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set. Firstly, the reference set of disease phenotypes requires characterisation with 
HPO terms, and here use of text mining was compared to manual curation – the 
utility of term quantification that can be derived from text mining was also tested 
against methods that use binary description. Secondly, machine-readable 
phenotypes must be algorithmically compared and their similarity quantified, and 
here vector-based cosine similarity was compared to Resnikavg,max|sym, a similarity 
measure utilised within many published tools. Lastly, estimated probabilities 
conferred by use of phenotype similarity were compared to the implicit uniform 
probability distribution implied by the use of virtual gene panels.  
6.1.1 OMIM phenotypic series 
The first chapter made use of the OMIM phenotypic series (PS) as the group of 
known similar diseases and tested different combinations of phenotype annotation 
and similarity methods for their ability to group these diseases with each other 
rather than with other diseases within the OMIM catalogue. This enabled a large 
number and wide phenotypic range of diseases to be tested (which was a good 
representation of the full phenotypic spectrum of known human rare diseases; 
Figure 11, page 78) in method comparisons. This is in contrast to Phenomizer 
benchmarking where individual patients were simulated based on phenotypic 
features observed in 44 comprehensively documented dysmorphology syndromes 
(Köhler et al., 2009), where the quality of the benchmarking gold-standard was 
likely to be much higher, but tested on a much narrower phenotypic range of 
disease. The use of OMIM PS has further limitations, as evaluation is based on 
query similarity to other distinct disease entities within OMIM rather than the 
correct matching disease – although such disease entities have been judged to be 
clinically similar, this is only an approximation of the process of identifying 
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equivalent diseases that match the patient phenotypic constellation. However, these 
provided an estimation of the noise associated with patient queries, adding terms 
likely to occur in the relevant phenotypic constellations, which is usually simulated 
by adding randomly selected terms (Buske, Girdea, et al., 2015; Köhler et al., 
2009). The use of the phenotypic series may also incur bias in the evaluation of 
both text-mined and curated reference sets: both the descriptive text and manually 
assigned HPO terms may be copied throughout diseases within the same OMIM 
phenotypic series. It is difficult to estimate the magnitude and effects of such bias. 
Due to these discussed drawbacks, OMIM phenotypic series benchmarking metrics 
were not sufficient alone to demonstrate superiority of any particular method of 
estimating phenotypic similarity. However, they demonstrated the potential of 
using text mining to characterise phenotypes and the use of the cosine rule to 
calculate similarity, particularly when HPO terms are quantified. 
6.1.2 DDD 
Benchmarking was then applied to a dataset of diagnosed patients from the DDD 
consortium study (The Deciphering Developmental Disorders Study, 2014; Wright 
et al., 2015). These represented a more homogenous group of patients (enriched for 
HPO terms within ‘Abnormality of the nervous system’, ‘Abnormality of head or 
neck’ and ‘Abnormality of the skeletal system’; Figure 17, page 100) due to it being 
a study of developmental disease, but the use of real patients emulates a genuine 
use case of the phenotype similarity methods. Similarity between patient queries 
and OMIM phenotypes was converted to gene similarity, and testing was based on 
both the rank and score of causative genes within the developmental disease virtual 
panel (DDG2P) that was used to diagnose patients. Testing the entire disease-
associated genome would be more realistic in some respects, but only DDG2P 
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genes were tested here as diagnoses were made based on this gene panel (therefore 
it was not possible for other genes to feature). This benchmarking not only used on 
ranks of similar phenotypes (as in the OMIM PS benchmarking) for evaluation, but 
also considered scores of the phenotypic matches and how this influences the belief 
that certain genes were causative. Instead of using raw phenotype similarity scores, 
scores were rescaled with a logistic function, using similarity measured between 
phenotypes within the same OMIM PS – although this is a flawed solution (for 
reasons mentioned when discussing flaws in the OMIM PS benchmarking metrics), 
it was considered superior to using the arbitrary scales of different similarity 
scoring algorithms. These benchmarking metrics fall short of the ultimate use case 
of these similarity methods because they don’t consider the sequence data of the 
phenotyped individuals – applying variant frequency and consequence filters to 
observed patient genetic variation dramatically reduces the number of potential 
variants (Figure 29, page 136), so it would be important to test how methods 
perform within this reduced search space. 
6.1.3 Clinic diagnoses 
Sequence data was available for diagnosed patients in the Guy’s genetics clinic 
dataset, which enabled methods to be evaluated on the reduced search space 
derived by filtering observed genetic variation. However, due to the low numbers 
of patients with both high confidence diagnoses and assigned HPO terms there was 
low statistical power to compare methods. Only 31 of 65 patients with class 4 or 5 
diagnostic variants were annotated with HPO terms. It is also not certain at which 
stage in the diagnostic process HPO terms were annotated, whereas the DDD stated 
that HPO term phenotyping was performed before diagnosis (Wright et al., 2015). 
Requesting HPO terms for the remaining diagnosed patients may be problematic 
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for benchmarking purposes because of the possibility that they would be biased by 
knowledge of the molecular diagnosis and the constellation of phenotypic features 
caused by the diagnostic gene.  
6.1.4 Towards optimal benchmarking  
It was important that benchmarking metrics moved from simulated queries to real 
patient queries and were ultimately used alongside patient sequence data. However, 
definitive conclusions could not be made due to a lack of sequenced individuals in 
the final comparison. It would be necessary to use another dataset – this would 
ideally involve requesting the DDD patient sequence data or using another 
equivalent dataset, although sufficiently large datasets with annotated HPO terms 
are difficult to curate. Benchmarking of variant prioritisation methods has 
commonly employed spiking disease-causing mutations from HGMD (Stenson et 
al., 2009) into exomes and simulating patient phenotypes (Buske, Girdea, et al., 
2015; Javed et al., 2014; Peter N. Robinson et al., 2014; Smedley & Robinson, 
2015; Zemojtel et al., 2014), whereas this thesis has focussed on using real-world 
data to inform gene prioritisation, as it contains the nuances of both the recorded 
phenotype information in clinics, as well as genotype data of rare disease patients. 
A common theme in the benchmarking of phenotype similarity methods is the bias 
that may be incurred either as a result of the gold-standard dataset (i.e. OMIM 
curated and text-mined annotations affected by knowledge of the OMIM PS 
groupings), or during the formation of the gold-standard dataset (i.e. HPO 
annotations of patients influenced by knowledge of disorders on OMIM). Such 
effects are difficult to quantify and account for, so it is important when curating 
future benchmarking datasets to delineate where the HPO term annotation of 
patients sits within the diagnostic workflow.  
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It is also clear within datasets of diagnosed patients that the ease with which the 
diagnosis has been made is highly variable. Although methodologies developed 
here and elsewhere are designed to be capable of identifying straightforward 
diagnoses as well as offering candidates in hitherto unsolved cases, they are mostly 
required for the latter group, and it would be interesting to measure how different 
methods perform on such patient populations. It may be difficult to design such 
studies as it is not obvious how to measure the ease with which a diagnosis was 
made – potential proxies exist such as size of the prescribed virtual gene panel and 
time taken for diagnosis but these are not without clear limitations.  
Though the range of disease phenotypes covered was reasonably homogeneous 
throughout benchmarking, it would be interesting to observe how methods perform 
on distinct disease areas, although large sample numbers for each area would be 
required for statistically powerful comparisons. Using the top HPO nodes below 
‘Phenotypic abnormality’ is unlikely to be the optimal representation of phenotypic 
areas but it was the most feasible way to visualise disease phenotype categories 
across multiple datasets. It would also be of interest to measure how methods 
perform on syndromic phenotypes (where multiple organ systems are affected) 
compared to disease affecting a single organ system. The number of top HPO nodes 
below ‘Phenotypic abnormality’ represented within the annotated patient HPO 
terms would be a feasible measure of how “syndromic” a patient’s disease 
phenotype is. 
Considering all of the drawbacks mentioned, it is useful to imagine the “perfect” 
benchmarking evaluation dataset and whether it exists (or can exist). This would 
consist of sufficient numbers of real patients with high confidence genetic 
diagnoses (made using virtual gene panels) where HPO term assignment was made 
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prior to molecular diagnosis. It would also additionally be beneficial for these 
patients to be categorised into respective disease areas to observe differential 
method performance, and whether this is correspondent to diagnostic rates in the 
different disease areas. The 100,000 genomes rare disease programme is one such 
example of a large-scale sequencing project where patients have been recruited in 
broad categories (GeCIP domains). Roughly 17,000 individuals with rare diseases 
will be sequenced (Genomics England, n.d.), and with an initial diagnostic rate of 
22% (Turnbull et al., 2018), an estimated 3,740 rare disease patients in total would 
be available for benchmarking. However, this again may contain some bias due to 
the increasing number of phenotype-driven tools that are used to aid diagnosis in 
such projects. 
6.2 Methodology comparisons  
6.2.1 Curation vs. text mining 
One methodology comparison undertaken in this thesis is the utility of text mining 
for phenotypes compared to manual curation. It is important to gauge the efficacy 
of text mining for phenotypes because machine-readable phenotype annotation is 
still not yet universally adopted. Even in instances where HPO annotations have 
been made, the diligence with which it is performed (and therefore the quality and 
depth of phenotyping) can be highly variable, so the use of text mining free-text 
descriptions can add value (especially as natural language processing methods 
become increasingly sophisticated). Without quantification of terms, text-mining 
of phenotypes was slightly inferior to manual curation in the OMIM PS 
benchmarking (Figure 12, page 81), and there was no significant difference in 
ranking causative genes in the DDD and clinic benchmarking (Figure 18, page 103; 
Figure 25, page 130; Figure 30, page 139).  
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Text mining also identified HPO terms in a subset of 14 individuals from the Guy’s 
genetics clinic, two of which had likely diagnostic variants. Both diagnostic 
variants were identified in first place when ranking genes by gene phenotype 
similarity to the text-mined HPO terms, and additionally, an interesting group of 
potential diagnostic variants (also ranked in first place) were identified in another 
individual, which may not have otherwise been identified.  
The OMIM reference phenotype annotation set used here was text-mined in 
February 2016, which was compared to the curated reference set downloaded at 
the same time to enable fair comparison between methods. These same annotation 
sets were compared throughout the benchmarking procedures, and the quantified 
text-mined reference set was used for HPO queries of the undiagnosed clinic 
patients – however, suggestion of diagnostic variants would be most effective if 
the most up-to-date version of the reference set could be used.  
6.2.2 Quantification vs. no quantification 
Testing also compared HPO term quantification using text-mining, which should 
allow more relevant or important terms to be up-weighted in subsequent analysis, 
against methods that don’t incorporate quantification. Quantified text-mined 
phenotypes were tested against manually curated phenotypes (where quantification 
information wasn’t used), as well as an unquantified version of the same text-mined 
set. In the OMIM PS benchmarking, the use of quantification of reference 
phenotypes greatly increased the ability to group relevant phenotypes together, 
though this was less clear when the query terms themselves were not quantified 
(Figure 12, page 81). In the DDD benchmarking, quantification of the phenotype 
reference set was significantly better at ranking patient causative genes (Figure 18, 
page 103), though there was no evidence of this in the clinic dataset (Figure 25, 
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page 130; Figure 30, page 139). Text-mining was limited to only the OMIM free-
text description, but could be expanded, for example to source publications cited 
in OMIM. Further text-mining would refine term frequencies based on relevance, 
though it would also introduce much more noise. Future work should include 
testing between text-mined and curated quantification, though this will require 
encoding the many missing quantification values in the curated dataset. 
6.2.3 Cosine vs. Resnik 
For calculation of similarity between a query and reference set of disease 
phenotypes, vector-based cosine similarity was compared to Resnikavg,max|sym, 
which was selected for comparison with vector-based cosine similarity due to its 
implementation in several tools (Javed et al., 2014; Köhler et al., 2009; Zemojtel 
et al., 2014). Vector-based similarity showed improvements ahead of the node-
based Resnik, particularly when the reference set was quantified (Figure 12, page 
81; Figure 18, page 103). P-value calculation was not incorporated in comparisons, 
which has been shown to be beneficial when imprecision is simulated (when 
imprecision and noise have been simulated separately) (Köhler et al., 2009). 
Incorporation of p-value estimation is likely to increase performance of any 
similarity measure and theoretically could be applied to any similarity method 
(including cosine similarity). P-value estimation considers the local score 
distribution of each reference phenotype, which is more specific than the logistic 
function developed which only considers the global reference set score distribution. 
6.2.4 BOQA and PhenIX 
Other published tools for suggestion of clinical diagnostics and variant 
prioritisation were compared to the methods investigated throughout this thesis. 
BOQA (Bauer et al., 2012) was compared within the DDD benchmarking, where 
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it was inferior in ranking disease genes (Figure 18, page 103), though it was able 
to identify a subset of the diagnoses with high confidence (Figure 19, page 106). 
When BOQA incorporated the reference disease phenotype frequency information 
(from both curated and text mining annotation), it did not produce significantly 
improved results. PhenIX (Zemojtel et al., 2014) was used for comparison in the 
variant prioritisation benchmarking of clinic patients (Figure 30, page 139), 
although this comparison did not have sufficient  power to draw any firm 
conclusion. 
6.2.5 Comparisons omitted 
There are a number of phenotype similarity methods that weren’t compared to 
those developed in this thesis, such as PhenoDigm (Smedley et al., 2013) and 
simGIC (Pesquita et al., 2007) which have performed notably well in other 
comparisons (Buske, Girdea, et al., 2015). Resnikavg,max|sym was selected for 
comparison as it underlies PhenIX, which has been demonstrated in multiple 
reviews to be superior at phenotype-based prioritisation of variants in known 
human disease genes (Pengelly et al., 2017; Smedley & Robinson, 2015). Ideally 
the maximal number of published methods would be compared in these 
benchmarking tests, though here the strengths and weaknesses of the various steps 
involved in calculating phenotype similarity were assessed, a non-trivial 




6.3 Considerations for all machine-readable phenotype 
similarity methodology 
6.3.1 Adding value to approaches that don’t utilise machine-readable 
phenotypes 
The utility of this methodology can firstly be demonstrated in the comparison to 
the use of the DDG2P panel in the DDD patient testing, where patient diagnostic 
genes are almost always ranked in the top 500 of the 3,303 gene panel. The 
diagnostic gene was prioritised within the top 100 in 56% of cases and the top 10 
in 23% of cases by the top-performing method (quantified text mining, cosine 
similarity; Figure 18, page 103). Furthermore, for the majority of methods the 
probability-rescaled scores of diagnostic genes were almost always superior to 
randomly selecting the gene from the panel. In the clinic patients there were 
superior statistics for the causative gene appearing in the top 10 and 100 disease-
associated genes were observed (34% and 69% respectively; Figure 25, page 130), 
but it remains to be seen how this benefit replicates upon observing patient genetic 
variation. The prioritised disease-associated genome was not compared to the use 
of gene panels, due to the highly variable size of gene panels (and resultant numbers 
of variants post-filtering), which was further complicated because the diagnostic 
gene wasn’t contained within some of the prescribed virtual gene panels. 
Further utility of this methodology is demonstrated with the suggestion of 
interesting variants in cases for which no answer has been found (though even if 
such suggested variants are confirmed, it is difficult to quantify this benefit in 
comparison to the standard operating procedure in diagnostic labs which can be 
variable between both labs and individuals within labs performing variant 
analysis). However, it is important to note that the incorporation of phenotype 
similarity metrics to rank/filter/suggest variants requires minimal effort other than 
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the annotation of patients with HPO terms (which is becoming increasingly 
adopted). It is also uncertain whether the suggested variants listed here have been 
highlighted or scrutinised previously, and whether evidence from phenotype 
similarity metrics would lend weight to assessment of pathogenicity, which is 
something not addressed in ACMG guidelines (which does consider other scoring 
such as tolerance/deleteriousness predictions). The use of text mining clinic letters 
also enabled the identification of possible compound heterozygous variants which 
are seemingly deleterious and within a gene highly relevant to the patient 
phenotype. HPO terms were not supplied for the patient and the gene was not in 
the prescribed gene panel so without these methods this variant may not have 
otherwise been identified. Text mining clinic letters for phenotypic information 
theoretically requires little additional clinical effort and can detect otherwise 
uncaptured HPO terms for the suggestion of potential diagnostic variants. 
However, in practice here it required manual anonymisation of clinic letters before 
transfer into a research environment (hence the low numbers of individuals for 
which this was performed), but this could be circumvented by including HPO text 
mining tools within installed software approved for use in diagnostic labs. 
6.3.2 Missing phenotype data 
In the limited sample of patients from the genetics clinic it was interesting to 
observe that only half of patients were annotated with HPO terms, and that the 
proportion was similar amongst diagnosed and undiagnosed individuals. Although 
machine-readable phenotypes are expected to be increasingly recorded through 
data models instituted by large rare disease sequencing projects (Caulfield et al., 
2015; The Deciphering Developmental Disorders Study, 2014), there is a need for 
methods that can identify phenotype information where it is not provided. The 
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potential of text mining health records has been demonstrated here, though it still 
requires rigorous testing against high-standard manual curation to properly assess 
the sensitivity and specificity with which it identifies HPO terms. HPO terms could 
also be identified using the latent phenotypic information contained in prescribed 
virtual gene panels by working backward from gene to OMIM disease, and then 
extracting HPO terms (potentially scoring them based on the proportion of gene-
phenotype pairs from the gene list that they feature in). Another interesting question 
is whether HPO annotations can be assessed for informative-ness among 
individuals to prioritise patients for sequencing (in highly informative cases) or 
further annotation (in non-informative cases). Such measures of informative-ness 
are available in PhenoTips data entry (via the Monarch phenotype specificity 
meter), though this only evaluates queries on the information content of their terms 
(Girdea et al., 2013). The quality of HPO content could be assessed based on the 
distribution of similarity scores between an individual’s annotations and the 
reference set, or the number of genes with a significant phenotypic match. 
The use of questionnaires can encourage more complete curation of clinical 
information by prompting the user to input data about specific phenotypic 
characteristics, though the application of such data models can only be instituted 
within a specific disease area (otherwise questionnaire options would be almost 
limitless). This method of phenotypic data collection was performed for patients 
with severe acne in cohorts from two genetic studies (Navarini et al., 2014; Petridis 
et al., 2018), with records available for 98% of individuals contained in the final 
analysis of these studies. These records contained large amounts of missing data, 
and it is unclear whether missing data should be interpreted as absent or 
inconclusive, and how such inferences should be numerically encoded. When 
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applying clustering methods missing data for binary questions was interpreted as 
absence of a particular clinical feature or clinical variant of acne and missing 
quantitative measures were replaced with median values. Additionally, one arm of 
the genetic association testing described in chapter 5 used individuals within the 
cohort with missing data for a particular question as controls, for which there is 
much less confidence in true control status than individuals where absence is 
explicitly stated. These solutions are not ideal, and could potentially be improved 
for specific questions: models could be trained to predict quantitative values (e.g. 
acne Leeds score) based on the type(s) and location(s) of lesions and scarring, and 
vice-versa. However, considering the overall response rate of the questionnaires, 
sample sizes would presumably be prohibitively low to train robust predictors. 
Future work could consider extensions to the standard HPO term annotation of a 
phenotype. Negative rare disease annotations were not considered by methods 
tested in this thesis (though negative annotations were made in many clinic patients 
due to functionality of the PhenoTips interface) – here all HPO terms not present 
were assumed to be absent. False negative probabilities can be estimated for HPO 
terms not contained in the query (which haven’t been negatively annotated), which 
is attempted in BOQA using uniform global levels of false negative probability for 
query terms (Bauer et al., 2012). Phenotypes could be “imputed” more specifically 
using observed data documenting co-occurring phenotypic features, but this would 
require a large and richly phenotyped dataset to make such predictions. This is 
further complicated as syndromic phenotypes in particular are not ‘static’ and 
different phenotypic features manifest at different timepoints in development. HPO 
clinical modifier terms exist for age of onset, pace of progression, phenotypic 
variability and positions among others, but these are not utilised by methods tested 
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in this thesis. Theoretically clinical modifier terms can exist as subnodes for every 
phenotypic term within the ontology, where maximal similarity is conferred in 
instances where both the term and its clinical modifier match (though such a model 
may experience difficulties with implicit annotation of ancestor terms). However, 
such data is not frequently annotated to the reference set (611 of 152,014 
annotations in the most recent curated HPO annotation set contain onset modifiers), 
and so would require a tremendous curation effort or sophisticated text mining and 
natural language processing techniques to associate such modifiers. 
6.3.3 Phenotypic clusters 
Based on severe acne patient questionnaire data, dimensionality reduction and 
density-based clustering methods were used to identify phenotypic clusters 
corresponding to putative acne subphenotypes. This was unsuccessful, with the 
only large and distinct clusters corresponding to individuals with high amounts of 
missing data, which separated based on the remaining data fields into sex and 
indication of the most common clinical variant of acne contained in the study, 
nodulocystic acne. It is possible that a genetically determined subtype of acne lay 
within smaller phenotypic clusters, but statistical power to identify genome-wide-
associated common SNPs is limited in such cases. Identification of phenotypic 
clusters was not attempted in the clinic patients – there were only 55 undiagnosed 
patients with HPO terms available (69 including those with VUS; Table 10, page 
119), which existed on a wide phenotype spectrum, causing the data to be sparse. 
It may be possible to identify small phenotypic clusters for rare disease using 
visualisation methods described above but these would likely correspond to the 
sharing of non-specific terms. Such methods may be more likely to work in larger 
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datasets, such as the undiagnosed DDD patients, in which the range of disease 
phenotypes would also be narrower than a genetics clinic. 
6.3.4 Estimating statistical significance of measures of phenotype similarity 
Scoring similarity between individual’s phenotype and a reference set, or other 
individuals’ phenotypes benefits greatly from consideration of the statistical 
significance of certain levels of similarity score. Methods developed in this thesis 
employ global empirical similarity score distributions in similar and non-similar 
phenotypes based on phenotypic series data to estimate the probability associated 
with observing a given level of similarity score. Phenomizer (and Phenomizer-
incorporating) methods utilise an alternative approach of assessing local similarity 
scores for each of the reference phenotypes by generating random searches for 
differing numbers of query terms (Köhler et al., 2009), and similar approaches may 
be suitable for assessing the complete probability distribution of patient HPO term 
similarity through random searches sampled on the relative frequencies of each 
phenotypic term within large rare disease patient datasets. 
6.3.5 Coding and non-coding variation 
The methodologies tested and applied here only consider variation within the 
coding regions of the genome. It is relatively straightforward to establish causality 
of a novel coding variant within a known disease gene through functional 
consequence and prediction data, compared to establishing the causality of the non-
coding variant. However, the frequency with which non-coding variants cause 
disease is unknown because disease mechanisms are often less clear and have been 
the subject of much fewer studies. The low diagnostic rate of rare disorders in 
general makes non-coding variation a potentially fruitful area of study. CADD 
scores are able to evaluate non-coding SNVs (Kircher et al., 2014), and variant 
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analysis frameworks (including additional scoring of non-coding positions) are 
available for the inclusion of non-coding variants in phenotype-aware variant 
prioritisers that combine phenotype and variant score (Smedley et al., 2016). 
However, in general, much progress will be need in the understanding of non-
coding causes of rare disease for the methods developed in this thesis to become 
directly applicable. 
6.3.6 Combining variant scoring with phenotype-based prioritisation  
In this thesis patient exome variants were filtered prior to phenotype-based 
prioritisation based on functional consequence (removal of synonymous variation) 
and estimates of allele frequency, and such information was not additionally used 
to prioritise variants (i.e. preferentially prioritising nonsense and frameshift 
mutations over missense). Pathogenicity prediction scores were also not used to 
filter variants or influence the prioritisation of post-filtering variants. Several 
published methods combine variant-level scoring (using combinations of variant 
frequency, consequence and pathogenicity prediction tools) with gene-level 
scoring (based on phenotypic relevance) (Bone et al., 2015; Javed et al., 2014; 
Sifrim et al., 2013; Singleton et al., 2014; Zemojtel et al., 2014). Addition of 
variant-level information is expected to increase performance of phenotype-based 
methods, as shown in benchmarking of these tools. Furthermore, mode of 
inheritance information can also be incorporated into variant filtering – firstly, 
genes can be removed where the patient genotype is not consistent with the known 
phenotype-gene relationships, and secondly, where there is a suspected mode of 
inheritance in the patient, this can be used to filter/prioritise variants based on 
whether the genotypes are consistent. Such additions also have potential to improve 




This thesis has demonstrated the utility of text mining in annotating rare disease 
phenotypes for both reference diseases and patient phenotypic descriptions. Novel 
benchmarking strategies have been employed using similar phenotypes defined 
within the reference set, as well as a group of diagnosed individuals in a publicly 
available dataset. Methods were also tested in the clinic, although the limited 
number of patients lowered the power of statistical comparison of methods. They 
were also applied to undiagnosed patients in the clinic, suggesting interesting 
candidate variants which warrant additional investigation. Lastly, questionnaire 
data for individuals with a common complex disease (acne) was used to identify 
subphenotypes, and despite the dataset containing large amounts of missing data, 
subsequent genetic analysis identified a genome-wide significant hit in a 
subphenotype which warrants further investigation. Taken together, this work has 
therefore demonstrated that careful utilisation of phenotype data has great potential 
to aid genetic diagnosis and discovery, and that further research in this area should 
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1.1 HPO terms for the patient with the MED12 nonframeshift deletion diagnosis 
(4.3.6) that wasn’t captured by the exome filtering strategy employed here. 
HPO code HPO term 
HP:0001274 Agenesis of corpus callosum 
HP:0001631 Atria septal defect 
HP:0001488 Bilateral ptosis 
HP:0004325 Decreased body weight 
HP:0002015 Dysphagia 
HP:0001332 Dystonia 
HP:0001508 Failure to thrive 
HP:0001290 Generalized hypotonia 
HP:0001263 Global developmental delay 
HP:0001528 Hemihypertrophy 
HP:0010864 Intellectual disability, severe 
HP:0000252 Microcephaly 
HP:0001561 Polyhydramnios 
HP:0000407 Sensorineural hearing impairment 
HP:0001518 Small for gestational age 
HP:0001629 Ventricular septal defect 
 
1.2 HPO terms for the patient with the CREBBP nonsynonymous SNV diagnosis 
(4.3.6) that wasn’t captured by the exome filtering strategy employed here. 
HPO code HPO term 
HP:0001999 Abnormal facial shape 
HP:0000593 Abnormality of the anterior chamber 
HP:0000481 Abnormality of the cornea 
HP:0000359 Abnormality of the inner ear 
HP:0002088 Abnormality of the lung 
HP:0000587 Abnormality of the optic nerve 
HP:0000356 Abnormality of the outer ear 
HP:0000479 Abnormality of the retina 
HP:0000069 Abnormality of the ureter 
HP:0000795 Abnormality of the urethra 
HP:0000925 Abnormality of the vertebral column 
HP:0002251 Aganglionic megacolon 
HP:0000062 Ambiguous genitalia 
HP:0011675 Arrhythmia 
HP:0001251 Ataxia 
HP:0001631 Atria septal defect 




HP:0000708 Behavioral abnormality 
HP:0003561 Birth length less than 3rd percentile 
HP:0100490 Camptodactyly of finger 
HP:0001836 Camptodactyly of toe 





HP:0000175 Cleft palate 
HP:0000204 Cleft upper lip 
HP:0001680 Coarctation of aorta 
HP:0000589 Coloboma 
HP:0001674 Complete atrioventricular canal defect 
HP:0000405 Conductive hearing impairment 
HP:0000776 Congenital diaphragmatic hernia 
HP:0001363 Craniosynostosis 
HP:0000028 Cryptorchidism 
HP:0004325 Decreased body weight 
HP:0000750 Delayed speech and language development 
HP:0000819 Diabetes mellitus 
HP:0001332 Dystonia 
HP:0002910 Elevated hepatic transaminases 
HP:0002032 Esophageal atresia 
HP:0001738 Exocrine pancreatic insufficiency 
HP:0006101 Finger syndactyly 
HP:0001371 Flexion contracture 
HP:0001543 Gastroschisis 
HP:0001290 Generalized hypotonia 
HP:0001263 Global developmental delay 
HP:0000085 Horseshoe kidney 
HP:0000953 Hyperpigmentation of the skin 
HP:0001010 Hypopigmentation of the skin 
HP:0000047 Hypospadias 
HP:0000601 Hypotelorism 
HP:0002659 Increased susceptibility to fractures 
HP:0010864 Intellectual disability, severe 
HP:0009816 Lower limb undergrowth 
HP:0000252 Microcephaly 
HP:0000568 Microphthalmia 
HP:0002011 Morphological abnormality of the central nervous system 
HP:0000639 Nystagmus 
HP:0001849 Oligodactyly (feet) 
HP:0001180 Oligodactyly (hands) 
HP:0001539 Omphalocele 
HP:0001561 Polyhydramnios 
HP:0100259 Postaxial polydactyly 
HP:0004467 Preauricular pit 
HP:0000384 Preauricular skin tag 
HP:0100258 Preaxial polydactyly 





HP:0000407 Sensorineural hearing impairment 
HP:0002652 Skeletal dysplasia 
HP:0001518 Small for gestational age 
HP:0001257 Spasticity 
HP:0010301 Spinal dysraphism 
HP:0000486 Strabismus 
HP:0001762 Talipes equinovarus 
HP:0001636 Tetralogy of Fallot 
HP:0001770 Toe syndactyly 
HP:0002575 Tracheoesophageal fistula 
HP:0009824 Upper limb undergrowth 
HP:0011276 Vascular skin abnormality 
HP:0001629 Ventricular septal defect 






Questions removed from the acne phenotype questionnaire.  
Data “Type” column coded as follows: 
- B: Binary 
- Q: Quantitative 
- F: Factor 
“Reason” column coded as follows: 
- M: Monomorphic 
- I: Irrelevant 
- T: Free-text (some binary columns are coded with the “free-text” reason for 
omission because they pertain to text entered in another column. 
- P: Phenotypic information but irrelevant to acne 
- F: Poorly filled 
Name Type %filled Unique Reason 
patientDetails: Forename F 100 27 I 
patientDetails: Surname F 100 26 I 
patientDetails: DateOfBirth Q 100 5139 I 
patientDetails: Ethnicity_Specify F 3.4 54 M 
familyHistory: Ps_FamilyHistory B 0.3 4 P 
familyHistory: Psoriasis F 0.2 9 P 
familyHistory: Acne F 11 116 T 
familyHistory: Ecz_FamilyHistory B 0.3 3 P 
familyHistory: Eczema F 0.3 12 P 
familyHistory: HS_FamilyHistory B 8.6 4 P 
familyHistory: Hidradenitis Suppurativa F 0.5 16 P 
diagnosis: Disease F 100 1 I 
diagnosis: Year_Diagnosis Q 100 6 I 
diagnosis: Age_Diagnosis Q 0.1 6 I 
diagnosis: Year_Onset Q 99.9 60 I 
acneDiagnosis: Disease F 100 1 M 
acneDiagnosis: Acne_Vulgaris B 100 1 M 
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Name Type %filled Unique Reason 
acneDiagnosis: Acne_EvidenceVirilisation B 97.4 3 M 
acneDiagnosis: Acne_Rosacea B 98 3 M 
acneDiagnosis: Acne_HormonalAbnormal B 98 3 M 
acneDiagnosis: Acne_Drug_Induced B 98.1 3 M 
acneDiagnosis: Acne_HH B 98.1 3 M 
acneDiagnosis: Acne_Occupation B 97.8 3 M 
acneDiagnosis: Acne_Occupation_Specify B 0 1 M 
acneDiagnosis: Acne_Other B 45.2 4 I 
acneDiagnosis: Acne_Other_Specify F 6.9 32 T 
acneDiagnosis: Acne_Isotretinoin B 95.6 4 P 
acneDiagnosis: Acne_LeedsScore B 74.9 4 I 
acneDiagnosis: Acne_YearMenarche Q 24.8 56 I 
acneDiagnosis: Acne_BloodTransfussion B 100 1 M 
clinical: Date_Clinical Q 71.2 1708 I 
clinical: Weight Q 0.6 44 F 
clinical: Height Q 0.6 29 F 
clinical: BMI Q 0.6 46 F 
clinical: Lesions_Site1 F 6.3 24 T 
clinical: Lesions_Site2 F 0.7 16 T 
clinical: Lesions_Site3 F 0 3 T 
clinical: Comedones_Site1 B 1.7 3 T 
clinical: Comedones_Site2 B 0.2 3 T 
clinical: Comedones_Site3 B 0 2 T 
clinical: Papules_Site1 B 3 3 T 
clinical: Papules_Site2 B 0.4 3 T 
clinical: Papules_Site3 B 0 2 T 
clinical: Pustules_Site1 B 2.5 3 T 
clinical: Pustules_Site2 B 0.3 3 T 
clinical: Pustules_Site3 B 0 1 T 
clinical: Cysts_Site1 B 2.2 3 T 
clinical: Cysts_Site2 B 0.3 3 T 
clinical: Cysts_Site3 B 0 2 T 
clinical: LeedsScore_Site1 Q 2.3 13 T 
clinical: LeedsScore_Site2 Q 0.3 6 T 
clinical: LeedsScore_Site3 Q 0 1 T 
clinical: Unknown_Chest B 12.7 4 P 
clinical: Unknown_Back B 13.1 4 P 
clinical: Unknown_Face B 14.7 4 P 
clinical: Unknown_Site1 B 1.7 3 P 
clinical: Unknown_Site2 B 0.2 3 P 
clinical: Unknown_Site3 B 0 1 P 
clinical: Scarring_Site1 F 5.8 22 T 
clinical: Scarring_Site2 F 0.6 15 T 
clinical: Scarring_Site3 F 0.2 9 T 
clinical: Scarring_General B 0 1 M 
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Name Type %filled Unique Reason 
clinical: Scarring_Site4 B 3.5 3 T 
clinical: Scarring_Site5 B 0.2 3 T 
clinical: Scarring_Site6 B 0.1 3 T 
clinical: Hypertrophic_Site4 B 0.7 3 T 
clinical: Hypertrophic_Site5 B 0.1 3 T 
clinical: Hypertrophic_Site6 B 0.1 3 T 
clinical: Keloid_Site4 B 0.5 3 T 
clinical: Keloid_Site5 B 0.1 3 T 
clinical: Keloid_Site6 B 0.1 2 T 
clinical: Atrophic_Site4 B 0.8 3 T 
clinical: Atrophic_Site5 B 0.2 3 T 
clinical: Atrophic_Site6 B 0.1 3 T 
clinical: IcePick_Site4 B 1.5 3 T 
clinical: IcePick_Site5 B 0.3 3 T 
clinical: IcePick_Site6 B 0.1 3 T 
clinical: Perifollicular_Site4 B 0.5 3 T 
clinical: Perifollicular_Site5 B 0.1 3 T 
clinical: Perifollicular_Site6 B 0.1 2 T 
clinical: PostInflam_Site4 B 1.3 3 T 
clinical: PostInflam_Site5 B 0.3 3 T 
clinical: PostInflam_Site6 B 0.1 3 T 
clinical: _Summary B 16.5 3 T 
clinical: Scarring_Overall F 44.5 76 T 
clinical: Lesion_Overall F 50.4 29 T 
treatments: Disease F 2.8 2 I 
treatments: Therapy F 2.8 4 I 
treatments: TherapyType F 2.8 4 I 
treatments: Dose Q 0 2 I 
treatments: Frequency Q 0 1 I 
treatments: Date_Start Q 2.4 82 I 
treatments: Date_End Q 0.3 22 I 
treatments: OnGoing B 1.6 4 I 
treatments: Date_OnGoing Q 1.1 69 I 
treatments: Responder* B 2.1 5 I 
 
DLQI: Dermatology Life Quality Index (Finlay & Khan, 1994). 
*Although “Response to treatment” is interesting in the context of genetic studies 
of acne, there were so few responses in the entire treatments section of the 




Questionnaire fields retained for analysis. T column is the data type (B: binary; Q: 
quantitative; F: Factor). U column is the number of unique responses. The final 
column displays the range and median for quantitative measures and the frequency 
of the most common response for other data types (excluding No/missing 
responses).  
Name T %F U Range (median) 
 or Top% 
patientDetails: Sex F 100 3 F: 56.6% 
patientDetails: Ethnicity F 100 3 White: 100.0% 
familyHistory: Acne_FamilyHistory B 18.8 3 Yes: 15.8% 
diagnosis: Age_Onset Q 79.4 38 1 - 41 (14) 
acneDiagnosis: Acne_Infatile B 20.6 3 Yes: 0.0% 
acneDiagnosis: Assoc_PCOS B 41.2 3 Yes: 1.0% 
acneDiagnosis: Acne_Nodulocystic B 56.4 3 Yes: 32.8% 
acneDiagnosis: Acne_Fulminans B 41.7 3 Yes: 0.3% 
acneDiagnosis: Acne_Conglobata B 41.8 3 Yes: 0.4% 
acneDiagnosis: Acne_Sandpaper B 42.3 3 Yes: 0.7% 
acneDiagnosis: Acne_Submarine B 42 3 Yes: 0.5% 
acneDiagnosis: Acne_HairBeforeEleven B 19.9 3 Yes: 3.3% 
acneDiagnosis: Acne_BeforePuberty B 68.8 3 Yes: 7.3% 
acneDiagnosis: Hirsutism B 1.2 3 Yes: 0.1% 
acneDiagnosis: AndrogenicAlopecia B 1.5 3 Yes: 0.0% 
acneDiagnosis: Acne_HasBeenPregnant B 10 3 Yes: 2.9% 
acneDiagnosis: Acne_UnwantedFacialHair B 9.9 3 Yes: 1.4% 
clinical: DLQI Q 27 32 0 - 30 (5) 
clinical: Comedones_Chest B 15.9 3 Yes: 7.9% 
clinical: Comedones_Back B 18.6 3 Yes: 11.2% 
clinical: Comedones_Face B 30.5 3 Yes: 25.2% 
clinical: Papules_Chest B 19.6 3 Yes: 12.1% 
clinical: Papules_Back B 24 3 Yes: 17.5% 
clinical: Papules_Face B 36.7 3 Yes: 32.3% 
clinical: Pustules_Chest B 16.7 3 Yes: 8.8% 
clinical: Pustules_Back B 20.7 3 Yes: 13.6% 
clinical: Pustules_Face B 31.6 3 Yes: 26.8% 
clinical: Cysts_Chest B 13.3 3 Yes: 4.6% 
clinical: Cysts_Back B 16.5 3 Yes: 8.6% 
clinical: Cysts_Face B 24.5 3 Yes: 18.6% 
clinical: LeedsScore_Back Q 21.8 14 0 - 12 (3) 
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Name T %F U Range (median) 
 or Top% 
clinical: LeedsScore_Chest Q 19.5 13 0 - 11 (1) 
clinical: LeedsScore_Face Q 27.2 14 0 - 12 (5) 
clinical: LeedsScore_Total Q 28.3 34 0 - 43 (7) 
clinical: Scarring_Chest B 14.3 3 Yes: 3.5% 
clinical: Scarring_Back B 16 3 Yes: 5.6% 
clinical: Scarring_Face B 23 3 Yes: 14.2% 
clinical: Hypertrophic_Chest B 12.6 3 Yes: 1.1% 
clinical: Hypertrophic_Back B 13.1 3 Yes: 1.8% 
clinical: Hypertrophic_Face B 13.1 3 Yes: 1.8% 
clinical: Keloid_Chest B 12.2 3 Yes: 0.7% 
clinical: Keloid_Back B 12.3 3 Yes: 0.8% 
clinical: Keloid_Face B 12.1 3 Yes: 0.5% 
clinical: Atrophic_Chest B 13 3 Yes: 1.6% 
clinical: Atrophic_Back B 14.4 3 Yes: 3.2% 
clinical: Atrophic_Face B 20.2 3 Yes: 10.4% 
clinical: IcePick_Chest B 12.2 3 Yes: 0.7% 
clinical: IcePick_Back B 12.9 3 Yes: 1.4% 
clinical: IcePick_Face B 18 3 Yes: 8.3% 
clinical: Perifollicular_Chest B 11.9 3 Yes: 0.6% 
clinical: Perifollicular_Back B 12.5 3 Yes: 1.3% 
clinical: Perifollicular_Face B 12.5 3 Yes: 1.3% 
clinical: PostInflam_Chest B 13.6 3 Yes: 2.4% 
clinical: PostInflam_Back B 15 3 Yes: 4.4% 
clinical: PostInflam_Face B 19.1 3 Yes: 9.9% 
clinical: Comedones_Summary B 32.2 3 Yes: 27.2% 
clinical: Papules_Summary B 39.1 3 Yes: 35.2% 
clinical: Pustules_Summary B 34.6 3 Yes: 30.3% 
clinical: Cysts_Summary B 27.7 3 Yes: 22.3% 
clinical: Scarring_Summary B 27.2 3 Yes: 18.7% 
clinical: Hypertrophic_Summary B 14.3 3 Yes: 3.3% 
clinical: Keloid_Summary B 12.9 3 Yes: 1.5% 
clinical: Atrophic_Summary B 21.7 3 Yes: 12.0% 
clinical: IcePick_Summary B 18.9 3 Yes: 9.3% 
clinical: Perifollicular_Summary B 13.3 3 Yes: 2.4% 





Question response rates between individuals in population 1 and 2 identified in the 
missingness PCA (Figure 36, page 177) sorted by the difference in response rates, 












clinical: Keloid_Face 0.005 0.9984 -0.9935 0.0833 0.989 
clinical: IcePick_Chest 0.0068 1 -0.9932 0.0606 0.9859 
clinical: Keloid_Chest 0.0068 0.9984 -0.9916 0.0303 0.9937 
clinical: Perifollicular_Chest 0.0041 0.9953 -0.9912 0.0 0.9826 
clinical: Keloid_Back 0.0083 0.9984 -0.9902 0.05 0.989 
clinical: Hypertrophic_Chest 0.0105 1 -0.9895 0.0 0.9859 
clinical: IcePick_Back 0.0138 1 -0.9862 0.0299 0.9796 
clinical: Perifollicular_Face 0.0099 0.9953 -0.9854 0.0208 0.9621 
clinical: Atrophic_Chest 0.0153 1 -0.9847 0.0135 0.978 
clinical: Perifollicular_Back 0.0107 0.9953 -0.9845 0.0192 0.9685 
clinical: Hypertrophic_Back 0.0161 1 -0.9839 0.0 0.9717 
clinical: Keloid_Summary 0.0151 0.9984 -0.9833 0.0274 0.9796 
clinical: Hypertrophic_Face 0.0169 1 -0.9831 0.0 0.9702 
clinical: Perifollicular_Summary 0.0194 0.9953 -0.9759 0.0106 0.9401 
clinical: PostInflam_Chest 0.0231 0.9953 -0.9721 0.0179 0.9653 
clinical: Hypertrophic_Summary 0.0302 1 -0.9698 0.0 0.9466 
clinical: Atrophic_Back 0.0308 1 -0.9692 0.0134 0.9529 
clinical: PostInflam_Back 0.0393 0.9953 -0.956 0.0158 0.9164 
clinical: Scarring_Chest 0.0324 0.9812 -0.9487 0.0064 0.9472 
clinical: Scarring_Back 0.0513 0.9827 -0.9315 0.004 0.9058 
clinical: IcePick_Face 0.0719 1 -0.9281 0.0029 0.8352 
clinical: IcePick_Summary 0.0825 1 -0.9175 0.0025 0.8273 
clinical: PostInflam_Face 0.0853 0.9953 -0.9099 0.0024 0.7918 
clinical: Atrophic_Face 0.0973 1 -0.9027 0.0021 0.8477 
clinical: PostInflam_Summary 0.1044 0.9953 -0.8909 0.002 0.7587 
clinical: Atrophic_Summary 0.1137 1 -0.8863 0.0018 0.8289 
clinical: Scarring_Face 0.1304 0.9859 -0.8555 0.0016 0.7643 
clinical: Scarring_Summary 0.1775 0.9859 -0.8084 0.0012 0.7357 
clinical: Comedones_Chest 0.0781 0.7692 -0.6911 0.1138 0.798 
clinical: Cysts_Chest 0.0535 0.7363 -0.6827 0.2046 0.8977 
clinical: Pustules_Chest 0.0884 0.7614 -0.6729 0.1028 0.8021 
clinical: Comedones_Back 0.1087 0.7771 -0.6684 0.0722 0.7515 
clinical: Papules_Chest 0.1201 0.7755 -0.6554 0.074 0.7449 
clinical: Cysts_Back 0.0893 0.741 -0.6517 0.1042 0.8178 














clinical: Papules_Back 0.1684 0.7865 -0.6181 0.0368 0.6567 
clinical: Cysts_Face 0.1734 0.7865 -0.6131 0.0381 0.5828 
clinical: Comedones_Face 0.235 0.8367 -0.6018 0.0273 0.4822 
clinical: Comedones_Summary 0.2529 0.8446 -0.5916 0.0212 0.4572 
clinical: Cysts_Summary 0.2093 0.7928 -0.5834 0.0286 0.5267 
clinical: Pustules_Face 0.2501 0.8148 -0.5647 0.0165 0.4701 
clinical: Pustules_Summary 0.2819 0.832 -0.5501 0.0139 0.4075 
clinical: Papules_Face 0.3048 0.8352 -0.5303 0.0129 0.4098 
clinical: Papules_Summary 0.3306 0.8509 -0.5202 0.0106 0.3635 
acneDiagnosis: Acne_Fulminans 0.3606 0.8462 -0.4855 0.9926 0.9963 
acneDiagnosis: Acne_Conglobata 0.3614 0.8462 -0.4847 0.9874 0.9981 
acneDiagnosis: Acne_Submarine 0.3643 0.8462 -0.4818 0.9836 1 
acneDiagnosis: Acne_Sandpaper 0.3668 0.8477 -0.4809 0.9792 0.9944 
acneDiagnosis: Acne_Nodulocystic 0.523 0.8728 -0.3498 0.3888 0.5558 
clinical: DLQI 0.2385 0.5118 -0.2733 0.0737 0.0583 
acneDiagnosis: Acne_BeforePuberty 0.659 0.9089 -0.2499 0.8968 0.8791 
clinical: LeedsScore_Chest 0.1783 0.3203 -0.1419 0.3001 0.4118 
diagnosis: Age_Onset 0.7783 0.9121 -0.1338 0.0 0.0 
acneDiagnosis: Assoc_PCOS 0.397 0.5275 -0.1305 0.9776 0.9613 
clinical: LeedsScore_Back 0.2038 0.3265 -0.1228 0.1886 0.3221 
clinical: LeedsScore_Total 0.2689 0.3862 -0.1173 0.0077 0.0285 
clinical: LeedsScore_Face 0.2585 0.3736 -0.1151 0.0208 0.0336 
acneDiagnosis: Acne_HairBeforeEleven 0.1891 0.2732 -0.0841 0.8361 0.8391 
familyHistory: Acne_FamilyHistory 0.1856 0.2041 -0.0185 0.1782 0.0385 
acneDiagnosis: Hirsutism 0.0112 0.0188 -0.0077 0.9815 0.8333 
acneDiagnosis: AndrogenicAlopecia 0.0143 0.0188 -0.0046 0.9855 1 
patientDetails: Sex 0.9998 1 -0.0002 0.0 0.0 
patientDetails: Ethnicity 1 1 0 0.0 0.0 
acneDiagnosis: Acne_UnwantedFacialHair 0.1025 0.0754 0.0271 0.8629 0.8542 
acneDiagnosis: Acne_HasBeenPregnant 0.1029 0.0754 0.0276 0.7129 0.6875 






Power calculation for each binary trait in the questionnaire, using numbers of controls for the original control dataset (C), “No” responses (N) and 
all non-“Yes” responses (N+X). Analyses were only performed if they had 80% power to detect a risk allele with 50% frequency and a genotype 
relative risk (GRR) of 2.0 (highlighted in bold; n=36). Effective cases and controls delineate the number of cases and controls after taking into 























C 863 21120 13 4976 850 16144 863 21120 1.4 
N 863 165 13 2 850 163 850 163 2.25 
N+X 863 4613 13 1734 850 2879 863 4613 1.4 
acneDiagnosis: Acne_Infatile 
C 1 21120 0 4976 1 16144 0 0 >3 
N 1 1127 0 7 1 1120 0 0 >3 
N+X 1 5475 0 1747 1 3728 0 0 >3 
acneDiagnosis: Assoc_PCOS 
C 56 21120 15 4976 41 16144 56 21120 >3 
N 56 2201 15 208 41 1993 56 2201 >3 
N+X 56 5420 15 1732 41 3688 56 5420 >3 
acneDiagnosis: 
Acne_Nodulocystic 
C 1794 21120 447 4976 1347 16144 1794 21120 1.25 
N 1794 1293 447 12 1347 1281 1794 1293 1.4 
N+X 1794 3682 447 1300 1347 2382 1794 3682 1.3 

























N 15 2269 3 45 12 2224 12 2224 >3 
N+X 15 5461 3 1744 12 3717 12 3717 >3 
acneDiagnosis: Acne_Conglobata 
C 23 21120 5 4976 18 16144 18 16144 >3 
N 23 2265 5 45 18 2220 18 2220 >3 
N+X 23 5453 5 1742 18 3711 18 3711 >3 
acneDiagnosis: Acne_Sandpaper 
C 40 21120 22 4976 18 16144 40 21120 >3 
N 40 2275 22 45 18 2230 40 2275 >3 
N+X 40 5436 22 1725 18 3711 40 5436 >3 
acneDiagnosis: Acne_Submarine 
C 29 21120 22 4976 7 16144 22 4976 >3 
N 29 2273 22 45 7 2228 22 45 >3 
N+X 29 5447 22 1725 7 3722 22 1725 >3 
acneDiagnosis: 
Acne_HairBeforeEleven 
C 178 21120 11 4976 167 16144 178 21120 1.95 
N 178 911 11 37 167 874 178 911 2.1 
N+X 178 5298 11 1736 167 3562 178 5298 1.95 
acneDiagnosis: 
Acne_BeforePuberty 
C 399 21120 41 4976 358 16144 399 21120 1.6 
N 399 3369 41 494 358 2875 399 3369 1.6 
N+X 399 5077 41 1706 358 3371 399 5077 1.6 
acneDiagnosis: Hirsutism 
C 3 21120 0 4976 3 16144 0 0 >3 
N 3 63 0 21 3 42 0 0 >3 
N+X 3 5473 0 1747 3 3726 0 0 >3 
acneDiagnosis: 
AndrogenicAlopecia 
C 1 21120 0 4976 1 16144 0 0 >3 
N 1 80 0 19 1 61 0 0 >3 
N+X 1 5475 0 1747 1 3728 0 0 >3 



























N 158 388 0 0 158 388 158 388 2.35 
N+X 158 5318 0 1747 158 3571 158 3571 2.05 
acneDiagnosis: 
Acne_UnwantedFacialHair 
C 75 21120 0 4976 75 16144 75 16144 2.7 
N 75 469 0 0 75 469 75 469 2.95 
N+X 75 5401 0 1747 75 3654 75 3654 2.75 
clinical: Comedones_Summary 
C 1490 21120 151 4976 1339 16144 1490 21120 1.3 
N 1490 272 151 1 1339 271 1339 271 1.85 
N+X 1490 3986 151 1596 1339 2390 1490 3986 1.35 
clinical: Papules_Summary 
C 1928 21120 198 4976 1730 16144 1928 21120 1.25 
N 1928 214 198 1 1730 213 1730 213 1.95 
N+X 1928 3548 198 1549 1730 1999 1928 3548 1.3 
clinical: Pustules_Summary 
C 1659 21120 133 4976 1526 16144 1659 21120 1.3 
N 1659 235 133 1 1526 234 1526 234 1.9 
N+X 1659 3817 133 1614 1526 2203 1659 3817 1.3 
clinical: Cysts_Summary 
C 1223 21120 81 4976 1142 16144 1223 21120 1.3 
N 1223 295 81 0 1142 295 1142 295 1.85 
N+X 1223 4253 81 1666 1142 2587 1223 4253 1.35 
clinical: Scarring_Summary 
C 1024 21120 79 4976 945 16144 1024 21120 1.35 
N 1024 463 79 10 945 453 1024 463 1.7 
N+X 1024 4452 79 1668 945 2784 1024 4452 1.4 
clinical: Hypertrophic_Summary 
C 180 21120 11 4976 169 16144 180 21120 1.95 
N 180 603 11 10 169 593 180 603 2.15 
N+X 180 5296 11 1736 169 3560 180 5296 1.95 

























N 84 625 3 11 81 614 81 614 2.8 
N+X 84 5392 3 1744 81 3648 81 3648 2.65 
clinical: Atrophic_Summary 
C 658 21120 66 4976 592 16144 658 21120 1.45 
N 658 529 66 10 592 519 658 529 1.7 
N+X 658 4818 66 1681 592 3137 658 4818 1.45 
clinical: IcePick_Summary 
C 508 21120 25 4976 483 16144 508 21120 1.5 
N 508 528 25 10 483 518 508 528 1.75 
N+X 508 4968 25 1722 483 3246 508 4968 1.55 
clinical: Perifollicular_Summary 
C 131 21120 3 4976 128 16144 128 16144 2.2 
N 131 597 3 11 128 586 128 586 2.4 
N+X 131 5345 3 1744 128 3601 128 3601 2.2 
clinical: PostInflam_Summary 
C 657 21120 35 4976 622 16144 657 21120 1.45 
N 657 482 35 11 622 471 657 482 1.75 
N+X 657 4819 35 1712 622 3107 657 4819 1.45 
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